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ABSTRACT 
 
Heparan Sulphate plays an important role in many life processes and so an understanding of its 
role as a universal co-receptor is of great importance. Traditionally oligosaccharides derived from 
the related molecule heparin have been at the forefront of molecular drug design, due to its 
similarity in structure and function. To obtain a more complex and detailed picture of the role of 
HS in structural biology further complex work must be undertaken on HS. Here in this study a 
number of HS derived octasaccharides have been purified. Alongside this is work carried on HS 
derived decasaccharides, of which all have undergone extensive molecular modelling 
simulations. The role of the Iduronates in the HS structure, at monosaccharide level has indicated 
a major role for these structures in biological activity. Further work has indicated the level of 
sulphation is also a requirement which in turn influences conformational behaviour. Up until now 
this has only really been studied at the monosaccharide level and so this study has generated a 
number of different HS models which can confirm the importance of iduronate conformation in 
biological activity. Not only that but it has also been identified that certain torsional geometries 
within the glycosidic bonds between monosaccharides also has a major influence on 
conformation. Local deviations in the molecular modelling data suggest there is a slight difference 
between active and inactive oligosaccharides with the ability to bind and activate the 
HS:FGF2:FGFR IIIc complex.  
The implications of these and other structural insights are discussed with the implication heavily 
towards a combination of both torsional geometry and iduronate conformation in biological 
activity. To further aid our understanding HS dp10 oligosaccharides were docked into a FGF2 
which was in a complex with a heparin hexasaccharide. Docking experiments were carried in 
order to attain structural information on the binding of these molecules. The Goodger 
oligosaccharides were docked into the X-ray crystal structure and were chosen specifically for 
their iduronate conformation or the torsional geometry. 
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1.1 Heparan Sulphate 
Heparan sulphate (HS), along with the chemically related heparin, are ubiquitous 
glycosaminoglycans (GAG’s) containing alternating sequences of repeating C1-C4 linked 
disaccharide units (Rabenstein, 2002). HS is ubiquitous in animal cells and found to be located 
on the surface of cells, but also in the extracellular matrix (ECM). HS is a member of a class of 
polysaccharides known as the GAG’s. It is classified according to the hexosamine component 
found to make up the chain (Lindahl et al. 1994). Both HS/heparin (hep) are classed as 
glucosaminoglycans because of their glucosamine content; where as other members of the family 
such as Chondroitin sulphate (CS) and Dermatan sulphate (DS) are classed as 
galactosaminoglycan because of their galactosamine content (Gallagher and Walker, 1985). HS 
contains the alternating sequence glucosamine and uronic acid. The glucosamine can be either 
α-D-N-acetylated (NAc) or α-D-N-sulphated (NS). The uronic acid can be either β-D-glucuronic 
acid (GlcUA) or the modified α-L-iduronic acid (IdoUA). The glucosamino part of the chain can 
also be referred to as an aminosugar (Powell et al., 2004), but for the purpose of this report, to 
maintain continuity, it will be referred to as a glucosamine.  
There are a number of structures which fall under the GAG family name. The table below (Table 
1.1) shows the names and what they are composed of, thus distinguishing them from each other. 
Table 1.1 
GAG Uronic Acid Galactose Hexosamine 
HS/Hep GlcUA/IdoUA  GlcNAc 
CS GlcUA  GlcNAc 
DS GlcUA/IdoUA  GalNAc 
KS  Gal GalNAc 
 
Table 1. 1 Disaccharide content of five different GAG structures.  
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Keratin Sulphate (KS) is the only chain which contains a galactose unit instead of uronic acid, as 
seen in table 1.1. The subtle differences in these give rise to completely different properties 
amongst the five chains shown.  
Both HS/hep contain negatively charged groups but it is the extent of the modification which 
separates the two chains. Initial biosynthesis of HS/hep chains leads to the production of a non-
sulphated polymer known as heparin or N-acetylheparosan, consisting of: 
-Glc β1-4 GlcNAc α1-4- 
This structure (above), is then converted into N-sulphated derivatives (Gallagher and Walker, 
1985). Additionally to this, many of the disaccharides contain one or more O-sulphate 
substituents. These can occur on C2 of the IdoUA forming α-L iduronic acid 2-O-sulphate, C6 of 
the glucosamine forming α-D-N-sulpho-glucosamine 6-O-sulphate (GlcNS(6S)) and α-D-N-acetyl-
glucosamine 6-O-sulphate GlcNAc(6S)). These are covered in more detail in the section GAG 
biosynthesis-chain modification.  
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1.2 Heparan Sulphate vs. Heparin: A Brief History 
HS is a component found on the surface of all mammalian cells. It has been structurally 
maintained throughout evolution and the amount of variability comes from the amount of modified 
sequences found on the chain (Nader et al., 1999). HS is rarely seen as a free entity but as part 
of what is known as a proteoglycan (PG) where it is involved with a protein core (Rabenstein, 
2002). It is this protein core which anchors the chains to the surface of the cell. The GAG chains 
of HS are associated with a variety of core proteins, the most prominent one thought to be 
perlecan. Heparin on the other hand, is only found in a few tissues amongst a few species and is 
identified in the form of granules confined to connective tissue type mast cells. Heparin is only 
involved with one core protein – serglycin (Lindahl et al., 1994). Heparin was discovered in 1916 
and has been in clinical use as an anti-coagulant since the 1930’s. It is second only to insulin as a 
therapeutic agent (Rabenstein, 2002). HS was discovered as an impurity of heparin but was then 
discovered to be just as critical in its own right. It is biologically important in cell-cell recognition 
and the control of growth (Nader et al., 1999).  
In terms of structural features, the differences between HS and heparin are less easy to identify. 
This is due to the somewhat ‘incomplete’ biosynthetic modification pathway the two chains 
undergo. The modification reactions are incomplete and therefore only a very small fraction of the 
potential modification targets are attacked by enzymes (Lindahl et al., 1994). These modifications 
are the main reason why polymeric heparan is converted into HS (Gallagher and Walker, 1985). 
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1.3 Proteoglycans 
The term proteoglycan (PG) refers to the complex in which a protein is attached to one or more 
GAG side chains. They are specifically made of a core protein to which unbranched 
polysaccharides are attached, either HS/hep, CS/DS, KS and HA. The proteoglycans represent a 
family of glycoprotein’s which are highly glycosylated and can contain one or a number of GAG 
side chains. There are approximately 30 proteins which interact and are post-translationally 
modified as a PG. Below are those which are mostly associated with HS chains.  
 
1.3.1 Heparan sulphate proteoglycans (HSPG’s) 
Those proteins which are associated with HS are collectively known as HSPG’s. These can be 
classed in a number of categories, as summarised below: 
• The Syndecans – type I transmembrane proteins. 
• Glypicans – bound by a glycosylphosphatidylinositol (GPI) protein linkage to the cell 
membrane. 
• Perlecan and Collagen XVIII and Agrin – present in the extracellular matrix, especially 
secreted into basement membranes. 
Both the protein core and the GAG side chains play important roles in many biological processes 
such as control of growth, angiogenesis, differentiation, tissue repair and tumour metastasis. The 
HS chains are presented at the surface of the cell for potential ligand binding. The following 
section will discuss the four proteins which interact with HS to make a HSPG. 
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1.3.1.1 Syndecan  
The syndecan protein family is made up of four members termed syndecans 1 – 4 in mammals 
and vertebrate; and are classed as type I (alpha-helical) transmembrane proteoglycans. 
Syndecan 1 was the first in the family to be cloned and since then the three other members have 
also been cloned, including one type in each of the following; D. melanogaster, C. elegans and 
A. crassispina. The numbering system found in the naming of the syndecan family is due to the 
order in which the cDNAs for each family member were first cloned. These are single 
transmembrane domain proteins which act as co-receptors for G-protein coupled receptors 
Ligands which bind these are such like hormones, neurotransmitters and pheromones and act by 
activating a signal transduction pathway and ultimately a cellular response inside the cell. They 
are a large protein family of transmembrane receptors that sense molecules outside the cell and 
activate signal transduction pathways inside the cell. These proteins can carry between 3 - 5 
long, unbranched HS/CS chains which are able to interact with a variety of ligands and play 
important roles in cell-matrix and cell-cell adhesion. The protein cores are 20 - 45 kDa in size and 
contain small cytoplasmic domains. These domains are found to be highly conserved and the 
relatively small size of these domains suggests that they lack any kind of intrinsic activity 
(Couchman, 2003).   
Syndecans 1 and 3 and syndecans 2 and 4 comprise of separate subfamilies arising from gene 
duplication and divergent evolution from a single ancestral gene. All of the type I transmembrane 
domains consist of an N-terminal signal peptide of 3 - 60 amino acids long which directs the 
post-translational transport of a protein. The syndecans consist of an ectodomain which is found 
to extend into the extracellular space and initiates contact with surface to signal proteins (Figure 
1.1). It has several consensus sequences for GAG attachment, but this seems to be the only 
function of this domain (Carey, 1997). It also consists of a single hydrophobic transmembrane 
domain and a short C-terminal cytoplasmic domain, which is split into three sections. The first 
section of the cytoplasmic domain is the C1 domain which is a region of conserved sequence and 
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is found proximal to the cell membrane. This houses the actin associated cytoskeleton and is 
followed by the V domain which is the variable region of this cytoplasmic domain, and is specific 
in all syndecans. The variability here refers to the comparison of one syndecan within family 
members; meaning the functions are unique to each member of that particular family. The most 
distal part of the protein is the C2 domain which is another region of conserved sequence. It 
contains the PDZ protein which helps to anchor the protein to the cytoskeleton of another cell 
(Couchman, 2003). The attachment site found in syndecans 1 and 3 occur in two distinct clusters. 
These attachment sites mostly contain HS chains but can also include CS/DS GAG chains. The 
first is found near to the N-terminus and the other is found near to the membrane attachment site. 
These sites are separated by a proline and threonine rich ‘spacer’ region. There is a tetrapeptide 
sequence found at the end of the C-terminus which is identical in all of the syndecan family. 
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 Figure 1.1  
 
  
 
 
 
 
TM = the transmembrane domain 
C1, V and C2 = the cytoplasmic domain 
EYFA = amino acids glutamate, tyrosine, phenylalanine and alanine.  
 
Figure 1. 1 The extracellular domains of syndecan. 
Here the four syndecans consist of several extracellular domains for HS attachment. The HS 
chains from here then interact with enzymes and a variety of different growth factors (EGF, FGF, 
HGF and HBGF).  
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The C2 part of the cytoplasmic domain contains an EYFA sequence, which is where PDZ 
proteins mentioned above bind, such as CASK and syntenin.  
Each syndecan is presented on the surface of the cell and is presented at specific times in 
development processes. All syndecans are referred to as “full time” proteoglycans except for 
those which have yet to undergo post translational modification and they each perform different 
functions (Couchman, 2003): 
Syndecan 1: found in early development on cells associated with tissue morphogenesis. 
Syndecan 2: (fibroglycan) is distributed in mesenchymal tissues and is abundant in the liver and 
neuronal cells. 
Syndecan 3: (N-syndecan) is mostly found in neural tissue but can also be found in 
musculoskeletal tissue.  
Syndecan 4: (amphiglycan/ryudocan) found in development and many other cell types such as 
the liver and kidney (Kim et al., 1994).    
 
1.3.1.2 Glypicans 
The glypicans (GPC) are a protein family which are substituted to HS side chains to make a 
HSPG. They are anchored to the cell surface via a covalent linkage to 
glycosylphosphatidylinositol (GPI) lipid anchor (De Cat and David, 2001). The GPI anchor is 
made up of a phosphatidylinositol group linked through a carbohydrate containing linker to the 
C-terminal amino acid of a mature protein (Figure 1.2). The size of the glypican core protein is 
between 60 - 70 kDa. They all display an N-terminal secretary signal peptide and a hydrophobic 
domain which is required for the addition of the GPI anchor to the C-terminus. This is involved in 
the formation of the GPI structure. The homology amongst most glypicans is moderate but there 
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is a positioning of 14 cysteine residues contained in a globular domain which are very highly 
conserved. This suggests the three-dimensional structure is very similar in all the glypicans 
(Filmus and Selleck, 2001). The positioning of the HS chains is a shared characteristic amongst 
all glypicans. Here the insertion site is restricted to the last 50 amino acids in the C-terminus. It is 
this GAG attachment site which is extended further than any of the other domains which places 
the HS chains close to the cell membrane, allowing for interactions with proteins close to the 
surface of the cell (De Cat and David, 2001).  
There are six members of the glypicans family identified so far in vertebrates named glypicans 
1 - 6 (Perrimon and Bernfield, 2000). Two have also been identified in D. melanogaster and one 
in C. elegans. Their role is to modify cell signalling pathways and to contribute to cellular 
proliferation and tissue growth. There has also been evidence linking glypicans with tumour 
progression (Filmus and Selleck, 2001). GPC-1 has been found to be expressed in significantly 
higher amounts in pancreatic cancer. It also inhibits the mitogenic response of cultured pancreatic 
cells to FGF2 and heparin-binding EGF-like growth factors. The mechanism by which this occurs 
still remains unclear.  
The sequence homology of the glypican core protein is 17-63% identical and it is at its highest 
level of similarity in the N-terminal domain. When the individual structures are compared in 
glypicans from different vertebrate species the homology is around 90% (De Cat and David, 
2001).   
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Figure 1.2 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 2 GPI anchor of a glypican core protein attached to the plasma membrane. 
The glypican protein is covalently linked to the plasma membrane of the cell by the C-terminal 
end via a GPI anchor. The presence of the disulphide bridges provides strength to the highly 
compact structure.  
 
GPI anchor 
Ethanolamine 
Glycan 
Phosphate 
 
 
  
Inositol 
C-terminal Glypican 
Phosphate 
Chapter 1: Introduction 
 12 
The disulfide bridges found in the core protein are there to give the structure the highly compact 
globular domain. The GAG side chains are attached to the protein core by the specific serine 
molecules found in the linker tetrasaccharide (Figure 1.2). The protein is attached to the plasma 
membrane at its carboxyterminus via the GPI anchor which is shown in the diagram below 
(Figure 1.3). 
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 Figure 1.3 
 
 
 
Adapted from (De Cat and David, 2001) 
 
Figure 1.3 GAG attachment to the core protein glypican. 
The GAG chains are linked to the protein via specific serine residues found in the linker 
tetrasaccharide. Here X can be classed as any other amino acid. 
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1.3.1.3 Perlecan  
Perlecan is a large HSPG which is expressed as an intrinsic constituent of basement 
membranes; as well as cell surface and peri-cellular proteoglycans (Mongiat et al., 2000). It is 
secreted into basement membranes and binds to and cross-links many extracellular matrix and 
cell surface molecules (Perrimon and Bernfield, 2000). Perlecan is thought to be the largest 
single chain polypeptide found in both vertebrates and invertebrate animals (Iozzo, 2005). It is 
synthesised by vascular endothelial and smooth muscle cells which are then deposited in the 
extracellular matrix. It has high affinity interactions with the Intergrin family of proteins and is 
involved in a number of pathological processes. It has evolved from ancient ancestry by gene 
duplication and exon shuffling and is therefore very highly conserved. Perlecan is made of a 
400 - 470 kDa core protein (Iozzo et al., 1994) to which numerous O-linked oligosaccharides and 
up to four HS chains of 70 - 100 kDa can be attached, making the molecular weight of this protein 
in excess of 800 kDa (Iozzo, 2005). Antibodies for perlecan identify just one single precursor 
product suggesting it is encoded by one single gene (Iozzo et al., 1994). One gene identified in D. 
melanogaster and C.elegans shows this PG has evolved from ancestors by exon shuffling and 
gene duplication (Friedrich et al., 1999). The core protein comprises of five distinct structural 
domains (Figure 1.4).  
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Figure 1.4 
  
 
 
 
 
 
Figure 1.4  The domain structure of Perlecan. 
The structure of perlecan is made up of five domains with a molecular mass of 470 kDa. In each 
domain exists a number of repeats, with the HS binding sites identified only in the first of the five 
domains.  
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The protein core is made up of a ‘collage’ of proteins and repeats which are shared by several 
ECM proteins involved in the uptake of nutrients and cell control. A major feature of perlecan is 
the presence of many internal repeats and the assortment of protein domains it is made up of. 
The different domains are involved in a variety of functions similar to other known 
polysaccharides including cellular growth, binding and the delivery of nutrients and lipids and 
many signalling pathways (Iozzo et al., 1994). The domains run from the N-terminus to the C-
terminus as shown in the above diagram. (Figure 1.4) 
Domain I: This domain is unique to perlecan and is the proposed site for GAG chain attachments. 
Specific sites have been found on heparin sulphate (Noonan and Hassell, 1993). This end of the 
structure is known as the N-terminus and begins with a signal peptide, followed by a small 
domain of amino acids containing the three ser-gly-asp (SGD consensus sequence) tripeptides 
(or triplets). This section is 172 amino acids in length and the SGD consensus sequences are the 
predicted attachment sites for HS chains (Noonan and Hassell, 1993; Iozzo, et al., 1994). The 
SGD sequence has shared features with other glycosylated sites found in other proteoglycans 
containing HS chains. What makes it different from other domains is the lack of any repeats and 
the lack of cysteine residues. It has an abundance of amino acids in the domain which is quite an 
unusual feature (Iozzo et al., 1994). This domain also contains an SEA module which has 
homology for sperm, enterokinase and agrin and it is this section of the domain which favours 
glycosylation (Iozzo, 2005).   
Domain II: This is made up of four repeats which are homologous to the LDL binding domain 
present in the LDL receptor gene (Noonan and Hassell, 1993). It contains four motifs which are 
cysteine rich and are found in a number of binding molecules (Iozzo et al., 1994). These are then 
followed by immunoglobulin (Ig) -like repeats (Iozzo, 2005). The LDL repeats are receptor class A 
repeats and are organized in a similar fashion to the LDL receptor. The first two of the four 
repeats are encoded by one exon of near identical size to that in the LDL receptor. The other 
repeats are encoded by a highly conserved exon. These exons are all interrupted by phase I 
introns which allows for the possibility of alternate splicing (Iozzo et al., 1994).  
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Domain III: Here the domain is made up of several different repeats, the first being homologous to 
internal globule rod-like regions found in laminin, particularly the laminin A chain (Noonan and 
Hassell, 1993; Iozzo et al., 1994). These are globular domains which are flanked on either side by 
nine laminin endothelial growth factor (EGF) repeats. These repeats interrupt the globular 
domains (Iozzo, 2005). The segments homologous to the EGF repeats are made up of a series of 
repeats, typically eight highly conserved cysteine residues and two glycine residues (Iozzo et al., 
1994). 
Domain IV: This has a similarity to the immunoglobulin super family and to N-CAM (neural cell 
adhesion protein), (Noonan and Hassell, 1993; Iozzo, 2005). This domain is the largest in human 
perlecan and contains 21 consecutive repeats of Ig-like repeats and is over 200 kDa in size. 
Mouse and the nematode worm have only 14 Ig-like repeats. 40 exons encode this region with an 
amino acid sequence of 70 - 100 residues. This part of the structure has three potential roles: 
• To stabilize protein-protein interactions. 
• To promote dimerization of molecules within the basement membrane. 
• To enhance adhesion of neighbouring cells carrying perlecan at the cell surface. 
(Iozzo et al., 1994) 
One N-CAM repeat separates domains two and three from each other and is 90% conserved with 
the same repeat found in mice (Noonan and Hassell, 1993).  
Domain V: The C-terminal end is encoded by 16 exons which encode three globular repeats 
which are very similar to domain G repeats found in the laminin A chain (Iozzo et al., 1994); 
(Noonan and Hassell, 1993). These are separated by two lots of two repeats of EGF-like repeats 
which are found to be cysteine rich (Noonan and Hassell, 1993). These EGF-like repeats are 
made of 40 amino acids and several glycine residues which are involved in the folding of this 
region (Iozzo et al., 1994). Also found in this domain (not shown in the diagram) is another 
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potential binding site for GAG chains, which consist of two SGXG tetrapeptides. These may be 
substituted for other GAG chains, not just HS chains.  
Perlecan is involved in many developmental processes at early and late stage embryogenesis. It 
also plays important roles in many cancers, such as breast carcinoma, colorectal carcinomas and 
cutaneous melanoma where increased amounts of perlecan are present. It binds to specific 
growth factors promoting activation and mitogenesis. It specifically binds to FGF2 forming a 
complex, causing blood vessel formation at higher rates than the HS-FGF complex. When 
suppressed it blocks autocrine and paracrine activities between FGF2 and human melanoma 
cells (Mongiat et al., 2000). This results in the decrease in cell proliferation and the invasion into 
other tissues.  
 The many repeated domains, structures and modular proteins indicate this protein is involved 
with binding to, and the delivering of nutrients and lipids. It is also involved in many signalling 
pathways and cellular growth (Iozzo et al., 1994). It is expressed in a variety of tissues, 
specifically by the sinusoidal epithelial cells found in the liver, but it is not expressed by the 
hepatocytes in the liver. This changes when the cells are cultured in vitro and they gain the ability 
to express perlecan. Surprisingly, it is found in normal articular cartilage, which is a type of tissue 
that does not contain blood vessels, and therefore does not contain a basement membrane. How 
the expression in this kind of tissue could well be due to the perlecan protein escaping the post-
translational modification step. This is the process in which HS chains are added onto the protein. 
These would then be released as a glycoprotein leading to a different role for the protein (Iozzo et 
al., 1994). 
This information leads to the conclusion that perlecan is more abundant than was previously 
thought. It is not just restricted to epithelial surfaces; and the quantitative and qualitative 
expression is highly specific. Under certain conditions it can escape the modification process, 
allowing for it to have a different role. 
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1.3.1.4 Collagen XVIII/Endostatin 
Collagen XVIII is a protein belonging to the sub family designated the multiplexins (multiple triple-
helix domains and interruptions). It is a constituent of almost all embryonic and adult basal lamina 
(Halfter et al., 1998). Collagen XV is also a member of this family and these are classed 
differently to other collagen proteins; where the domain structure is very much different to other 
collagen proteins (Zatterstrom et al., 2000). It is a component of the basement membrane and is 
quite unique in that it has structural properties of both collagen and a proteoglycan (Marneros and 
Olsen, 2005). Collagen XVIII along with collagen IV are the only members of the collagen family 
that are conserved from D. melanogaster to C. elegans to humans and so suggests an important 
role of the protein in evolution (Dong et al., 2003). Collagen XVIII is the third basal lamina HSPG, 
after perlecan and agrin, and is the first of the collagen family to contain HS chains which 
determine it as a HSPG (Halfter et al., 1998). It also has the characteristics of a HSPG, in that it is 
a long heparitinase sensitive carbohydrate chain which is highly negatively charged.  
Collagen XVIII is made up of 10 collagenous (COL) domains or repeats which are flanked on 
either side and interrupted by non-collagenous (NC) domains (Halfter et al., 1998; Marneros and 
Olsen, 2005). It is structurally rigid, inextensible, and is made of a large triple-helical region, which 
the collagenous domains are found. The non-collagenous domains introduce flexibility into the 
structure between these helical regions (Zatterstrom et al., 2000). It has typical features as a 
member of the collagen family existing as a non-covalently linked oligomer under non-denaturing 
conditions and the core protein of collagen XVIII is sensitive to enzymatic digestion (Halfter et al., 
1998). The NC domains contain the Ser-Gly (SG) sequences which are the attachment sites for 
the GAG chains (Zatterstrom et al., 2000). These are similar to the SGD consensus sequences 
identified in perlecan, just without the presence of aspartic acid. The presence of a number of 
amino acids either before or after the SG sequences promotes the attachment of the GAG 
chains. There are eight potential GAG sites with three of them confirmed as carrying GAG’s; thus 
confirming the protein as a PG (Dong et al., 2003). Western blot studies of intact chick collagen 
XVIII carried out with chondroitinase had no affect and resulted in no shift in molecular weight, 
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which would suggest that the GAG chains present are not CS. The same study was carried out 
with the use of heparitinase and lead to the reduction in size of the protein from 300 kDa to 180 
kDa showing that the GAG chains are in fact HS chains. Treatment with collagenase reduced the 
protein to nothing (Halfter et al., 1998).  
The GAG attachment sites were found using the following criteria: 
• Peptides containing GAG’s run on SDS-PAGE shown as a smear rather then a clear 
band. 
• The digestion of heparitinase or chondroitinase results in a major drop in molecular 
weight; this can clearly be seen in PAGE. 
• GAG-glycosylated peptides bind to anion exchange beads. Elution involves the use of 
NaCl greater then 1M.  
 
The C-terminal part of the protein is the most conserved region, known as NC1. This part of the 
protein contains an 18 kDa peptide which has been shown to have anti-angiogenic properties and 
is known as Endostatin. This also has tumour suppressing activity (Halfter et al., 1998). It was 
first identified as an endogenous angiogenic inhibitor and was derived from a larger protein 
isolated from conditioned media from a murine endothelial tumour cell line. The Endostatin 
peptide is released from collagen XVIII by proteolysis (Figure 1.5). This releases the NC1 
terminal as a whole, which consists of three major segments: a 5 kDa N-terminal trimerization 
domain, a central protease sensitive hinge region and the endostatin domain (Zatterstrom et al., 
2000). The role of endostatin has evolved as a sensor for the release of proteolytic activities 
associated with angiogenesis. It also acts as a negative control by releasing angiogenic 
fragments. However, the role of endostatin is not thought to play a major role in angiogenesis, but 
is just one component of many which acts as a balance between pro and anti-angiogenic 
regulators (Marneros and Olsen, 2005).  
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Figure 1.5 
 
Figure 1.5 The release of the endostatin peptide from collagen XVIII.  
The endostatin fragment is released from the C-terminal domain of collagen XVIII via proteolytic 
cleavage. It is the only known collagen that carries HS chains.  
132 - 315 
60 10 
Protease sensitive 
hinge region 
Endostatin 
released 
fragment 
Inhibition of angiogenesis 
Proteolytic 
enzymes 
Endothelial 
cells 
Triple 
helical 
domains 
Trimerization 
region 
Chapter 1: Introduction 
 22 
Collagen XVIII has been shown to play a critical role in the maintenance of ocular structures 
identified in Knobloch syndrome. This is an autosomal recessive disorder which is characterised 
by macular degeneration, high myopia and many other abnormalities. These lead to blindness at 
a very young age in patients with this condition. These results come from studies from a Brazilian 
family who showed a homozygous mutation in one particular gene; COL18A1. This has a 
particular mutation in the AG sequence of the gene. This affects the short form of collagen and 
not the long isoform, (collagen is made up of both long and short isoforms) the short form being 
identified in all vascular and epithelial basement membranes and the long isoform in the liver. 
This seems to suggest a requirement for collagen XVIII in the eye (Marneros and Olsen, 2005).   
 
 
1.3.1.5 Agrin  
The HSPG agrin is a 220 kDa protein of basement membranes which is highly concentrated in 
nervous tissue, the brain (Tsen et al., 1995), and in the synaptic basal lamina at the 
neuromuscular junction. Agrin is a large, multidomain PG composed of domains which are 
homologous to others found in other ECM components. The agrin gene has been shown to 
encode multiple isoforms of the protein, through alternative splicing at three different sites in the 
gene. These spliced variants lead to different roles for the proposed protein (Groffen et al., 2001). 
The use of SDS-PAGE gives a diffused band at around 400 kDa and after treatment with 
heparitinase or nitrous acid the band shifts to 220-250 kDa confirming that this is in fact a 
heparan sulphate proteoglycan (Tsen et al., 1995). 
The domain structure is composed of an N-terminal found in domain I, which comprises of a 
laminin binding domain and a signal peptide. This is known as the NtA domain (Denzer et al., 
1998) (Figure 1.6). Domain II then contains nine follistatin-like (FS) domains and within these the 
first potential binding site for GAG attachment is identified. The FS domains share homology to 
Kazal-type protease inhibitors, these include follistatin, elastase inhibitors and pancreatic trypsin 
to name a few (Groffen et al., 2001). Two laminin (LF) EGF repeats separate FS nine from the 
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other repeats (Winzen et al., 2003). Also in domain II, based in the central part of the domain are 
two serine/threonine (ST) rich domains. These have extremely high levels of serine, threonine 
and proline (Groffen et al., 2001). The second of the potential GAG sites is found on the first of 
the ST domains. These adopt a rod-like shape and are extensively O-linked glycosylated which 
gives them an elongated, flexible structure and this is encoded by 365 amino acids (Denzer et al., 
1998). The two ST regions are interrupted by an SEA module which is also thought to be heavily 
involved in O-glycosylation. This module is found in sperm protein, enterokinase, agrin and 
perlecan. The final part of the domain is the EGF-like repeats. Domain III, IV and V each contain 
a laminin G-like domain which are separated by four EGF-like domains. In III and V there are 
alternatively spliced sites known as spliced sites X and Y. Another of these sites is found between 
the SEA module and the second ST site found in domain II. This has been designated as spliced 
site X. These variations lead to functions which differ greatly (Groffen et al., 2001).  
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Figure 1.6 
 
 
 
 
Figure 1. 6 The domain structure of Agrin.  
 
Like perlecan, agrin comprises five domains each of which consist of many repeats. It is a 220 
kDa protein found in basement membranes. This figure has been adapted from Groffen et al 
(Groffen et al., 2001). 
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The first of the two HS attachment sites located in domain II between the seventh and eighth FS 
domains contains three SG sequences. The second site found in domain II is more centrally 
located in the ST rich domain and this contains four SG sequences (Winzen et al., 2003).  
Agrin is known to play an important role in the organization of the neuromuscular junction during 
embryonic development (Winzen et al., 2003). Studies have shown agrin mediates the induction 
of AchR (acetylcholine receptors) clustering around the neuromuscular junction. This process is 
inhibited by the action of Hep/HS, showing that this protein interacts with GAG chains at the cell 
surface (Halfter et al., 1998). The elimination of agrin in studies on mice leads to neonatal death 
due to the inability of the mouse to breathe (Winzen et al., 2003). There is a high presence of 
agrin transcription in the human lung and kidney. Lung localization was confined primarily to 
capillary and alveolar basement membranes (BM), where as in the kidney it is confined to the 
glomerular BM but has also been found in tubular BM’s (Groffen et al., 2001). 
An unusual role for agrin is as a major component in senile plaques found in patients who suffer 
with dementia (particularly Alzheimer’s). Agrin interacts with an amylodogenic peptide Aβ, found 
in a fibril state. This action is GAG dependant and this process accelerates the formation of Aβ 
fibrils. The presence of the HS chains possibly shield agrin from the action of proteolysis meaning 
that these senile plaques remain for a longer period of time in the body (Winzen et al., 2003).  
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1.4 GAG biosynthesis 
Structural diversity of all GAG’s is generated in the Golgi apparatus of each and every cell and 
this is where each GAG chain undergoes biosynthesis. Chain biosynthesis occurs in three 
different phases, each one playing a major role in the biosynthesis of proteoglycans. The three 
steps involved are:  
• Chain Initiation 
• Polymerization 
• Polymer Modification 
The high complexity found in the structure of all GAG chains depends highly on the regulated 
expression of multiple enzymes, leading to a set of biosynthetic reactions which allows for the 
backbone of the polysaccharide to be modified (Wei et al., 1993). These enzymes include 
sulphotransferases, glycosyltransferases and an epimerase which are found in the lumen of the 
Golgi apparatus. Another set of enzymes, the cytoplasmic enzymes are needed to transfer the 
nucleotide sugars to the forming chain. For this to occur, membrane transporters are required to 
transport these nucleotides from the cytosol to the lumen of the Golgi apparatus. Many of the 
sugars and sulphates needed are activated by nucleotide consumption in the cytosol of the Golgi 
apparatus to form their specific UDP-sugars. All of these reactions require the need of a sulphate 
donor in the form of 3’-phosphoadenosine 5’-phosphosulphate (PAPS) (Salmivirta et al., 1996). 
These are then transported into the endoplasmic reticulum (ER) and the Golgi lumen. The 
presence of PAPS is essential as it is the only sulphur donor to all of the sulphotransferase 
enzymes (Prydz and Dalen, 2000), thus allowing this process to continue.  
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1.4.1 Chain initiation 
The determining step in the process of chain initiation is the presence of an O-serine residue. 
This is the start of what is known as the common GAG-protein linker region for all GAG species 
(Gallagher and Turnbull, 1992; Kim et al., 2001). To this O-serine is the addition of a Xylose 
molecule which is added to the hydroxyl group of the O-Serine by the action of the UDP-Xylo-
transferase enzyme (xylT). Two D-galactose monosaccharides are added to this. The first being 
added by the enzyme UDP-Gal transferase I and the latter with the UDP-Gal transferase II 
enzyme (Carey, 1997). The final step in the initial biosynthesis of this GAG - protein linkage 
region is the addition of a D - Glucuronic acid residue by the enzyme UDP - GlcA transferase I. 
This reaction is catalyzed by the transfer of the glucuronic acid from the UDP - GlcA transferase I 
onto the O-3 of the terminal gal 2 (Figure 1.7). This occurs with an attack by the 3-hydroxyl group 
on the growing chain on the glucuronic acid at the C-1 position (Pedersen et al., 2000). It is at this 
point in the chain that the GAG and its specific proteins are covalently attached to each other 
(Perrimon and Bernfield, 2000; Prydz and Dalen, 2000). Here the linker region serves as an 
acceptor for the first of the monosaccharide units to be attached which will commit the process 
towards the outcome of either a galactosaminoglycan chain or a glucosaminoglycan chain 
(Salmivirta et al., 1996). The formation of the linker tetrasaccharide is thought to occur either in 
the lumen of the Golgi apparatus, or slightly earlier in the secretary pathway. It is thought that in 
chicken (Gallus gallus domesticus), chondrocytes xylosylation appears to occur in a pre-Golgi 
compartment of the cell in the ER and then this process continues into the Golgi apparatus thus 
allowing for galactose, glucuronic acid and sulphate groups to be added (Vertel et al., 1993).  
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Figure 1.7  
 
 
Figure 1. 7 Initial GAG biosynthesis for all GAG structure – The GAG-Protein linker region.  
 
The biosynthesis of HS and CD/DS diverge after the formation of this GAG-Protein linker region. 
The four enzymes shown are solely responsible for the formation of this region with the next 
addition determining the generation of the GAG chain. This has been adapted from Sugahara and 
Kitagawa, (Sugahara and Kitawaga, 2000).  
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The pathways for HS and CS/DS biosynthesis diverge after the formation of a common core 
protein linkage tetrasaccharide (see text). Four separate enzymes XylT, GalT-I, GalT-II and 
GlcAT-I are responsible for the formation of this tetrasaccharide. The next enzyme to act either 
GlcNAcT-I or GalNAcT-I directs synthesis to HS/heparin or CS/DS (see text).  
Once the GAG-protein linker region has been synthesised, the next addition determines which 
generation of chain it is to become; a HS/heparin chain (glucosaminoglycan) or a CS/DS chain 
(galactosaminoglycan). The following determines the steps for the biosynthesis of the GAG 
chains, discussing firstly the polymerization of HS/Hep, followed by CS/DS polymerization.  
 
1.4.2 HS/Hep Chain Polymerization 
Chain polymerization continues with the addition of an α - GlcNAc by the enzyme α - GlcNAc 
transferase I (Kim et al., 2001). Once this specific addition has been made, the chain is then 
classed as a HS/Hep chain. The same enzyme can also add GalNAc, which is the defining unit in 
the biosynthesis of the CS/DS chain pathway. The α - GlcNAc transferase I enzyme belongs to 
the family of enzymes known as hexosaminyl-transferases (Salmivirta et al., 1996). This enzyme 
also goes by the name of EXTL2. This is a member of the exostosin family (EXT); which are a 
family of tumour suppressor genes. EXTL1 - 3 all have high homology to the EXT family. EXTL2 
exhibits activity which will transfer only the first of the α,1 - 4 GlcNAc residues (Kim et al., 2001).  
Following on from this is the stepwise addition of two alternating monosaccharides, starting with 
GlcUA and then GlcNAc by the action of EXT1 and EXT2 respectively. They are transferred from 
their UDP - sugar nucleotide and are added to the non-reducing end of the forming chain 
(Salmivirta et al., 1996; Esko and Lindhahl, 2001). EXT1 and EXT2 are known as HS 
polymerases and act as a copolymer exhibiting dual catalytic activities (Merry and Wilson, 2002). 
They act by elongating the HS chain by the alternative addition of both GlcUA and GlcNAc to the 
HS/Hep backbone (Kim et al., 2001). It is thought that the GlcNAc/GalNAc which are added onto 
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the elongating chain are different from those added onto the GAG-protein linker region of the 
chain (Salmivirta et al., 1996). These enzymes mentioned above catalyze these reactions and 
execute this role with incredibly high substrate specificity. The role of the HS polymerases can 
add in the region of 50 - 200 sugar units to the growing chain (Merry and Wilson 2002). Human 
EXT2 has been found to have a high sequence homology to human EXT1 (31% identity, 69.5% 
similarity), (Sugahara and Kitagawa, 2000). The EXT1 and EXT2 proteins join together to form a 
hetero-oligomeric complex leading to the accumulation of both of these proteins in the Golgi 
apparatus (Lamanna et al., 2007). This complex contains both the GalNAc and GlcA transferase 
enzymes also known as HS polymerase. The enzyme complex contains two independent 
domains, one of which is able to transfer the hexosamine unit to the growing chain and the other 
domain adds the hexuronic part (Kolset, et al., 2004).  
The specificities of the EXT family 1 - 3 overlap amongst the family members but they still have a 
distinct role from each other (Kim et al., 2001). EXTL3 is thought to have a role which is similar to 
EXTL2; in that it too transfers the first GlcNAc residue which initiates HS/Hep chains. It is 
possible that although these both have the same role they will act on different core proteins which 
contain HS chains. This would take place because the enzymes would be able to discriminate 
between the different amino acid sequences found in front of the binding sites (the SG consensus 
sequence) (Kim et al., 2001). 
 HME (hereditary multiple exostosis), also known as HMO (hereditary multiple osteochondromas), 
is an autosomal dominant disorder which is characterized by benign cartilage-capped skeletal 
excrescences (bone tumours). This is found around areas of active bone growth leading to 
skeletal abnormalities. A genetic linkage of this disorder has been identified on three independent 
loci on chromosomes 8q24.1 (EXT1), 11p11-12 (EXT2) and also 19p (EXT3). The exostoses are 
characteristically benign bone tumours, however 2% of HME patients have been found to develop 
malignant transformations into chondrosarcoma or osteosarcoma (Sugaya et al., 2008). This 
indicates that these genes responsible for HME may well encode tumour suppressor genes.  
Chapter 1: Introduction 
 31 
1.4.3 HS/Hep Chain Modifications 
As chain polymerization occurs, chain modification takes place. Initially the polymer undergoes 
N - deacetylation/N-sulphation to create N-sulphated products. All N-acetyl-D-glucosamine 
residues (GlcNAc) will need to undergo the action of N - deacetylase in order for N - sulphation 
reactions to take place (Wei et al., 1993). Only selected GlcNAc residues will go through the 
modification process, thought to be in the region of 40-50% of those residues (Merry and Wilson, 
2002). This action occurs by the Golgi enzyme glucosaminyl N-deacetylase/N-sulphotransferase 
(the NDST’s) (Perrimon and Bernfield, 2000). All sulphotransferases require PAPS to be the 
donor for all sulphate groups (Salmivirta et al., 1996; Kakuta et al., 1999). However; it should be 
noted that the presence of PAPS is not a requirement for N-acetylase activity as shown by Wei et 
al (Wei et al., 1993). They were also able to show that the activity of the NDST’s is compromised 
by the presence of NaCl with the loss of 90% activity at physiological conditions. The NDST 
enzymes contain the active sites for both N-deacetylation and N-sulphation. Currently there are 
four NDST’s which have been identified and in vitro studies suggest that each enzyme catalyzes 
the same reaction just in a different chemical context. The analysis of the four enzymes show a 
large overlapping distribution of two of the four enzymes, NDST isoforms 1 and 2 (Pikas et al., 
2000). This is indicative that both isoforms are needed and both play a role in HS modification. 
The occurrences of multiple isoforms are the products of different genes or spliced variants of the 
same gene.  
 The action of the NDST enzymes result in modified residues from the original GlcNAc residue. 
The enzymes replace the N - bound acetyl group found on this residue and replaces it with a 
sulphate group (Lindahl et al., 1998). The possible outcomes of this are: 
GlcNAc  GlcNAc – some residues will remain unmodified and are referred to as 
unmodified domains (see section on Domain structure). 
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GlcN – the residue is N - deacetylated but is not N-sulphated (thought to 
be very rare) 
GlcNS – the residue is N - deacetylated with the removal of the acetyl 
group and is then N - sulphated.  
The addition of these sulphates can alter the functional specificity and diversity of HS (Kakuta et 
al., 1999). 
The GlcN residues are more varied in HS than in heparin, of which they are predominantly 
N-sulphated. In HS the chain shows a more varied pattern with appreciable proportions of 
N-acetylated and N-sulphated residues and a very small amount of N-unsubstituted GlcN units 
(Lindahl et al., 1998). Ultimately it is the NDST’s which have a key role in the determination of the 
final structure of the polysaccharide chain (Ringvall et al., 2000).  
The N-deacetylation/N-sulphation step is a prerequisite for GlcUA to be converted to IdoUA by 
the enzyme GlcA (Glucuronyl) C5 epimerase. This is sometimes also referred to as Uronosyl C5 
epimerase, but for the purpose of this report it will be referred to as the former. The epimerase 
converts GlcUA residues into IdoUA and are typically found in the Golgi apparatus (Pinhal et al., 
2001). This epimerase belongs to a family of enzymes known collectively as isomerases. These 
catalyze the stereochemical inversion of the configuration about an asymmetric carbon atom in a 
substrate which has more than one centre of asymmetry. This involves the abstraction and re-
addition of the C5 proton onto the pyranose ring via a carbanion intermediate (Figure 1.8). This 
results in an inversion of configuration so that the carboxy group is shifted across the plane of the 
pyranose ring. This reaction is freely reversible in a solubilised enzyme system in the presence of 
3H2O and will result in the incorporation of 
3H into both of the HexA units in the chain. The work 
carried out by Hager-McWhirter et al (Hager-McWhirter et al., 2000) shows the reversible reaction 
with regards to two different substrates: N - sulphated K5 polysaccharide (which contains only 
GlcA components) and O-desulphated heparin (predominantly made up of IdoUA components). 
After incubation with C5 epimerase with increasing amounts of time, the polysaccharides were 
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then recovered and subjected to nitrous acid. Results from the N - sulphated K5 polysaccharide 
showed that the proportion of IdoUA units reached a maximum level after approximately 1 hour. 
This maximum level did not increase further regardless of the amount of time left to incubate with 
the addition of fresh enzyme to the reaction. The opposite effect was shown with the O-
desulphated heparin polysaccharide. Here an excess of IdoUA decreased over time due to the 
action of the epimerase. Equilibrium was once again reached after approximately 1 hour. It was 
also shown that the action of the epimerase did not have an effect on any HexA units located 
adjacent to any 6-O-sulphate glucosamine. 
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Figure 1.8 Basic mechanism for the C-5 epimerization reaction 
 
The figure gives a step by step process of the conversion of the GlcUA to IdoUA with the use of 
the enzyme C5 epimerase. This figure has been adapted from Hagner-McWhirter et al (Hagner-
McWhirter et al., 2000) 
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A glucuronic acid residue is likely to be a substrate for D-glucuronosyl 5-epimerase if it is located 
between two N - sulphated glucosamine residues as shown below: 
GlcNS – GlcUA – GlcNS    GlcNS – IdoUA – GlcNS 
(Jacobsson et al., 1984; Salmivirta et al., 1996) 
 
The role of the epimerase is to introduce flexibility into the GAG chain (the IdoUA residues are 
highly flexible, see Structural Conformation), (Prydz and Dalen, 2000). The epimerization reaction 
is thought to be a freely reversible reaction and is also thought to be promoted by the presence of 
an O-sulphate group found on the C2 position of an IdoUA residue (Lindahl et al., 1998). This 
process produces the most common abundant unit found in HS/Hep chains, the IdoUA residue 
(Salmivirta et al., 1996). Studies undertaken by Pinhal et al (Pinhal et al., 2001), suggest that C5 
epimerase and 2-O-sulphotransferase form a complex and so therefore may work in co-operation 
with each other.  
The final step in chain modification is the addition of sulphate groups carried out by the 
O-sulphotransferases. These catalyze the transfer of sulphate groups to various sites in the HS 
chain from a donor molecule, the most common one being 3’-phosphoadenosine 
5’-phosphosulphate (PAPS). O - Sulphation can then take place, specifically at the C2 position of 
the IdoUA and the C6 position of both the IdoUA and all glucosamine structures (Merry et al., 
1999; Kreuger et al., 2006). In rare cases O - sulphation also occurs at the C3 position of the 
glucosamines (Stringer and Gallagher, 1997; Sasisekharan and Venkataraman, 2000).  
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1.4.3.1 2-O-Sulphotransferase 
Heparan sulphate 2-O-Sulphotransferase (HS2ST) is a critical enzyme which is responsible for 
the biosynthesis of HS (Merry and Wilson, 2002). Its role is to catalyze the transfer of sulphate 
groups from the molecule PAPS to the C2 position on the L-iduronic acid (IdoUA), (Kobayashi et 
al., 1997). This enzyme produces 2-sulphated L-iduronic acid (IdoUA(2S)) which is a universal 
component in HS chains. It is found in varying amounts throughout the chain. This enzyme 
predominantly acts on IdoUA and so is generally only thought to act in the S-domain region of the 
chain (Merry and Wilson, 2002). HS2ST is thought to play an important role in HS degradation 
(Habuchi, 2000), and is known to share a common subunit with the 6-O-sulphotransferase 
(Kobayashi et al., 1997). This could be a possibility when considering the following structure: 
IdoUA(2S) – GlcNS(6S) 
This could be synthesised by both enzymes, with the HS2ST acting on the substrate first followed 
by HS6ST (6-O-sulphotransferase) (Habuchi et al., 2000). It has also been shown that, if there is 
a loss of HS2ST leading to an overall decrease in charge on the HS chain; there is an increase in 
the expression of both N and 6-O-sulphotransferase (Figure 1.9). This leads to more of a balance 
in charge on the whole chain. This is generally found in the S-domain region of the chain (Merry 
and Wilson, 2002).  
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Unmodified domains 
 
 
S - Domains 
2-O-Sulphotransferase 
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Figure 1.9 
 
 
 
 
 
 
 
 
 
Figure 1. 9 Composition of S-domains with and without 2-O-sulphotransferase. 
A crude example of the difference in structure between the unmodified domains and those which 
undergo structural modification.  
 
Panel A. Both HS2ST and HS6ST enzymes have acted on the substrate giving it a variety of 
sulphate groups. 
Panel B. A loss of 2-O-sulphotransferase has lead to an increase in 6-O-sulphotransferase and 
also N-sulphotransferase (not shown).  
A. 
B. 
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1.4.3.2 6-O-Sulphotransferase 
Heparan sulphate 6-O-sulphotransferase (HS6ST) catalyzes the transfer of a sulphate group from 
3’ - phosphoadenyl sulphate to the C6 position of a glucosamine (Habuchi et al., 2000; Habuchi, 
2000).  This is one of the key enzymes in the formation of HS domain structure (see Domain 
structure). There is a similarity between human and mouse HS6ST; with mouse HS6ST having 
three isoforms. The enzyme found in D. melanogaster has similar structural features to that found 
in vertebrates, but there is only one isoform dHS6ST. There is also only one isoform found in C. 
elegans (Kamimura et al., 2001). HS6ST-1 has been shown to transfer sulphate groups to GlcNS 
units in the disaccharide sequence: 
IdoUA – GlcNS  
(Nakato and Kimata, 2002; Sedita et al., 2004). 
This study also showed that the HS6ST-2 isoform will transfer sulphate groups to different 
substrates at different concentrations:  
GlcUA – GlcNS (at high concentrations) 
IdoUA – GlcNS (at low concentrations)  
(Sedita et al., 2004). 
The third isoform HS6ST-3 acts on both substrates (Habuchi et al., 2000; Nakato and Kimata, 
2002; Sedita et al., 2004). However, it is thought that if a GlcNS residue is flanked on either side 
by IdoUA(2S) giving a structure of: 
IdoUA(2S) – GlcNS – IdoUA(2S) 
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then this may escape modification (Salmivirta et al., 1996), possibly due to the already heavily 
modified residues flanking each side of the GlcNS residue. Other studies by (Sedita et al., 2004) 
have shown that 6 - O-sulphation occurs on specific sequences such as: 
IdoUA – GlcNAc 
HexA – GlcNS 
HexA – GlcNS(3S) (found very rarely) 
Here the HexA can be either of the uronic acids IdoUA or GlcUA. According to Harbuchi 
(Harbuchi, 2000) a good acceptor for HS6ST was GlcNS in either of the following sequences: 
IdoUA – GlcNS 
IdoUA(2S) – GlcNS 
All of these sequences show that HS6ST does not transfer O-sulphate to any GlcNAc residues. 
This suggests that the process is catalyzed by a different enzyme, which is consistent with results 
from (Habuchi et al., 1995).  
It is thought that the regulation of the sulphation of IdoUA-GlcNS by HS6ST-2 is due to the GlcUA 
C5 epimerase. This is due to the product of this enzyme which inhibits the sulphation of IdoUA – 
GlcNS (Habuchi et al., 2000). There is a pH dependence of HS6ST, which is thought to be 
between pH 6.2 – 6.4, and the activity of this enzyme is decreased by the addition of NaCl. 
(Habuchi et al., 1995).  
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1.4.3.3 3-O-Sulphotransferase 
The action of the 3-O-sulphotransferase enzyme (3-OST-1) acts on the C3 of N-sulphated GlcN 
residues (Razi and Lindahl, 1995). This is the final important modification during the biosynthesis 
of HS (Liu et al., 1996). 3-OST-1 is not a transmembrane protein like the other modification 
enzymes, but is thought to be an intra-luminal protein (Habuchi, 2000). It is a key enzyme which 
is involved in converting non-anticoagulant HS into anticoagulant HS (Liu et al., 1999); with the 
formation of the antithrombin III binding region found in HS (Razi and Lindahl, 1995; Habuchi 
2000). This shows that 3-O-sulphated GlcNS(3S) is one residue required for the generation of the 
antithrombin binding site (Liu et al., 1996). The inhibition of the 3-OST seems to be due to the 
action of both IdoUA(2S) and GlcNS(6S) which have been found in selectively desulphated 
heparin (Razi and Lindahl, 1995). The antithrombin III binding domain does seem to require the 
action of the other enzymes in order for its generation. These include the action of the NDST’s, 
HS2ST, HS6ST and the C5 epimerase (Habuchi, 2000).   
3-OST-1 is expressed in brain, kidney and in the heart (Habuchi, 2000). 3-OST-2, 3-OST-3a and 
3-OST-3b are all isoforms of the enzyme but these lack the anticoagulant activity. However they 
are still able to transfer sulphate groups to the C3 position of all glucosamine residues (Liu et al., 
1999). 3-OST-2 is expressed strongly in the brain, whereas 3-OST-3a and b are expressed in 
various tissues throughout the body (Habuchi, 2000).  
3-OST-2 has specific sequences to which it can transfer sulphate groups to. These are 
transferred to the GlcNS residue on: 
GlcUA – GlcNS 
IdoUA(2S) – GlcNS 
The specific sequence for 3-OST-3a and b is just:  
IdoUA(2S) – GlcNS 
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This shows that the sulphation of glucosamine is dependant on different structures around the 
glucosamine residue (Liu et al., 1999). Figure 1.10 contains a detailed description of the GAG 
biosynthesis processes for a HS/Hep chain. Those positions which are modified by the O-
sulphation process are shown highlighted. The rare 3-O-sulphation is shown by the red arrow on 
the second monosaccharide in the diagram.  
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Figure 1.10 GAG biosynthesis of HS/hep chains. 
 
The modification process is quantitatively incomplete and so results in a HS/hep chain with a very 
highly complex structure. Most of the modifications that occur are non-random and are thought to 
be interdependent.  
Mature HS comprises 40-50% GlcNS residues compared to heparin which has a higher level, 
approximately 85%. GAG biosynthesis occurs in the Golgi apparatus of all cells. This figure has 
been adapted from Prydz and Dalen (Prydz and Dalen, 2000). 
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(Prydz and Dalen 2000) 
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1.4.3.4 The Role of the Sulfs 
Once synthesis and expression of HS is complete then the chain can undergo further modification 
to its structure and function. This occurs in extracellular compartments and the two enzymes 
presently known to take on this role are heparanase and heparan sulphate 6-endosulfatase (Dai 
et al., 2005). The sulfs are a recent discovery, they are extracellular HS  6-O-endosulfatases 
which work by removing the sulphate groups from the C6 of specific groups within S-domains 
(Langsdorf et al., 2007; Kiran-Safran et al., 2009). The sulfs are secreted from the Golgi 
apparatus and become localised at the cell surface, or are released into the extracellular matrix 
(ECM) (Dai et al., 2005). Their enzymatic activity and ability to dock in the correct place on the 
cell surface is due to the conserved sequences found contained in the members of the sulfatase 
family (Dhoot et al., 2001).  
The first family member to be identified was Qsulf - 1; sulfatase - 1 from quail (Dhoot et al., 2001; 
Dai et al., 2005). This particular enzyme has preference towards a specific substrate sequence, 
the trisulphated: 
IdoUA(2S) – GlcNS(6S)  
(Ai et al., 2003). 
Then came the cloning of other sulfs identified in humans (Hsulf -1 and Hsulf -2) and murine 
(Msulf). Qsulf-2 was also identified, which is very similar to Qsulf-1 but differs in gene sequence 
(Dai et al., 2005). Qsulf-1 has less of an effect on the following sequence: 
GlcUA – GlcNS(6S) 
With no effect whatsoever on the sequence: 
IdoUA – GlcNS(6S) 
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Extended reaction times showed no change from this result (Ai et al., 2003).  
Hsulf-1 is present in tumour cell lines and has been shown to be down regulated in these, 
whereas it is expressed at higher levels in normal tissue (Dai et al., 2005). Sulfs also play 
important roles in muscle regeneration, specifically involving quiescent and activated satellite 
cells (self renewing muscle cells) and involves Msulf-1 and Msulf-2 (Langsdorf et al., 2007). 
Mutations in these enzymes introduce the loss of function in specific pathways. Sulphation in 
itself is a process which is incomplete and so this alone creates a very complex structure seen in 
the form of S - domains and non - modified domains (Ai et al., 2007). When the action of the sulfs 
is added into the equation this adds even more complexity into the structure, bearing in mind the 
first round of modifications already created earlier on in the biosynthetic pathway.   
 
1.4.4 CS/DS Chain Polymerization 
The biosynthesis of the CS/DS is slightly different to that of HS/hep chains. The enzymes 
responsible for the biosynthesis of the CS/DS chains are localised in different sub-domains of the 
Golgi apparatus specifically the trans-golgi network which is the most distal part of the Golgi 
complex. The enzymes responsible for the biosynthesis of HS/hep chains are located further in 
the Golgi network, specifically in the lower end of the trans-golgi network and also the medial-
golgi network (Prydz and Dalen, 2000). These enzymes are a completely different set of enzymes 
to those found in the biosynthesis of HS chains. Once the formation of the linker tetrasaccharide 
has been completed the diverging point for CS/DS chains is the addition of GalNAc by the 
enzyme EXTL2. This is the same enzyme which would add GlcNAc to HS chains. It is also known 
as GlaNAcT1 but is a different enzyme to that which adds GalNAc to the linker tetrasaccharide in 
chain initiation. This addition to the chain leads to the synthesis of the repeating disaccharide 
-4 GlcUA β1-3 GalNAc β1-. This is done by the action of GlcUA transferase II and GalNAc 
transferase II, which are specific enzymes for the backbone synthesis of CS/DS (Sugahara and 
Kitagawa 2003). They are thought to exist either as a complex or they reside in a single 
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polypeptide. Their results show that the enzymes co-elute together by gel filtration 
chromatography and further chromatographic separation processes were unable to separate the 
two enzymes. This can lead to the addition of 40 - 100 disaccharide units in length for each of the 
chains (Sugahara and Kitagawa, 2003). The following diagram (Figure 1.11) highlights the CS/DS 
biosynthesis pathway. Again O - sulphation positions are shown by the red boxes.  
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Figure 1.11 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 11 Biosynthesis of Chondroitin/Dermatan sulphate chains. 
Biosynthesis of CS/DS chains occurs in different compartments of the Golgi apparatus, 
specifically the trans-golgi network. This figure has been adapted also from Prydz and Dalen 
(Prydz and Dalen, 2000).  
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After backbone synthesis epimerization of GlcUA to IdoUA occurs with the same C5 epimerase 
enzyme used in HS/hep chains. If epimerization occurs then this chain will be classified as a DS 
chain as IdoUA residues are not found in CS chains. The only hexuronic acid present in CS is D-
glucuronic acid,  whereas in DS there are both D-glucuronic acid and L-Iduronic acid (Prydz and 
Dalen, 2000). The alternating action of GlcUA and GalNAc transferase II continues along with the 
action of the sulphotransferase family of enzymes. Here; like in the HS/hep biosynthesis, the 
chain can undergo 2, and 6-O-sulphotransferase but it can also undergo 4-O-sulphation too.  
 
1.4.4.1 CS/DS O - Sulphotransferase 
CS/DS can undergo 4 and 6-O-sulphation. Chondroitin-6-sulphotransferase, also known as 
C6ST, is secreted into the extracellular space of the trans Golgi network. It catalyzes the transfer 
of sulphate groups to position 6 of GalNAc residues. The product of this modification is 
Chondroitin-6-sulphate. The accepted structure for C6ST is the following: 
GlcUA – GalNAc   GlcUA – GalNAc(6S) 
Chondroitin-4-sulphotransferase catalyzes the transfer of sulphate groups to position 4 of GalNAc 
residues. The acceptor for this is the same sequence as above: 
GlcUA – GalNAc  GlcUA – GalNAc(4S) 
Both of these enzymes are type II transmembrane proteins (Habuchi, 2000). The action of 
Uronosyl 2 - O - sulphotransferase acts only on DS chains. This adds the sulphate group onto 
position 2 of GlcUA/IdoUA in the following: 
    IdoUA – GalNAc    IdoUA(2S) – GalNAc 
IdoUA – GalNAc(4S)              IdoUA(2S) – GalNAc(4S) 
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GlcUA – GalNAc(6S)   GlcUA (2S) – GalNAc(6S) 
During this process the second C5 epimerase comes into action, again converting GlcUA to 
IdoUA (Prydz and Dalen, 2000). However; because of the location of the enzymes more of the 
CS/DS chain remains unmodified, unlike in HS/hep chains. CS/DS chains are often found as a 
co-polymeric structure (Sugahara and Kitagawa, 2003).  
 
1.5 De-Polymerisation Techniques 
There are two favoured methods of de - polymerization of the HS chain. These are chemical and 
enzymatic and can either be used separately a combined to give different products.   
 
1.5.1 Chemical de-polymerisation 
The chemical technique involves the use of the chemical nitrous acid to depolymerise HS/hep 
chains. This acts on the following sequence and does so selectively and quantitatively 
(Rabenstein 2002) and releases inorganic SO4.: 
GlcNS – HexA 
It also converts GlcNS, GlcNS(6S), GlcNS(3S) and GlcNS(3,6S) into 2, 5 - anhydro D - mannose 
(aMan). With this technique it avoids the production of the ∆UA (formed in enzymatic 
depolymerisation and not a naturally occurring ring structure) and can be used at a high pH (3 - 4) 
or a low pH (1.5). The reducing end of the HS chain seems to be more resistant to this treatment, 
possibly due to the local chemical environment around this area making it resistant (Merry et al., 
1999).  
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1.5.2 Enzymatic de-polymerisation 
The enzymes used for the enzymatic depolymerisation of HS chains are naturally produced from 
the soil bacterium, Flavobacterium heparinum. It is able to use heparin as its main source of 
carbon, nitrogen and sulphur. For this to occur it must produce a range of enzymes which include 
glucuronidases, heparitinases (heparin monosulphate lyase), sulphotransferase and 
sulphamidases (Galliher et al., 1981). It is the heparitinase enzyme which has become the 
enzyme of use for HS/hep depolymerisation (Dietrich et al., 1973). This enzyme is an α 1 - 4 
eliminase which acts specifically on glucuronic acid linkages between GlcNS-HexA; resulting in 
the formation of polysaccharides with a reducing end and a α - β unsaturated acid at the non-
reducing terminal (Linker 1979). This process produces an unsaturated double bond between C4 
and C5 on the non-reducing end of the chain which is termed ∆UA or just simply UA. This ∆UA is 
a sensitive UV chromophore with a maximum absorbance at 232 nm. This allows for the enzyme 
digestion process to be followed to completion and also allows for detection of the fragments 
produced via this method (Murphy et al., 2008).  
 
The useful activity of this enzyme allows for NS domains to be released from the chain (with the 
use of a specific enzyme – heparanase III). There are three types of lyase produced by the 
bacterium used to study HS/hep structures. Each acts on a different substrate in the chain, 
allowing for different sections of the chain to be released. These enzymes are: 
Heparanase I (hep I): Acts on the sequence: 
GlcNS + 6S – IdoUA(2S) 
This releases di/trisulphated disaccharides and therefore releases the modified NS domains 
(Murphy et al., 2004). This is also found in heparin in invertebrates (Nader et al., 1999).  
 
Chapter 1: Introduction 
 51 
Heparanase II (hep II): Acts on the sequences: 
GlcNS/NAc + 6S – IdoUA + 2S 
GlcNS/NAc + 6S – GlcUA 
This is the least specific of the three enzymes and cleaves a wide range of sequences (Murphy et 
al., 2004). Heparin from invertebrates is also susceptible to the action of hep II (Nader et al., 
1999).  
Heparanase III (hep III): Acts on the sequence: 
GlcNS/NAc – GlcUA/IdoUA 
This enzyme has a strong preference for GlcUA (Murphy et al., 2004).  
Generally even-numbered oligosaccharides are generated and are the most studied 
oligosaccharides throughout nature. However; odd numbered oligosaccharides may be generated 
by the mercuric ion-catalyzed removal of the unsaturated hexuronic acid from the non-reducing 
end.  There is currently no method available to remove saccharides from the reducing end 
(Deakin et al., 2008).  
 
1.6 Domain Structure  
Heparin is made up of a structure where >80% of the GlcN residues are N-sulphated (Gallagher 
and Walker, 1985) leading to the conclusion that it can also be heavily O - sulphated. It also 
contains a high portion of both GlcUA/IdoUA. In contrast to this, HS has a lower proportion of 
N - sulphated residues, thought to be closer to 50% of the GlcN residues being N - sulphated. It 
also has a lower amount of IdoUA and therefore a lower amount of N-sulphation (Gallagher and 
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Walker, 1985; Lindahl et al., 1994). Complete modification of the chain leads to the trisulphated 
disaccharide being the most common sequence identified in the structure: 
IdoUA(2S) – GlcNS(6S) 
 
The incomplete modification of HS  suggests it contains less of these trisulphated disaccharides 
and also fewer N - and O-sulphate groups (Gallagher and Walker, 1985). It is the difference in 
these sulphated and unsulphated structures which allows for the identification between HS and 
heparin. The most common disaccharide found in heparin is the trisulphated disaccharide 
mentioned above. The most common disaccharide found in HS is the unsulphated GlcUA- 
GlcNAc. These types of structures help to give HS its well known domain structure (Rabenstein, 
2002; Powell et al., 2004) and will make it easier to identify it from a typical heparin structure. The 
unsulphated disaccharide makes up the NA domain identified in the chains; which are known as 
the unmodified sections of the chain (also seen as NAc domains). Here no O-sulphation is 
identified and it is this area which is identified as being N-acetyl rich (Gallagher, 2001). These 
domains are thought to act as spacers between the more active and modified domains 
(Rabenstein, 2002). The NA domains make up a significant amount of the chain and are thought 
to play no role in the interaction with protein ligands (Murphy et al., 2004). Segregated from this 
domain are the active sequences/domains known as the S domains or sulphated domains (Vives 
et al., 1999). This section of the chain undergoes the most modification is found to be distributed 
evenly along the chain (Gallagher, 2001). These are also identified as NS domains and are 
typically 3 - 8 disaccharides in length (Rabenstein, 2002). This leads to a domain which is N-sulf 
rich and these are found completely separate from the N-acetyl rich domains (Gallagher and 
Walker, 1985). N-sulf is an incomplete process and it is this that helps to define the NS domains 
as this type of modification occurs only in defined regions (Vives et al., 1999). The amount of 
variation available in the NA and NS domains also has great variety between different sources in 
the human body and also in different species (Powell et al., 2004). It is the NS domain which bind 
to protein ligands but also the varying sulphation and sequence patterns, which play a key role in 
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this interaction between HS chains and different protein ligands (Merry et al., 1999). It is this 
specific interaction that has lead to the study of NS domains in great detail. HS is thought to be 
the mediator of not just binding to but also the activation of these ligands (Vives et al., 1999).  
There has been identified a third type of domain which brings together the NS and NA domains 
and thus shows that the two domains mentioned are not quite two separate domains in their own 
right, as was initially thought. The unmodified NA domains are typically made of approximately 15 
disaccharide units (Gallagher, 2001). Towards the end of this domain; just before the beginning of 
the NS domain, is what is known as a transition zone (Gallagher, 2001; Rabenstein, 2002; 
Murphy et al., 2004). This has been termed the NA/NS domain and although not much is known 
about these with regards to interactions with proteins (Murphy et al., 2004), they are thought to be 
functionally significant in helping NS domains to interact with specific ligands (Rabenstein, 2002). 
These are areas of the chain which have undergone slight modification but not to the same extent 
as the NS domains. For instance the modification 6 - O - sulphate has been found in the transition 
zone (Maccarana et al., 1996). The previously held domain structure of HS chains can be seen 
(Figure 1.12), alongside a comparison of the heparin chain. 
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Figure 1.12 
 
 
Figure 1. 12 HS/Heparin domain structure.  
 
A representation of the previous held HS domain structure which is made up of highly modified 
blocks (NS-domains) separated by unmodified sequences (NA domains). The structure of heparin 
is essentially one continuous modified domain only interrupted by the occasional region of low 
sulphation.  
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The introduction of the NA/NS domains changed the view of the domain structure and added 
more complexity to the chain giving it a unique characteristic (Turnbull and Gallagher 1991). 
These were first demonstrated by Gallagher and Walker (Gallagher and Walker 1985) and 
followed up by Murphy et al (Murphy et al., 2004) with the use of a different enzyme K5 lyase. 
The additional characteristic of these NA/NS domains is that they are more dynamic than were 
first thought. This additional flexibility would enable the NS domains to explore more of the space 
around it, thus enabling it to adapt more to the number of protein ligands by adapting their shape 
(Mobli et al., 2008). This process has been shown by Stringer and Gallagher (1997) in HS platelet 
factor 4 (PF4). Here the NS domains are separated by long NA domains which are able to 
interact with two binding domains found on a PF4 tetramer, one identified on each side of the 
protein. 
 
1.6.1 Action of K5 Lyase 
The enzyme coliphage K5 lyase cleaves within non-sulphated sequences of four or more GlcNAc 
disaccharides. Meaning it cleaves within sequences that are found outside the NS domains; 
therefore concentrating solely within the NA domains (Figure 1.12). Further analysis showed 
these NA/NS domains were in fact in conjunction with NS domains or at least in close proximity to 
them (Murphy et al., 2004). However, there is some confusion as to whether they flank both sides 
of the NS domains equally (Figure 1.13, Panel A), or are found on one side more than the other 
(Figure 1.13, Panel B). 
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Figure 1.13 
 
 
 
 
 
Figure 1. 13 A refined model of the domain structure of HS after treatment with KS lyase 
enzyme.  
 
The arrows identify areas of the chain where K5 lyase enzymatic action takes place on HS and 
heparin. However it is unknown as to whether the NA/NS domains equally flank both sides of the 
NS domain (Panel A), or it occupies one side more then the other (Panel B).  
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Interestingly, the cleavage sites for both Heparanase I and K5 lyase appear to be around the 
same area, approximately 16 - 18 disaccharides away from the NS domains (Murphy et al., 
2004). The NA/NS were frequently found to contained unsulphated IdoUA residues with half the 
glucosamines containing 6-O-sulphate groups (Gallagher and Walker, 1985; Maccarana et al., 
1996). Some sequences were found to be resistant to the action of K5 lyase, namely the NS 
domains and the alternating sequences of GlcNAc – GlcNS. It would also only work on substrates 
with an α 1 - 4 linkage and not a β 1 - 4 linkage (Murphy et al., 2004). With this devised new 
structure it is even more important in determining the position and placement of both the NA/NS 
and NS domains because these will both play major factors in the specificity and the local 
dynamics of the chain (Mobli et al., 2008).    
 
1.7 Structural conformation 
It is a well known fact that carbohydrates do not contain secondary and tertiary structures but 
rather they populate multi conformations (Kirschner and Woods, 2001). These conformations are 
found in all HS ring structures and fall into three configurations; 1C4, 
4C1 and 
2S0 (the two chair 
conformations and one skew boat conformation respectively). These conformations play a major 
role in the complexity of the HS chain. Each residue in the chain can exist in its own conformation 
and these can have a specific influence on other residues upstream or downstream. Each residue 
will also have the ability to influence not only the binding but also the activity on specific protein 
ligands. Each of the different conformations will be discussed. 
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1.7.1 ∆UA/UA 
The terminal uronic acid, produced by the action of the heparanase enzymes from the soil 
bacterium Flavobacterium heparinum, is characterised by the unsaturated double bond found 
between C4 and C5 on the non-reducing end of the chain. This terminal residue exists in the form 
of equilibrium between the 1H2 and 
2H1 half chair conformations (Figure 1.14). This equilibrium is 
thought to be due to the substitution pattern or controlled by it (Bazin et al., 1998). This ring 
structure is thought to be conformationally flexible (Ragazzi et al., 1993).  
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Figure 1.14  
 
 
 
 
 
 
 
 
Figure 1. 14 Structural conformation of the terminal Uronic acid.  
 
The pyranose ring of the terminal UA is thought to exist in equilibrium between the two low 
energy structures identified.  
Panel A. The UA in the 2H1 conformation. 
Panel B. The UA in the 1H2 conformation.  
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In the 1H2 conformation all the bonds are found in the axial conformation. For 
2H1 the structure is 
almost flat in comparison, showing the equatorial conformation (Ragazzi et al., 1993). As this 
structure does not exist in nature, it is not likely to have any role in biological interactions.  
 
1.7.2 The N-glucosamines and The Gauche Effect 
The collective term for this group of monosaccharides is the N-glucosamines and is made up of 
GlcNS, GlcNS(6S), GlcNAc and GlcNAc(6S). All of these are found in the conformationally locked 
4C1 conformation (Rabenstein, 2002; Powell et al., 2004). This conformation is characterised by 
all of the non - hydrogen groups attached to the residue being held in an equatorial conformation, 
apart from the anomeric OH group (Rabenstein, 2002). There is an added feature with these 
residues which adds flexibility to the ring structure. This is the relative motion, or degrees of 
freedom, seen in the C5 - C6 bond shown by Hricovini et al (Hricovini et al., 1995) on heparin 
epoxide (a derivative of heparin). This motion can be seen in all glucopyranosides and has been 
identified as the ω - angle, characterised by the O6 - C6 - C5 - O5 torsion angle (Figure 1.15) 
(Kirschner and Woods, 2001).  
There are three possible conformations known as gauche orientations or rotamer populations 
which are known as: 
• gg – gauche - gauche  
• gt – gauche - trans 
• tg – trans – gauche 
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Figure 1.15  
  
 
 
 
 
 
 
 
 
 
 
Figure 1. 15 The ω-angle identified in all N-glucosamines and the possible gauche 
orientations.   
 
The GlcNAc residues is stable in the 4C1 conformation exists in three possible rotamer 
conformations around the C5-C6 bond. The three rotamers are termed gg, gt and tg.  
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The conformations are thought to be solvent dependant as H2O allows the disruption of the H 
bonds, thus allowing the rotamer populations to be determined by electronic and steric repulsion 
(Kirschner and Woods, 2001).  
Studies by Hricovini et al (Hricovini et al., 1995) have been unable to confirm the relative 
abundances of these orientations. However other studies have concluded that the rotation around 
the C5 - C6 bond is slightly hindered and that the gg rotamer is favoured (Mulloy et al., 1994). 
Further work carried out by Kirschner and Woods (Kirschner and Woods, 2001), using molecular 
modelling have been able to show actual populations for these rotamers: 
gt/tg/gg = 40/6/54 
 
It has also been shown that excluding the O6 attachment shows no real difference in the rotamer 
populations, showing that the O6 attachment has no overall effect on the conformation of these 
residues. These studies mentioned at least agree in that the gg rotamer is the most favoured 
above the other conformations. 
These populations are attributed to the gauche effect, which is defined as the tendency for a 
particular molecule to adopt a structure which has the maximum number of gauche interactions 
between adjacent electron pairs and their polar bonds (Clayden et al., 2001).  
 
1.7.3 Uronic Acids 
1.7.3.1 GlcUA  
The conformation of the GlcUA like the N-glucosamines is fixed in the 4C1 configuration 
(Rabenstein, 2002; Powell et al., 2004). This residue is highly rigid in comparison to its modified 
iduronate counterpart (Figure 1.16); which have undergone C5 epimerase (see HS/hep chain 
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modifications). It is this conversion from the rigid β-D-glucuronate to the α-L-iduronate which 
alters the conformational and dynamic properties of the chain.  
 
   GlcUA                                IdoUA 
            4C1                              
1C4, 
2S0 and 
4C1 
                                      Stable conformation                  Flexible conformations 
 
Adapted from (Mulloy and Forster, 2000). 
 
1.7.3.2 IdoUA  
The majority of the flexibility in HS chains comes from the presence of three different 
conformations. These are the common chair forms, 1C4 and 
4C1 and then the more unusual 
2S0 
skew boat form (Figure 1.16), (Murphy et al., 2008). Both the 1C4 and 
2S0 conformations are 
found on internal iduronates, whereas the 4C1 form is thought to only occur on the terminal 
iduronate residues (Ferro et al., 1990).  
C5 epimerase 
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Figure 1.16 
 
 
 
 
 
 
 
 
 
Figure 1. 16 Structural conformation of the Iduronates. 
 
The methyl-α-L-Iduronic acid exists in equilibrium between three low energy conformations. It is 
thought that the 4C1 conformation is only found to form the terminal unit in an oligosaccharide. 
Cremer-Pople puckering parameters are characterised as θ = approx 160° (1C4) and θ = approx 
90° (2S0). 
 
IdoUA 4C1 conformation IdoUA 1C4 conformation IdoUA 
2S0 conformation 
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These conformations have been confirmed by the use of NMR with 3 - bond proton - proton 
coupling constants (3JH-C-C-H) along with molecular modelling studies (Hricovíni and Bízik, 2007). 
This change in configuration had also been shown by previous work carried out by Hricovini et al 
(Hricovini et al., 1995) on heparin epoxide which converts from the ‘normal’ 4C1 to a half chair 
configuration not previously identified in any HS structures.  
 
When interactions between specific proteins are involved then the conformation of a particular 
IdoUA seems to fall into one of the two favoured conformations. This has been identified in 
heparin when it binds to the molecule histidine. Here it was found to bind in the 1C4 conformation 
(Chuang et al., 2000). Another study with heparin which involved binding to antithrombin III (used 
in preventing blood coagulation) is shown to bind to a particular sequence in the HS chain: 
GlcNS(6S) – GlcUA – GlcNS (3,6S) – IdoUA(2S) – GlcNS(6S) αOMe 
αOMe is the α-methyl glycoside, (Das et al., 2001). 
 
Results from the crystal structure showed both 1C4 and 
2S0 conformations present in the structure. 
All the other residues were identified in the rigid 4C1 conformation. However the resulting NMR 
data identified only the 2S0 conformation. It is thought that the presence of the neighbouring 
sulphate groups, in particular the 3- and 6-O-sulphate group were the main driving force in the 
resulting configuration (Murphy et al., 2008).  
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It is thought that the main reasoning behind these conflicting findings is that when in a bound 
complex the 2S0 conformation is shown as the ‘active’ conformation. When unbound both of the 
configurations are seen but with the equilibrium firmly towards the 2S0 conformation: 
2S0    
1C4 
                                90%                       10%     
(Hricovini et al. 2001) 
 
This belief is also shared by Das et al (Das et al., 2001) who also found the iduronate, when 
bound to antithrombin III, adopts the 2S0 skew boat form.  
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1.8 Interactions with proteins 
1.8.1 HS Binding – Consensus sequence 
HS has been shown to bind to a number of proteins, in fact over 200 proteins have so far been 
identified (Kreuger et al., 2001; Forsten-Williams et al., 2008). The most well known proteins are 
antithrombin III, IL - 8 and the FGF family (Bitomsky and Wade, 1999). It is the ionic interactions 
which are important for the promotion of the binding sites found in specific HS binding proteins. 
Consensus sequences found on the surface of proteins are made up of positively charged amino 
acids (Hileman et al., 1998) and these specifically interact with negative groups on the HS chain. 
These negative groups are specifically the sulphate and the carboxylate groups found on all GAG 
chains (Bitomsky and Wade, 1999), allowing them to participate in electrostatic interactions with 
proteins and cations (Turnbull and Gallagher, 1991) which are found in the sulphated domains 
(NS domains) found throughout the HS chain (Kreuger et al., 2006). It is these domains which 
provide multiple binding sites for protein ligands. The GAG - protein consensus sequences are 
defined as an array of basic amino acid clusters of lysine, arginine and histidine found in 
formations such as: 
XBBXBX or XBBBXXBX 
B = basic residues 
X = hydropathic residues (Hileman et al., 1998). 
 
There is a distance of 20 Ǻ between one set of positively charged residues and the next binding 
site (Bitomsky and Wade, 1999). 
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1.8.2 Fibroblast Growth Factor Biology 
There are currently 22 identified members of the fibroblast growth factor family (FGF’s) in humans 
and mice (Rieckmann et al., 2007) and are recognised as fundamentally important in 
embryogenesis (Kreuger et al., 2005). They have also been identified in C.elegans, D. 
melanogaster, vertebrates and some anthropod viruses (Harmer et al., 2004). These FGF’s are 
then split into different sub-families. FGF’s were initially purified from bovine pituitary glands as a 
mitogen which could stimulate the growth of NIH3T3 cells. It has been identified in D. 
melanogaster which is known to contain just one type, known as branchless (bnl). C. elegans 
also contain just the one type, known as Egl - 17 (Ornitz, 2000). They are involved in a number of 
activities within the body such as tumour cell replication, migration, invasion, vascularisation, 
targeting and attachment by bacteria, protozoa and viruses (Hileman et al., 1998). 
The 22 known FGF’s are all similar and are related in both sequence and structure, however the 
most universal of them all is FGF1 which is able to bind to all FGFR’s (Wu et al., 2003). The 
internal core is made up of 28 highly conserved amino acids with 6 invariant amino acids (Ornitz, 
2000). They are 15 - 30 kDa proteins with the whole core region having homology to 120 - 130 
amino acids. The FGF’s have homology for the IL - 8 form of growth factor (Harmer et al., 2004). 
These amino acids make up the β - trefoil fold which comprises of 12 β strands arranged in three 
lots of four β sheets (Olsen et al., 2003). Β - trefoil structures β structures with a pseudo - 3 fold 
axis of symmetry (Harmer et al., 2004). Further diversity is created through alternative splicing of 
the FGF’s and also through a variety of post - translational modifications. They all act specifically 
with different FGFR’s, with the most specific being FGF7. This will only bind to the receptor 
FGFR2 IIIb (a spliced variant) (Duchesne et al., 2006).  
 
1.8.3 Fibroblast Growth Factor Receptors – The FGFR’s  
The FGF’s are known to bind to two types of receptor: 
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• HSPG’s - low affinity cell surface receptors (Ic 50 ~ 5-50 nM) (Thompson et al., 1994).  
• Tyrosine kinase receptors (FGFR’s) – FGFR 1 - 4 with high affinity (Pye et al., 2000). (Ic 
50 ~ 10-200 pM) (Thompson et al., 1994).  
The latter are known as fibroblast growth factor receptors and are products of five distinct 
mammalian genes (Goodger et al., 2008). These FGFR receptors bind to FGF with a varying 
amount of affinity and are found to be mostly specific: 
• FGFR1 – expressed mostly in connective tissue.  
• FGFR2 – found primarily in bone. 
• FGFR3 – found in cartilage. 
• FGFR4 – Identified in muscle.  
Diversity is also found in cloned receptors such as FGFRL1. This lacks the cellular tyrosine 
kinase domain which is required for the signal transduction found in muscle and cartilage 
(Rieckmann et al., 2007). FGFR’s are also found in spliced variants A, B and C, of which it is 
domain III which is spliced. Spliced variant A is secreted and functions as a receptor. Type’s B 
and C display different binding ligand requirements, such as FGFR2 IIIc can bind to both FGF1 
and FGF2 equally. FGFR IIIb binds FGF1 increasingly more then FGFR IIIc, but binds to FGF2 
1000 fold less (Goodger et al., 2008). The different receptors and their spliced variants result in 
the binding of a variety of different ligand binding domains (Nugent and Iozzo, 2000) and the fact 
that it is tissue specific adds to the great amount of diversity (Ornitz, 2000).  
The FGFR’s are composed of an extracellular region of three Ig - like domains: Ig I, Ig II and Ig III. 
They have a single transmembrane helix and an intracellular tyrosine kinase domain (Harmer, 
2006). In between domain I and II is a stretch of 30 acidic residues (Wu et al., 2003). X-ray crystal 
structures show domains II and III are separated by an α 4 - linker peptide, removing any kind of 
interaction between these two domains (Stauber et al., 2000). The three domains here are 
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membrane proximal IgG domains with domains II and III containing the FGF binding sites. 
Domain II also contains a second binding site for binding to HS (Harmer et al., 2004). The HS 
binding site is situated on the loop between β strands 10 and 11 and is composed of several 
basic amino acids. It is this structure that forms the binding site, particularly for FGF2 (Ornitz, 
2000). The domain structure of domain II means there is a cannon or space of positive charge 
which is the area where HS/hep chains are able to bind or bridge the complex (Schlessinger et 
al., 2000). It has been shown that domain I is dispensable with II and III showing an equal degree 
of binding (Wu et al., 2003). 
 
1.8.3.1 FGF Isoforms and diversity 
Splicing of the receptor domains leads to a generation of diverse protein isoforms. These in the 
presence of HS/hep bind with varying affinities to different FGF ligands (Ornitz et al., 1996). The 
splicing of the receptors increases the intricacy and the diversity of the receptors; which is 
enhanced by the splicing of the FGF mRNA (Schlessinger et al., 2000). It has been shown that 
FGF’s can bind differently to different ligands (Wu et al., 2003). An example of this is FGF1 can 
bind to FGFR2 IIIb and FGFR2 IIIc. However FGF2 can not bind to FGFR2 IIIb, but it is able to 
bind FGFR2 IIIc. The most specific receptor is thought to be FGFR IIIb which can only bind to 
FGF 1 and 9. (Ornitz et al., 1996). The expression of the FGFR’s is thought to be cell specific. 
This alongside the added degree of diversity in both the FGF’s and FGFR’s allows for the 
generation of a wide range of ligand - receptor combinations. They are produced at different 
times when needed to perform the many functions in a tightly controlled manner (Powell, 2001).  
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1.8.4 Signalling pathways of the FGF’s 
FGF signalling is induced by the binding of specific ligands to HS chains and depends on the size 
of the chain and the sulphate content of the chain. It has been shown that the FGF can interact 
with four to five residues on a GAG chain, but most result in an inactive complex (Goodger et al., 
2008). The signalling is subject to a range of regulatory inputs; those that are either operative at 
the level of formation of the complex, or are active inside the cell on the active receptor complex 
(see HS/FGF/FGFR complexes) (Duchesne et al., 2006). Signal transduction requires the 
association of both the receptor and the HSPG into a complex, found on the surface of the cell 
(Pellegrini et al., 2000). The FGF works as part of a dual receptor system, interacting with both 
the FGFR and HSPG complex enabling it to exert its effects on the cell. It is the FGFR which acts 
as the signal transducing component and the HSPG plays a secondary part in this dual system 
(Casu et al., 2002). Here the two receptors combine together and are able to transduce the signal 
to the interior of the cell (Rieckmann et al., 2007). The interaction here leads to receptor 
dimerization which then has a knock on effect causing subsequent tyrosine autophosphorylation 
of the receptor (Pye et al., 2000). This leads to a cascade of activation of the different tyrosine 
receptors (Stauber et al., 2000), leading to multiple - cellular response. This interaction will 
depend on the initial cell surface binding of an FGF ligand to a particular FGFR (spliced or 
unspliced) and would depend on the concentration and the binding kinetics of the FGF (Nugent 
and Iozzo, 2000). FGF’s will bind more favourably to patterns of modulation on the backbone of 
the HS/hep chain. The FGF - FGFR complex has a higher degree of specificity than either of 
them alone, this is due to the FGF being able to rapidly bind and release a number of different 
sequences before activation occurs. This allows for a greater sampling of a wider range of 
sequences in a chain giving it the ability to bind the correct sequence needed for activation 
(Harmer 2006),  
The eventual signalling response will depend on the level of receptors available, the duration of 
time the receptor is activated for and also the environment of the cell (Powell, 2001). Any 
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problems in the signal transduction cascade will inevitably lead to many disorders observed in 
humans (Stauber et al., 2000), such as human metastatic melanoma (Nikitovic et al., 2008). 
 
1.8.5 The Role of HS in FGF Signalling 
The specificity of HS was first identified in early work with the protein antithrombin III (AT III). 
Here it was identified that NS domains played a crucial role in providing multiple sites for protein 
ligand binding and activation (Kreuger et al., 2006). Work involving FGF binding and mitogenic 
assays have aided in backing this theory, with NS domains being identified as being of great 
importance. Work undertaken by Ornitz (Ornitz, 2000) has shown that highly sulphated regions 
are significantly more active compared to the unsulphated domains. The role of HS is to aid 
stability and to localise FGF’s in the vicinity of the cell surface (Faham et al., 1996). It is thought 
of as a co - receptor in that it is able to bring together the FGF and the FGFR (Kreuger et al., 
2001; Goodger et al., 2008) allowing for a complex formation (Pellegrini et al., 2000; Duchesne et 
al., 2006). The interactions between HS, FGF’s and FGFR’s are looked upon as either highly 
specific ‘lock and key’ mechanisms, or a non-specific electrostatic association (Maccarana et al., 
1993 ). Another important part of the interaction between HS and FGF is that the HS chain is able 
to protect the FGF2 protein from proteolysis (Ornitz, 2000) and protect both FGF1 and FGF2 from 
thermal denaturation (Zhang et al., 2001).  
For HS to bind FGF and/or FGFR interactions between many different molecules must first take 
place. HS is known for its high negative charge and so cations such as Na+ have to bind to 
minimise this effect. When HS therefore needs to bind to a protein these cations must first be 
displaced in order for the charged amino acids found on the surface of the protein to bind the HS 
chain. This process is known as the Polyelectrolyte Effect and can be seen in the following 
equation: 
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Protein + GAG (m sites)     Protein – GAG + m (1-f) Na+ 
Where: m = the number of Na+ released 
Where: f = the fraction of anion (Hileman et al., 1998). 
It is the release of Na+ in this reaction which gives it its name. The FGF’s can signal directionally 
and reciprocally across the epithelial - mesenchymal boundaries and it is this that needs to be 
regulated via FGF activity and receptor specificity (Ornitz, 2000).  
 
1.8.6 HS/FGF/FGFR Complexes 
The complex formation of an FGFR, and HSPG is a well known requirement for signal 
transduction (Pellegrini et al., 2000). The interaction of FGF with both HSPG and FGFR’s leads to 
receptor dimerization, which then leads to subsequent tyrosine autophosphorylation of the 
receptor (Pye et al., 2000). An investigation into the stability of the complexes (both binary and 
tertiary) showed the tertiary complex to be the most stable. Thermal stability tests looked at 
heating of the complexes to three different temperatures and results from this showed stability 
increased as the complex increased in size:  
 
HS:FGFR1  HS:FGF1  FGF1:HS:FGFR1 
             Least stable complex          Most stable complex 
(Wu et al., 2003) 
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The complexes were firstly heated to 47 °C. At this temperature the HS:FGFR1 binary complex 
decreased dramatically. It was then heated to 60 °C and at this point both binary complexes were 
lost (HS:FGFR1 and HS:FGF1), only the tertiary complex was stable at this temperature. The 
tertiary structure was finally lost when heated to 100 °C. A dual - receptor system is in place in 
which the HS:FGF binding will allow or facilitate the binding of FGF2 to its corresponding receptor 
(FGFR). This suggests that HS acts almost as a template which can bring together FGF2 with its 
required FGFR (Pye and Gallagher, 1999). FGF signalling is brought about by FGFR 
dimerization. The formation of the signalling complex can occur in one of two ways: 
1. FGF1 is oligomerized by HS which then presents it to the FGFR (Ornitz, 2000; Pellegrini 
et al., 2000)  
2. HS acts almost like a bridge between FGF and FGFR bringing the whole complex 
together (Guimond et al., 1993).  
The above theory would agree with HS being a membrane associated co - receptor, coordinating 
the interaction between FGF and FGFR’s (Goodger et al., 2008). Here a 2:1 HS:FGF1 complex 
was favoured; even with excess HS present. FGF2 has been proposed to have two receptor 
binding sites, which suggests it is able to bind either two receptors or the same receptor in two 
different places (Nugent and Iozzo, 2000). This would allow it to bind both the receptor and HS 
together; however a high level of FGF is able to activate FGFR in the absence of HS. Here a 
FGF:FGFR complex can be formed but is not a stable complex formation. It does however result 
in partial activation of the complex (Ornitz, 2000). The addition of HS into the complex gives 
greater stability and allows for further activation of the complex.  
An active dimer has been identified by Digabriele et al (Digabriele et al., 1998) which involve two 
FGF2 molecules interacting with one heparin chain. The FGF molecules cluster along opposite 
sides of the HS chain and the distance between the two binding sites is approximately 40 Ǻ.  
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1.8.6.1 Complex Ratios 
A symmetrical dimer consisting of 2 X 1:1 FGF:FGFR complex is able to form; however it has 
already been identified and has shown to be quite unstable (Ornitz, 2000). Stabilisation of this 
comes from receptor - receptor interactions between the FGF of one complex and the FGFR of 
the other complex (Schlessinger et al., 2000). Domain II of the receptor contains a positively 
charged pocket or canyon in which HS/hep chains are able to fit, therefore providing a crosslink 
which connects the complex together (Zhang et al., 2001). A 1:1 complex can involve two 
different ways of binding (Figure 1.17): 
1. Ligand and receptor both interaction with HS/Hep. 
2. Ligand is in contact with HS/hep but the receptor has no contact with the chain (Ornitz, 
2000; Pellegrini et al., 2000) 
The interactions between FGF, HS and FGFR can interact in three different ways: 
• Cis 
• Trans 
• Mix – contains both cis and trans interactions.  
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Figure 1.17 
 
 
Figure 1.17 Interactions of HS with FGF and FGFR.  
 
HS can interact with FGF and FGFR in a variety of different ways, in a cis, trans or a mixed 
interaction. This figure has been adapted from Wu et al (Wu et al., 2003). 
 
FGF FGFR HS 
A. 
Cis interaction 
B. 
Trans interaction 
C. 
Mix interaction 
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Work carried out by Wu et al (Wu et al., 2003) has shown the smallest HS oligosaccharide (dp6) 
can interact with two FGF1’s in a trans interaction. A HS dp12 is the minimum size to form a 1:1 
FGF:FGFR in a cis interaction and for the mix interaction, a HS dp16 can fully span a 2:2 
FGF1:FGFR2 complex.  
The complexes thought to exist in nature are thought to contain a combination of different sized 
HS/hep chains and different ratios of FGF and FGFR. The complexes identified are: 
• 2 x FGF2 + HS + 2 x FGFR 
• FGF + HS + FGFR 
• FGF + HS + 2 x FGFR (Pye and Gallagher, 1999) 
• FGF2 tetramers implicated as an active complex such as cytokines (Interferon γ and 
PF4) (Moy et al., 1997).  
 
1.8.6.2 The Symmetrical Complex 
X-ray crystallography data used to confirm or dismiss these structures has been used and the 
first structure identified was the symmetrical complex (one of the more well known complexes) 
(Figure 1.18) (Schlessinger et al., 2000). It involves a 2:2:2 complex and the crystal structure 
identified a binding cleft in which it was first thought that a hep dp10 would be able to facilitate the 
complex. However not one, but two hep dp10 chains were identified in the X-ray crystal structure. 
Here the non-reducing ends were found in the centre of the canyon, with the remainder of the 
chain then interacting with the high affinity binding sites. The stability of this complex is aided by 
the hydrogen bonds, which stabilize the configuration of the heparin chains.  
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Figure 1.18 
 
 
 
 
 
 
 
 
Figure 1.18 The X-ray crystal structure of a symmetrical complex of a 2:2:2 
FGF2:FGFR1:heparin ternary complex.  
 
The co-ordinates for this structure were taken from the protein data bank file 1FQ9 (Schlessinger 
et al., 2000). The FGF molecules are shown in dark blue and the FGFR’s are red and dark red 
respectively.  
It is not immediately obvious that there are two heparin chains from Panel A. This becomes more 
apparent in Panel B, where the two chains can be seen running along the top of the complex.  
 
Heparin 
chain 1 
Heparin chain 2 
A. B. 
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In the crystal structure the GlcNS(6S) was found in the chair form and the IdoUA was found in 
both the chair conformation and the skew boat conformation. The symmetrical complex is shown 
to have extensive protein - protein contact and so is thought to be the more stable of the two 
complexes. This complex is thought to be responsible for mitogenic activity (Goodger et al., 
2008). The FGFR plays a role in determining which heparin sequence binds to the complex, with 
the length of the chain and the sulphation pattern required to elicit a response. The formation and 
separation of the complex is rapid and as a result the FGF is able to sample many sequences 
before it has the opportunity to bind to the FGFR (Harmer, 2006); therefore binding many 
sequences until it ultimately identifies the correct sequence needed to elicit a response.  
 
1.8.6.3 The Asymmetrical Complex 
The other well known model is the FGF receptor ectodomain bound to both FGFR and heparin. 
This is known as the asymmetrical complex, where a single chain is involved and can be 
assembled by itself internally. There is no contact between the FGF and the FGFR so they are 
reliant on the joining of the hep chain to bring the complex together (Goodger et al., 2008). It 
identified FGFR2, FGF1 and a hep decasaccharide in a 2:2:1 ratio (Figure 1.19). This involved 
human FGFR2 IIIc:FGF1:hep decasaccharide and was confirmed by the presence of a single 
peak using SEC (Pellegrini et al., 2000).  
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Figure 1.19 
 
 
Figure 1.19 The FGF1:FGFR2:heparin complex. 
 
The coordinates were taken from the protein data bank, file 1E0O (Pellegrini et al., 2000). The 
FGF molecules are shown in red, the FGFR in blue with the one HS chain spanning the whole 
complex. A number of electrostatic interactions will be evident between the various negatively 
charged groups on the HS chain. These will involve the carboxyl and sulphate groups on the 
chain and the positively charged amino acids present in the FGF and FGFR molecules, which are 
exposed at the surface of the proteins.  
 
Heparin 
chain 
FGF 
FGFR 
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1.8.7 Interaction of HS with FGF1 and FGF2 
The two most studied members of the FGF family are FGF1 known also as aFGF and FGF2 
known as bFGF. They are both expressed by vascular smooth muscle cells, neurons, fibroblasts 
and epithelial cells. FGF2 is also released by macrophages in response to inflammation and by 
platelets in response to blood vessel injury (Goodger et al., 2008). FGF activation is quite specific 
and is dependant on certain sequences in the HS chain. It is particularly dependant on sufficient 
chain length, sulphation pattern and the more recently observed phenomenon; the configuration 
of individual residues in the chain (Guglieri et al., 2008). The involvement of HS is therefore due 
in some respect to the biological modifications it has undergone during biosynthesis (Wu et al., 
2003). The interaction of HS with FGF’s is essential for the many signalling events to occur 
(Harmer, 2006) and the FGF’s are implicated in development of almost every major structure and 
tissue type in the body (Harmer et al., 2004).  
 
1.8.7.1 FGF1 
FGF1 is thought to be the universal ligand in the FGF family in that it is able to bind with high 
affinity to all of the FGFR’s. The FGFR’s are classed as the signalling receptors so this interaction 
is very important. However, it is thought to bind to HSPG’s with relatively low affinity (Pye et al., 
2000). FGF1 is very much similar in terms of structure to all the FGF family (DiGabriele et al., 
1998; Harmer, 2006).  
It is a small, compact, non - glycosylated protein which adopts a β-trefoil structure or fold 
(Pellegrini et al., 2000). This consists of 12 anti-parallel β - sheets with a 3 - fold internal 
symmetry. The β - sheets form a barrel like structure at one end with the use of the amino and 
carboxyl terminal strands. Inside; the barrel is hydrophobic, whilst the outside is rich in amino 
acids (Olsen et al., 2003). These charged amino acids play a major role in the interaction with the 
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sulphate (SO3
2-) and the carboxyl (COO-) groups found on the HS chain (Bitomsky and Wade, 
1999). Docking experiments by Digabriele et al (Digabriele et al., 1998) have shown the 
interaction of FGF1 on specific heparin oligosaccharides and was able to identify a specific 
binding area within the FGF, especially for binding to heparin (Figure 1.20). The binding site 
involves amino acids 112 – 128, with 112 – 113 showing the highest probable interaction and was 
clearly shown when binding FGF1 with a hexasaccharide. Results from the docking with 
monosaccharides and disaccharides also suggested the importance of this region with the same 
sequences able to dock with a fully active dimer of FGF promoters. Interactions with each 
monomer linked back to the binding seen in the decasaccharide with the specific charged groups, 
with no protein - protein contact observed (Bitomsky and Wade, 1999).  
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Figure 1.20 
 
 
 
 
 
 
 
 
Figure 1. 20 The specific binding interaction between FGF1 and a heparin hexasaccharide. 
 
The specific role of the charged amino acids in the binding site can be seen in Panel A. The 
binding site involves amino acids 112 – 128 with 112 and 113 showing the highest probable 
interaction. This figure has been adapted from Digabriele et al (Digabriele et al., 1998).  
Panel A. The binding site involved in heparin binding. Atoms are colour coded (C = white; O = 
red; S = yellow; N = blue; with the interactions shown by the yellow dashed line. 
Panel B. The electrostatic potential; mapped onto the surface of an FGF1 promoter. The dark 
blue area is representative of positive electrostatic potential. 
 
A. B. A. B. 
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As shown by dynamic light scattering, gel filtration and sedimentation velocity ultracentrifugation, 
the heparin decasaccharide was able to dimerize FGF1 in solution. The complex was also able to 
promote tyrosine autophosphorylation, activating the receptor and inducing neutrite outgrowth in 
living cells (DiGabriele et al., 1998). 
The binding site was also confirmed by work carried out by Pellegrini et al (Pellegrini et al., 2000), 
who were able to identify residues Asn 118, Lys 112 and 113 (identified as the area with the 
highest probability of binding a heparin hexasaccharide), Asn 114, Lys 118, Arg 119 and 122, Gln 
127 and Lys 128 in the binding site. GAG - protein consensus sequences are known to be rich in 
lysine, arginine and histidine which all contain polar side chains (Hileman et al., 1998). Lysine and 
arginine make up a majority proportion of the residues identified in the binding sites mentioned 
above. It is also interesting to note that arginine is known for its high affinity towards HS; whereas 
lysine shows the opposite effect and has been known to decrease or lower overall affinity 
(DiGabriele, Lax et al., 1998). The fact that both of these are present in the binding site contribute 
towards an intermediate effect (Hileman et al., 1998). Asn 18 has also been identified in the 
binding of FGF1. All of the mentioned residues make ionic contact with sulphate (SO3
2-) and the 
carboxyl (COO-) groups on the HS/heparin chain (DiGabriele et al., 1998).  
 
1.8.7.2 HS interacting groups with FGF1  
HSPG’s interact with FGF’s and the FGF signalling pathway (Guglieri et al., 2008), but the 
specificity is somewhat unknown. When bound in a complex with HS, it is the interaction of the 
polar groups from the FGF and the NS groups from the HS chain which are most important. 
Interestingly the protein - protein interactions (FGF-FGFR interactions) are not thought to be as 
important, even when HS/heparin bridges the complex (DiGabriele et al., 1998). FGF1 is known 
to bind with low affinity to HS via the NS domains (Pye et al., 2000). FGF activation has been 
shown to be dependant on the sulphate pattern; as well as sufficient chain length and the 
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conformation of specific residues (Guglieri et al., 2008). The sequences identified as important in 
this binding are: 
IdoUA(2S) – GlcNS(6S) 
(DiGabriele et al., 1998) 
Work carried out by Wu et al (Wu et al., 2003) identified 6S to be critical in the formation of a 
complex involving both FGF and FGFR. 3S was also found to help in binding FGF’s, but not in 
the tertiary complex. HPLC results, using FGF1 and HS, showed the binding of FGF1 occurred 
with a NaCl concentration greater then 0.5 M; with those sequences containing a greater amount 
of sulphate groups then those binding with less then 0.5 M NaCl (Kreuger et al., 2001). 
Experiments on selectively de - sulphated heparin showed there is a requirement for IdoUA(2S) – 
GlcNS(6S), for binding to FGF1 (Maccarana et al., 1993 ), which agrees with the work carried out 
by Digabriele et al (Digabriele et al., 1998). This tri - sulphated disaccharide cannot be substituted 
by any other O-sulphate group. This was shown by comparing two groups with the same amount 
of 6S groups present, found in different positions. It showed a varying amount of affinity amongst 
the two groups. By increasing the 6S content the affinity was found to increase (Kreuger et al., 
2001). The effect of O-sulphation on FGF1 was also carried out by Jastrebova et al., (Jastrebova 
et al., 2006); here the amount of both 2S and 6S were investigated by affinity chromatography. 
This was used to identify the differences in the binding of both FGF1 and FGFR. Results are as 
follows with the amount of 2S groups increasing stepwise: 
2 X 2S groups + variable 6S groups = produced a moderate complex involving FGF1 and 
FGFR1c and 2c. 
3 - 4 X 2S groups + variable 6S groups = produced an increased amount of the complex with 
FGFR1b and 1c. 
8 - 10 X 2S groups + variable 6S groups = formed a strong complex formation with FGFR4.  
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The complexes were observed and assessed by affinity chromatography. The results indicated 
that as the amount of NaCl increases, the number of 6S groups found on the chain also 
increases, therefore the binding increases. This agrees with work carried out by Kreuger et al 
(Kreuger et al., 2001). They were able to show that the amount of 6S groups increased from zero 
groups up to 4 6S groups as the concentration of NaCl increased. Alongside this the affinity of the 
complex increased.  
 
1.8.7.3 FGF2  
FGF2, like FGF1, has the same common β - trefoil structure and shares approximately 55% 
homology (Olsen et al., 2003). It is the most studied member of the FGF family because it is 
involved in a wide range of biological processes including embryonic development; especially in 
the lungs and limbs of embryos. Here it is the primary inducer of mesoderm formation in 
embryogenesis (Zhang et al., 2001), is involved in cell growth and tissue repair. FGF2 is a potent 
angiogenic stimulator which puts it in the forefront for targeted drug design. Angiogenesis is the 
well known process by which new blood vessels are formed from pre - existing ones. This is a 
normal process found in wound repair and myocardial infarction; but is also the fundamental step 
in tumour growth and metastasis. It is an essential process in the transition of a tumour from its 
dormant to a malignant state (Folkman, 2006). FGF’s are secreted by tumours (known as 
pro - angiogenic molecules) in an autocrine or a paracrine manner. This is used to determine 
many cancers by their increasing amount of FGF present (Goodger et al., 2008). Human 
metastatic melanoma has been found to express high levels of FGF2 (Nikitovic et al., 2008). 
FGF2 is found in an inactive form in normal tissue but has been found to be activated upon injury, 
inflammation or in tumour invasion (Casu et al., 2002). Interestingly the inactivation of FGF2 or 
the target of FGF2 with antibodies can lead to the inhibition of cells (Nikitovic et al., 2008). 
FGF2 also known as bFGF belongs to the HBGF family along with FGF1 as well as at least two 
oncogenes, int-2 from stomach tumour cells and also hst/ks from Kaposi sarcoma cells (FGF4 is 
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also known as Kaposi sarcoma FGF) (Ishihara, 1994). Like FGF1 it is composed of 12 anti-
parallel β-strands, each of which is H - bonded to β - strands adjacent to the primary sequence. 
This forms a barrel structure which is closed by amino and carboxy strands. The core is 
inaccessible to any solvent and is found to be packed with hydrophobic and aromatic chains 
(Zhang et al., 1991). It was initially thought that HS binding to FGF was to protect from proteolysis 
and thermal denaturation. It is also thought to act as a reservoir for growth factors, these being 
released by enzymes to degrade (Zhang et al., 2001). FGF2 and HS bind either at the surface of 
the cell or in the extracellular matrix, providing convenient storage for the FGF’s (Maccarana et 
al., 1993 ).  It comprises a 15 KDa protein which is the proteolytic product of an 18 KDa protein 
and has 90% homology across all species (Nugent and Iozzo, 2000). The activity of FGF2 can be 
lost completely if binding to HS is hampered in any way. Without the presence of HS, binding 
would not occur (Guimond et al., 1993). Therefore cells lacking HS, or even unsulphated HS, will 
not respond to FGF unless this is added into the equation (Maccarana et al., 1993 ).  
 
1.8.7.4 HS interacting groups with FGF2 
The binding site for heparin has been identified as residues 27, 28, 101, 102, 103 and 120 - 137 
(Faham et al., 1996) (Figure 1.21). These are similar to the binding residues identified for the 
FGF1:HS interaction (see pg 79). The binding of heparin to FGF2 is mediated by the same 
negatively charged groups found on the HS chain (Schlessinger et al., 2000). Further work on the 
X-ray crystal structure identified 25 H - bonds between FGF and heparin which provided further 
information on the binding site between these two molecules: 
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Heparin binding site (- Hydrogen bonds) = Asn 27 found on the β1 - 2 loop. 
     = Arg 120 and Thr 121 on the β9 - 10 loop.  
= Lys 125, 129, Gln 134, Lys 135 and Ala 136 found on 
the                                         β11 - 12 loop  
(Schlessinger et al., 2000) 
 
All other interactions occur via S - mediated interactions between heparin and FGF with NS and 
2S groups. X-ray crystallography structures show the importance of a sequence repeat, (also 
identified in FGF1); the trisulphated: 
IdoUA(2S) – GlcNS(6S) 
(Faham et al., 1996). 
 
These are particularly important when considering the sulphate groups found in the identified 
sequence, and also the amino acid side chains involved in the binding of the protein (Pye et al., 
1998). The minimum binding sequence consists of NS and 2S groups found on continuous 
GlcN - IdoUA sequences. The binding site forms a distorted anti-parallel β- turn on the surface of 
the protein. Also identified were Tyr 114 and 115 which are thought to be a strong binding 
determinant and contour maps showed a rather prominent centre of positive charge 
corresponding to a cluster of lysine amino acids: 119, 120, 125, 129 and 135 (Zhang et al. 1991). 
For a HS chain to be able to bind to more then one molecule a long chain structure is required 
with the same or similar sequence (Casu et al., 2002). DiGabriele et al (DiGabriele et al., 1998) 
also identified the same binding sequence but without the attached 6S group: 
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IdoUA(2S) – GlcNS  
(DiGabriele et al., 1998; Harmer, 2006). 
These results do not agree on how important the 6S group is in binding. However; the 
involvement of the 6S group has been identified in the stability of the tertiary complex formation. 
The presence of the sulphate groups on the NS residues gives the tertiary complex stability 
(Jastrebova et al., 2006).  FGF2 binding is thought to be capable with only one type of 
O-sulphation, identified as 2-O-sulphation. This is identified in an epitope containing:  
IdoUA(2S) - GlcNS - IdoUA(2S) 
which FGF2 interacts with strongly. This was identified in HS obtained from pig intestinal mucosa 
(Kreuger et al., 2005).  
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Figure 1.21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.21  FGF2 binding site with a heparin hexasaccharide fragment.  
 
The binding site identified in FGF2, with the heparin hexasaccharide fragment binding to the 
molecule. The highlighted section shows the identified binding site between the FGF and the 
heparin chain (see Preliminary results of 1BFC and 1FQ9). This figure has been adapted from 
(Faham et al., 1996). 
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1.8.8 The importance of specific groups on the HS chain and chain 
length – interactions for both FGF1 and FGF2 
The binding of HS/heparin chains to FGF has been shown to be highly rich in IdoUA(2S) 
residues, particularly in binding FGF2. The affinity increases with the addition of more IdoUA(2S) 
in the chain and also with an increase in chain length (Pye et al., 1998). Binding studies have 
pinpointed the importance of a single IdoUA(2S) which was determined by investigating bound 
and unbound fractions of HS digested with Hep I and nitrous acid, alongside investigating the 
minimum sized chain able to bind the FGF’s. Hep I has been shown to cleave sequences 
between GlcNS-IdoUA(2S) (Murphy et al., 2004), thus allowing for the confirmation of the 
presence of this important IdoUA(2S) residue. The smallest and least sulphated oligosaccharides 
capable of binding FGF2 were identified as octasaccharides of which contained essentially all 
GlcNS with a single IdoUA(2S) residue (Maccarana et al., 1993 ). The position of this IdoUA(2S) 
was thought to play a major role in what would determine some sequences to be active when 
bound to FGF and others to remain inactive but bound (or unbound altogether). The following 
sequences show the possible importance of the IdoUA(2S) group (Figure 1.22). 
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Figure 1.22 
A. HS dp8 
 GlcUA – GlcNS – IdoUA(2S) – GlcNS – HexA – GlcNS – HexA – aMan  
B. HS dp8 
 GlcUA – GlcNS – HexA – GlcNS – IdoUA(2S) – GlcNS – HexA – aMan 
 
FGF binding pentasaccharide sequence 
 
Figure 1.22 An example of the difference between active and inactive sequences due to the 
position of a single IdoUA(2S) residue.  
 
This figure has been adapted  from (Maccarana et al., 1993) and shows that a change in position 
of only one sulphate group can have an effect on the biological activity of the sequence.  
1  2        3            4 5   6  7   8 
1      2    3    4       5           6  7 8 
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Both these sequences are the made up of the same residues but with the IdoUA(2S) found in a 
different position on the chain. Firstly it is found in position 3 in the inactive sequence (A) and in 
position 5 of the active sequence (B). The FGF binding pentasaccharide sequence is also 
identified in the above structure (B). These sequences show the 2-sulphate group as being of 
great importance in the binding of FGF2 to HS/heparin chains. Studies have also shown that the 
presence of any 6S group is not a requirement here (Schlessinger et al., 2000), as clearly none 
are seen in the above structure (Maccarana et al., 1993 ).  
The pentasaccharide binding sequence proposed by Maccarana et al (Maccarana et al., 1993) is 
thought to be the minimum length of saccharide needed for binding FGF2 but longer is needed 
for biological activity. The 2S and 6S groups identified on IdoUA(2S)-GlcNS + (6S) (the identified 
binding sequence needed for FGF binding (Faham et al., 1996; DiGabriele et al., 1998)), has 
been shown to neither promote nor impede the interaction with growth factors (Guimond et al., 
1993). This could be due to the size of the oligosaccharides used in this study.  
An X-ray crystal structure was used to study the length of chain required, but was also used to 
locate the IdoUA(2S) residues in the chain (Faham et al., 1996). Resulting from this, it was found 
that heparin itself was too heterogeneous to crystallise and therefore it was decided to use 
tetrasaccharide and hexasaccharide sized fragments were used in replacement of the heparin 
chain. The structures were determined and found to be: 
UA – GlcNS – IdoUA(2S) – GlcNS(6S) – IdoUA(2S) – GlcNS(6S) 
 
Residues 1-4 make up the tetrasaccharide sequence. Interestingly the high affinity sites identified 
on the surface of FGF2 had a common interaction with residues 2 and 3 on the heparin chain 
above. This corresponds to the GlcNS-IdoUA(2S) residues both in the tetrasaccharide sequence 
and the hexasaccharide sequence.  
1        2   3           4     5               6
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Further down the chain a low affinity site was identified which was occupied by rings 5 and 6, 
residues IdoUA(2S)-GlcNS(6S). This result is interesting in that the proposed low affinity binding 
site involves the previously mentioned residues which make up the high affinity site. Also worth 
nothing are the different conformations identified for the IdoUA(2S) residues in the chain (Figure 
1.23). 
 It is thought that the binding of FGF2 to heparin can occur when both conformations identified 
above are present (Faham et al., 1996). Binding information regarding the sequence mentioned 
above can be found in Table 1.2; with information on the high and low affinity binding sites 
identified when bound to FGF2. 
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Figure 1.23 
 
UA – GlcNS – IdoUA 2S – GlcNS 6S – IdoUA 2S – GlcNS 6S 
 
 
 
Figure 1.23 An example of a heparin sequence with both high and low affinity binding 
sites. 
 
Here the high affinity site has been identified in the 1C4 conformation, with the low affinity binding 
site in the 2S0 conformation. This is thought to be the optimum binding conformation required for 
all active oligosaccharides. 
 
          1        2             3            4             5       6  
  
          1C4            
2S0 
 
  High affinity        Low affinity      
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Table 1.2  
 
Residue Affinity Interactions with HS Conformation of IdoUA 2S 
Lys 27 Low 5 and 6 2S0 
Asn 28 High 2 and 3 1C4 
Asn 102 Low 5 and 6 2S0 
Arg 121 High 2 and 3 1C4 
Lys 126 High 2 and 3 1C4 
Gln 135 High 2 and 3 1C4 
Lys 136 Low 5 and 6 2S0 
 
 
Table 1. 2  High and low affinity binding sites in FGF2. 
 
The main interacting amino acids in the FGF2 molecule and their interaction with specific 
residues in the heparin chain. This figure has been adapted from (Faham et al., 1996). 
 
Ultimately it is still unknown exactly which conformation or combinations of conformations are 
required to have a lasting effect on the binding of FGF’s and FGFR’s. Hileman et al (Hileman et 
al., 1998) have shown that an FGF bound to a hexasaccharide has a tight interaction with one 
IdoUA(2S) found in the 2S0 conformation. The other IdoUA(2S) is thought to adopt a weaker 
interaction and therefore stays in the 1C4 conformation, unable to flip to the ‘active’ conformation. 
This result contradicts results shown in above (Table 1.2), (Faham et al. 1996). It has been 
proven many times that the IdoUA + (2S) are a flexible ring structure and can adopt multiple 
conformations (see Structural Conformation). When a protein such as an FGF molecule interacts 
with HS/hep, a kink is introduced into the structure. This is known as the kink motif and is 
identified as the following structure: 
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GlcNS 6S – IdoUA 2S – GlcNS 6S/OH 
 
The GlcNS groups are found in the fixed 4C1 conformation with the IdoUA(2S) in the 
1C4 
conformation. Here the kink motif allows for maximum contact with the FGF molecule. However; 
interesting is the presence of the 6S group (Guglieri et al., 2008) in the kink motif. Up until 
recently the importance of the 6S group had been dismissed, but the presence of it in this 
sequence alongside the conformation of the IdoUA + (2S) may play an important relationship 
after all.  
The most studied structure is one which contains both the FGF2 binding site (Figure 1.24) and 
the kink motif, identified above. The IdoUA(2S) plays an important role in both the kink motif and 
in the binding site of FGF2 and is found in a 1C4 conformation.  
4C1  
         1C4    
4C1 
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FGF-2 binding site 
The kink motif 
The Pentasaccharide binding sequence 
Figure 1.24 
  
 
UA – GlcNS 6S – IdoUA 2S – GlcNS 6S/OH – IdoUA 2S – GlcNS 6S/OH 
 
 
 
 
 
GlcNS – IdoUA 2S – GlcNS – IdoUA – GlcNS 
 
 
 
 
 
 
 
Figure 1.24 HS sequences identified with binding properties 
 
The FGF2 binding motif is highlighted in green, with the Kink motif highlighted in red. The 
highlighted sulphate groups are identified as playing an important role in the interaction with 
protein ligands. Also shown is the minimum pentasaccharide binding sequence, which is thought 
to be the minimum sequence able to activate ligand activity. 
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A single IdoUA(2S) has been identified which is required for appreciable binding to FGF2 and any 
additional 2S groups will increase further binding (Kreuger et al., 2001) The minimum 
pentasaccharide sequence identified contains an IdoUA(2S) in position five which had been 
previously identified as important for binding, (Figure 1.24, shown in green), and the IdoUA(2S) in 
position three was thought increase affinity, alongside the 6S group upstream of the iduronic acid 
residue (Figure 1.24, shown in red). A HS decasaccharide sequence was found to contain a 
minimum of three IdoUA(2S)-GlcNS repeats substituted with one or two 6-O-sulphate groups 
increases the biological activity of the FGF2: HS complex (Guimond et al., 1993; Pye et al., 
2000).  
 
1.9 Modelling of HS dp10 
Work undertaken by Goodger (Goodger, 2003) on HS dp10’s showed an inability of certain 
sequences to activate FGF2 when bound with FGFR1 IIIc. However a slight change in the 
sequence, such as an extra sulphate group on the chain, or a change in conformation then 
allowed for some of these sequences to become active when bound to the same complex. This 
shows that a certain amount of specificity is required when dealing with active and inactive 
sequences. The following work will look at the issue of specificity and which sequences are 
essential for promoting the ability of FGF2 with FGFR1 IIIc to bind HS and become active. This 
was initially undertaken using a cell line devoid of HS, namely BaF-32 cells. The sequences 
shown (Figure 1.26) are taken from work done by Goodger (Goodger, 2003) who was able to 
show that some fully sequenced HS dp10 sequences were active in the presence of HS and 
others were not (Figure 1.25). 
 
These sequences were investigated by using molecular modelling software – AMBER 9; and 
molecular docking software – Autodock; to try and identify the essential components in the HS 
chain which allow for some sequences to bind and activate the complex; whilst other HS 
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sequences are unable to do this. This involved identifying specific sulphate groups in the chain, 
extracting information for torsion angles (torsional data) and finally conformational changes in the 
ring structures (from Cremer-Pople puckering parameters).  
It should be noted that once sequenced the residue at position 9 in all four sequences was not 
determined (sequences 1, 3, 5 and 7). Therefore models will be created using one of two different 
residues at this position, either a GlcUA or an IdoUA.  
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Figure 1.25 
 
 
 
 
Figure 1.25 HS sequences of active and inactive in BaF-32 cells transfected with FGFR1 
IIIc.  
 
Work carried out by Goodger (Goodger, 2003) identified two active and two inactive HS 
sequences using BaF-32 cells devoid of HS and transfected with FGFR IIIc.  
FGFR1 IIIc + 10ng/ml FGF-2 
+ Organon 10-A 
 
FGFR1 IIIc + 10ng/ml FGF-2 + 
Celsus 10-F 
FGFR1 IIIc + 10ng/ml FGF-2 
+ Organon 10-B6 
 
FGFR1 IIIc + 10ng/ml FGF-2 
+ Organon 10-E1 
 
Active HS sequences 
Inactive HS sequences 
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Figure 1.26 HS dp10 sequences.  
 
The Goodger isolated HS sequences isolated from a number of HS sources; namely Celsus HS 
and Oregon HS. These were purified as in the procedure described (chemical digestion) using 
nitrous acid. 
Panel A. The sequences of the identified Goodger oligosaccharides, with additional sequences 
where the residue could not be determined (sequences 2, 4, 6 and 8).  
Panel B. HS decasaccharide structures of active and inactive sequences; with FGF2 and FGFR1 
IIIc. Sequences 1 and 2 are Celsus 10-F. Sequences 3 and 4 are Org 10-A. Sequences 5 and 6 
are Org 10-B6. Finally sequences 7 and 8 are Org E1. 
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1. UA - GlcNAc - GlcUA - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - IdoUA - GlcNAc(6S) 
2. UA - GlcNAc - GlcUA - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - GlcUA - GlcNAc(6S) 
 
3. UA - GlcNAc - GlcUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA - GlcNS - IdoUA - GlcNAc(6S) 
4. UA - GlcNAc - GlcUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA - GlcNS - GlcUA - GlcNAc(6S) 
 
 
 
5. UA - GlcNAc - GlcUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - IdoUA - GlcNAc 
6. UA - GlcNAc - GlcUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - GlcUA - GlcNAc 
 
7. UA - GlcNS - IdoUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS - IdoUA - GlcNAc(6S) 
8. UA - GlcNS - IdoUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS - GlcUA - GlcNAc(6S) 
 
 
 
Figure 1.26 A. 
Active Sequences: 
Inactive Sequences: 
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Inactive sequences: 
Active sequences: 
 
Figure 1.26 B. 
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1.9.1 Cremer-Pople puckering parameters.  
The ring conformation is a mathematical measurement of the pyranose ring conformation 
determined by Cremer and Pople (Cremer and Pople 1975; Cremer, 1984). The values are given 
based on the order that they are selected within the ring system (Forster and Mulloy, 1993). For 
the purpose of this study they were designated in the order O5-C1-C2-C3-C4-C5 and therefore 
should be comparable to the majority of the previous work undertaken. The only exception being 
the work of Regazzi et al (Regazzi et al., 1986; Regazi et al., 1993) where the chosen order was 
C1-C2-C3-C4-C5-O5. The number of the rings was first established by Cremer and Pople 
(Cremer and Pople, 1974); where the ring oxygen is assigned atom 1 with the carbon linked to 
the glycosidic bond assigned as atom number 2. Note this numbering is different to those 
assigned when picking the Cremer-Pople puckering parameters. This is in accordance with 
IUPAC rules in numbering ring structures.  
All types of ring puckering can be mapped on the surface of a globe, with the poles at θ = 0° or 
180°, corresponding to the canonical chair conformations (Haasnoot, 1992).  
 
1.10 Molecular Modelling 
 
1.10.1 AMBER 
 
The name AMBER refers to a suite of programmes which allows the user to perform molecular 
dynamic simulations on biomolecules. It consists of two parts, AMBER Tools and AMBER 10, 
which was released as the latest version in April 2008. The information flow of AMBER involves a 
number of different programmes; the ones used in this report are highlighted (Figure 1.27).   
 
Leap: the primary programme which allows the building of a new system, or to modify an old 
system. 
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Antechamber: is responsible for assigning partial charges to the model, assigning atom types 
when creating a new system, recognizing atom types, generating residue topology files, finding 
missing parameter force fields and supplying reasonable substitutes. 
Sander: is the basic energy minimiser and molecular dynamics programme. This is able to relax 
the structure by moving the atoms down an energy gradient until a low energy minima has been 
obtained.  
Ptraj: a general purpose programme for analysing and processing trajectory and coordinate files 
created from molecular dynamic simulations.   
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Figure 1.27 
 
Figure 1.27 Information flow in the AMBER suite of programmes 
 
The flow of information using AMBER 9, which was released from The Scripps Research Institute 
in March 2006. 
. 
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1.10.1.1 Torsion angles Φ and Ψ vs. Conformational Energy 
To be able to define the orientation of each disaccharide pair found in the decasaccharide 
structure, torsion angles play an important role. The torsion angles are used to assign the 
stereochemistry of a glycosidic linkage. In the case of heparan sulphate, a 1 - 4 linkage occurs 
joining one ring system to the next. The Φ (phi) torsion angle is determined as H1, C1, O4, C4 in 
literature (Mulloy et al., 1994) which determines the angle from the non - reducing side 
monosaccharide (Figure 1.28, Panel A).  
The other angle is known as the Ψ (psi) torsion angle. This is defined as C1, O4, C4, and H4 in 
literature (Mulloy et al., 1994) (Figure 1.28, Panel B). 
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Figure 1.28 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.28 Definition of the phi and psi torsion angle 
 
Panel A. The phi torsion angle is defined as H1, C1, O4, and C4.  
Panel B. The psi torsion angle is defined as C1, O4, C4 and H4.  
 
 
A. 
B. 
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Each disaccharide pair within an oligosaccharide will have different torsion angles and the lowest 
energy conformations will be sought and used to build static models of the oligosaccharides (see 
Experimental Materials and Procedures). These values can be either positive or negative 
depending on the position of the lowest energy minima in the energy maps.  
 
1.10.1.2 The Exo and Endo - Anomeric Effect 
The exo-anomeric effect is characteristic of ring substituents to reside in the usually 
energenetically favoured position; the equatorial orientation. This is favoured due to steric 
interactions from the surrounding environment. is not favoured and the axial orientation becomes 
the preferred position (Figure 1.29).  
The opposite of this is the endo - anomeric effect and is characterised by the preference of 
specific groups, such as the acetyl groups to reside in the axial position, as opposed to the 
equatorial position (identified in pyranose ring structures). This is due to the lone pairs on the ring 
oxygen interacting with the non-bonded electrons attached to the O5-C1 bond causing them to 
move to different rotamer positions. The endo-anomeric effect is thought to give general 
preference for gauche conformations (Krawczuk, 2005). It is the exo-anomeric effect which is 
thought to cause a barrier that reduces free rotation around the Φ and Ψ torsion angles.  
According to this theory; all the C1 substituents found within HS will have a preference for the 
axial orientation. This includes the glucuronic acid and N- glucosamine residues which are 
technically classed as βC1-C4 but only through naming nomenclature (the C1-C4 bonds being 
classed as βC1-C4). The C1 substituents are actually positioned axially as are all the HS internal 
units (Murphy, 2007). The energetically ‘unfavoured’ axial orientation is favoured over the 
equatorial orientation shown by the larger arrow pointing towards the axial orientation (Figure 
1.29, Panel A).  
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Figure 1.29 
 
 
 
 
 
Figure 1.29 The Exo- and endo-anomeric effect 
 
The anomeric effect, also known as the endo-anomeric effect is the preference for certain 
substituents bonded to the anomeric carbon to reside in the axial position. The energetically 
favoured position (the equatorial position) is unfavoured due to steric interactions.  
 
Panel A. The axial orientation (α orientation).  
Panel B. The equatorial orientation (β orientation) is the ‘energetically’ preferred position and is 
known as the exo-anomeric effect.  
 
 
 
A. B. .. 
.. .. 
.. 
The dipoles are in the opposite 
direction so is thought to be most 
stable 
The dipole repels each other 
and so is thought to be less 
stable 
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1.10.1.3 Preparing the model in explicit solvent 
All molecular dynamic simulations in this study are run in explicit solvent with periodic boundaries 
(the effect of the solvent is not included in the calculations). Firstly, the structure needs to be free 
from all charge. This is achieved by the addition of Na+ which is added at positions of high 
negative electric potential. These electronegative groups have been identified as: 
1. The carboxyl group on UA. 
2. The N-sulphate on GlcNS. 
3. The 2-O-sulphate group on IdoUA(2S). 
4. The carboxyl group on IdoUA.  
5. The N-acetyl group on GlcNAc. 
These are the positions in which the xleap programme will add neutralising counter ions to 
neutralise the negative charge on the molecule (Walker, 2006).  
A truncated octahedral box of pre - equilibrated water is then added into which the structure will 
be encased. This water is known as TIP3P water because of the three bonds each individual 
water molecule contains and is made up of triangulated water models which have an extra bond 
in the structure due to the high bending frequency of the water molecule (Figure 1.30) with no 
charge on the extra bond.  
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Figure 1.30 
 
 
O
H H
 
 
 
Figure 1.30 A simple water model showing the TIP3P water model 
 
The simulated water used in all molecular models carried out in this study use the TIP3P water 
model. It is a triangulated water model bonded on all three sides due to the high bending 
frequency identified in the molecule. This makes the water molecule more effective in terms of 
computational time.    
 
104.52° 
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TIP3P belongs to the simplest water model group as it is rigid and will only rely on non-bonded 
interactions. It is labelled as TIP3P because of the number of interaction sites available on the 
molecule, these corresponding to the three atoms of the water molecule. Coulomb’s law is used 
to model electrostatic interactions and the Lennard - Jones potential is used for dispersion and 
repulsion forces, but this is applied only to the interaction between the oxygen atoms in each of 
the models (Walker, 2006). TIP3P water is the most common water model used because of its 
simplicity and its computational efficiency.  
 
1.10.1.4 The use of a Periodic Boundary 
A periodic boundary is used to make sure there are no ‘holes’ between the solvent, the 
carbohydrate and the solvent and the edges of the box. These gaps can lead to vacuum bubbles 
forming in the system and lead to the instability during the simulation (Steinbrecher, 2006). The 
boundary keeps the pressure constant and so allows the volume of the box to change, thus 
allowing the water to equilibrate around the carbohydrate and attain an equilibrium density. All 
particles being simulated are enclosed in a specific sized box and are then replicated in all three 
dimensions which give a periodic array. A 2D array can be seen (Figure 1.31) where movement is 
replicated across all the boxes available. 
 
The box in grey shows the central box, which houses the main carbohydrate structure and 
contains all the water molecules. All the other boxes around it are a replica of this central box. As 
a particle moves out of the box, as shown by the arrow in the central box (in this case particle 1), 
another particle is able to enter from the box below, therefore being replaced by another atom. 
This makes the number of particles in the central box constant and this occurs in all boxes 
(Walker, 2006).   
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Figure 1.31 
 
Figure 1.31 An example of a periodic boundary with the box coloured in grey housing the 
carbohydrate to undergo MD simulation.  
1 
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A suitable cut off point is needed so that when a particle leaves one side of the box the same 
image is not seen twice. This can be done by making sure the size of the box is more than twice 
the cut - off distance, therefore a particle will find it impossible to interact with two images of the 
same particle simultaneously. For all simulations carried out, the cut - off size has been 
determined to be 6 Å. The carbohydrate structure from here is now ready to go through 
minimisation and molecular dynamics (see Molecular Modelling in Experimental Materials and 
Procedures, pg 117) with any experimental analysis carried out after this process.  
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2.1 Experimental Materials: 
Porcine intestinal mucosal heparan sulphate was purchased from Celcus laboratories (Cincinnati, 
OH, USA). Heparinase I (Flavobacterium heparinum; EC 4.2.2.7), Heparinase II (F. heparinum no 
EC number assigned) and Heparinase III (F. heparinum EC 4.2.2.7) were all purchased from 
Grampian enzymes, (Orkney, Scotland, UK). Bio-gel P-10 (fine grade gel) was purchased from 
Bio - Rad (Hemel Hempstead, UK). PD - 10 prepacked disposable Sephadex G - 25 columns 
were purchased from GE Healthcare UK Ltd (Buckinghamshire, UK). The ProPac PA - 1 
semi - preparative strong anion exchange HPLC column was from Dionex (Camberley, Surrey, 
UK). The TSK3000PW gel filtration column was from Phenomenex (Macclesfield, Surrey, UK). 
HPLC grade sodium chloride and calcium acetate were purchased from VWR International 
(Leicestershire, UK). Ammonium bicarbonate and sodium acetate were from Sigma Aldrich 
(Dorset, UK). Disodium phosphate was purchased from DH Scientific Ltd (Huddersfield, UK). D2O 
was purchased from GOSS scientific (Essex, UK) and the Shigemi NMR micro tube was 
purchased from Sigma Aldrich (Dorset, UK).   
 
2.2 Experimental Procedures: 
2.2.1 Enzymatic Digestion of Heparan sulphate 
Porcine Intestinal mucosal HS was depolymerised using the enzyme heparinase III. To 10 g of 
HS 50 ml is added of 0.1 mM calcium acetate, 0.1 mM sodium acetate (heparinase/hep buffer), 
pH 7.0, and 20 mU of heparinase III was added. Further additions of 20 mU of enzyme were 
made every 24 hours until digestion was complete (as detailed by analytical gel filtration). In total, 
25 identical digests were carried out from the 10 g of HS starting material. All digests were carried 
out at 25 °C. 
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2.2.2 Gel Filtration Chromatography Analysis of Heparinase III 
Digestion 
2.2.2.1 Analytical  
Each 10 µl aliquot containing 200 µg of HS was applied to a TSK3000PW gel filtration column. 
The column was pre - equilibrated with PBS (phosphate buffered saline, 0.15 M NaCl, 20 mM 
Na2HPO4, at pH 7.2). The sample was eluted from the column using the same PBS at a flow rate 
of 0.4 ml/min and this was monitored in - line for absorbance at 232 nm.  
 
2.2.2.2 Preparative  
Each 200 mg digest was applied to a Bio-gel P10 column with a column size of 3 x 120 cm. The 
samples were then eluted from the column with ammonium bicarbonate (NH4HCO3) 0.25 M at a 
flow rate of 9 ml/hr. 3 ml fractions were collected and their absorbance monitored at 232 nm to 
create a HS digest profile. The relevant fractions were then pooled together and frozen. These 
samples were then lyophilised and the concentration of NH4
+ ions was reduced by repeatedly 
re - dissolving the samples in 5 ml of H2O and again lyophilising.    
 
2.2.3 SAX – HPLC (Strong Anion Exchange Chromatography) 
Each pooled fraction corresponds to a different sized HS oligosaccharide. The HS 
octasaccharides were applied to a ProPac PA - 1 column (9 x 250 mm) pre - equilibrated with 
distilled water adjusted to pH 3.5 with HCl. Elution of the samples was with HPLC grade NaCl set 
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at a gradient of 0 - 1.2 M NaCl over 90 minutes. The flow rate was set to 4 ml/min. Those 
gradients were chosen according to Merry et al (Merry et al., 1999). The resulting peaks were 
measured for absorbance at 232 nm and 4 ml fractions were collected. All relevant, identical 
fractions were pooled together and concentrated initially by rotary evaporation and then by freeze 
drying (it was then decided that freeze drying was the better of the two methods and so this was 
used for the rest of the project). The resulting sample was then diluted in H2O, desalted on a 
PD10 desalting column and eluted with H2O. The sample was then concentrated again and 
lyophilised.  
 
2.2.4 NMR Spectroscopy 
All NMR spectra were recorded by Dr. Neil Mclay (Department of Chemical and Biological 
Sciences, University of Huddersfield).  
For NMR measurements; the total quantity of the sample was dissolved in 250 µl of PBS (0.15 M 
NaCl, 20 mM NaPO4 at pH 7.2). It was then repeatedly exchanged in 1 ml 
2H2O with lyophilization 
immediately between these steps. Analysis was carried out using a 5 mm Shigemi tube, with the 
sample volume being kept at 250 µl throughout. The 1H - NMR spectra were acquired using a 
Brucker NMR spectrometer operating at a 1H frequency of 500 MHz. The reported chemical shifts 
are in ppm and are relative to the sample reference tetramethylsilane. TOCSY and NOESY 
spectra were recorded using the phase sensitive mode using states TPPI. 256 experiments of 
2048 data points were recorder with 128 scans over a width of 2741 KHz in both dimensions.  
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2.2.5 Molecular Modelling 
All molecular modelling was carried out using the AMBER 9 molecular modelling software 
package. (Case et al., 2004).   
For all molecular models, all carboxyl, sulphate and sulphamate groups were modelled in their 
de-protonated form and charges were added to them using the antechamber module of AMBER 9 
with the AM1 – BCC charges and GAFF atom types assigned. 
 
2.2.5.1 Calculation of the lowest energy minima across glycosidic 
bonds 
All calculations were carried out using the Glycam04 force field for carbohydrates, provided in the 
AMBER suite of programmes. Extra parameters needed for the C4 to C5 double bond found on 
the non-reducing end uronic acid were taken from the General Amber Force Field (GAFF).  
For each glycosidic linkage conformational energy maps were created as a function of the Φ and 
Ψ torsion angles. Each torsion angle was varied over the full possible range of angles (-180° to 
+180°) and the non - bonded energy was calculated at 20° intervals with torsional restraint of 
10000 Kcal/mol until the RMS derivative for the whole structure was less than 0.01 (Mulloy et al., 
1993).  
 
2.2.5.2 Preparation of the model  
All simulations were carried out as explicit solvent models where the effect of the solvent is not 
included in any of the calculations. Each model built was placed in a truncated octahedral box of 
explicit TIP3P water molecules. This water has not felt the influence of the charges added to the 
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structure, neither has it felt the influence of the carbohydrate. Na+ ions were added to the 
structure using the addions method in the xleap programme in AMBER to ensure there is no 
overall net charge on the molecule. An 8 Å buffer of water was generated around each of the 
models to the edge of the water box in each dimension. Standard molecular modelling techniques 
were then used to run minimisation and molecular dynamics in explicit solvent.  
 
2.2.5.3 Minimisation 1 
The first part of minimisation involves holding the molecule fixed while the positions of the water 
and the ions are minimised. This is known as “positional restraints” which works by essentially 
keeping the atoms fixed in the same position, in this case the starting position. These atoms are 
restrained to conform to this structure via the use of a constant force. Minimisation is turned on 
and has 1,000 total steps of minimisation, with molecular dynamics switched off. (500 steps of 
steepest descent minimisation, followed by 500 steps of conjugate gradient minimisation). The 
volume is kept constant and it has a cut - off of 6 Å.  
 
2.2.5.4 Minimisation 2  
This involves minimising the entire system; including the water and the ions with no restraints on 
the system. (This involves 1,000 steps steepest descent minimisation, 1,500 steps conjugate 
gradient minimisation). Again constant volume is used and the cut - off is 6 Å.  
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2.2.5.5 Molecular Dynamics 1 
Phase 1 involves a heating phase with restraints on the molecule. The system is allowed to heat 
up from 0 K to 300 K. A weak restraint is used to ensure there are no fluctuations in the system. 
The Langevin temperature equilibration system is used in this instance which maintains and 
equilibrates the system temperature using a collision frequency of 1.0 ps -1. This is kept at a 
constant volume for 20 ps. The restraints are then switched off and it changes to constant 
pressure with a periodic boundary (average pressure of 1 atm) in which time the water is allowed 
to relax during 100 ps of molecular dynamics. Running at constant temperature over 100 ps 
closely resembles laboratory conditions.  
All hydrogen atoms in the system have no effect on large scale dynamics and therefore can be 
fixed in position. Using the SHAKE algorithm, all bonds involving hydrogen are constrained, thus 
removing hydrogen motion which has the highest frequency oscillation in the system. This allows 
for an increase in time steps from 1 fs (10-15) to 2 fs without introducing any instability in the 
molecular dynamic simulation, meaning more molecular dynamics can be run in a shorter amount 
of time. 
 
2.2.5.6 Molecular Dynamics 2 
The subsequent MD run involves equilibration of the whole system using constant pressure so 
the density of the water can relax. The temperature is set at 300 K and the restraints are 
removed. This is run for anywhere from 100 ps to 10 ns in time with 100 ps running a total of 
50,000 molecular dynamic steps with a 2 fs11 time step. SHAKE is again used in this part of the 
simulation. The system coordinates were output to a trajectory folder every pico - second (for the 
100 ps run) resulting in a final trajectory file for each run consisting of 1,000 frames per structure.  
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2.2.6 Molecular Docking 
Firstly; the receptor oligosaccharide was prepared in AutoDockTools (ADT) version 1.5.4, revision 
30. It offers a complete visualization, which is required for the setup of each docking process. 
Here all polar hydrogen’s were added (those not already included in the pdb file) and then 
Gastiegar charges were automatically calculated. The file was then saved as a PDBQT file ready 
for input into Vina. PDBQT files are the input file type for both Vina and Autodock 4. These 
include all of the coordinates needed including atomic coordinates, Autodock atom types and all 
the partial charges needed. A gridbox; using the gridbox function is used to visibly judge the size 
of the search area (the area where Vina will calculate the lowest energy conformation for the 
docked ligand onto the protein). This box needs to be of large enough size to contain the entire 
oligosaccharide and the binding site on the protein, in general a restricted area of the protein 
(Seeliger and de Groot, 2010). Here the gridbox was set up using the following steps found in the 
configuration text (conf.txt): 
 
receptor = FGFfahnam_nowater.pdbqt 
ligand = frame.pdbqt 
 
out = out.pdbqt 
 
center_x = 1.02 
center_y = 0.004 
center_z = 58 
 
size_x = 62 
size_y = 52 
size_z = 42 
 
num_modes = 40 
 
This reads in the receptor and the ligand as the names given and prints all of the output files to a 
file called out.pdbqt. The num-modes (number of modes) will tell it to produce a maximum of 40 
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low energy conformations. The number of modes did not change when the value was increased 
to 60 or decreased to 20. 
Next the ligand was prepared which involved choosing the number of rotatable bonds in the chain 
and the positions of them. For all the Goodger decasaccharide structures, 46 rotatable bonds 
were identified but this was initially reduced to zero rotatable bonds, making the structure 
completely rigid. This makes them computationally fast in terms of computing time as adding in 
rotatable bonds increases the amount of conformations available in each space. The Vina 
software will try to calculate the affinity of all the possible conformations. It is only later on in the 
process that it will then discard these structures as part of the Genetic Algorithm (GA). This is the 
only type of search which Vina can perform.   
The frames chosen for the Vina docking experiments were taken from data obtained from the 
Puckering-torsion data. Separate frames from both the 1 ns and the 10 ns MD simulations were 
taking for docking analysis and these were chosen based on changes in the ring conformation 
and also the torsional geometry. Each individual frame chosen, was set rigid in the as described 
above. Through this process, many different frames are chosen and docked to the x-ray crystal 
structure. The aim; to find the correct conditions in terms of ring conformation, sulphate pattern 
and torsional geometry required for FGF2 binding. 
 
A multi-model file is created with all of the created conformations ranking in order from lowest to 
highest energy which is based on Vina’s unique scoring function (Trott 2009). The docking 
process uses random seed when performing the search which will bring a degree of randomness 
to the search and is used in all docking simulations. The likelihood of not finding the correct 
binding conformation can be reduced by increasing what is known as ‘exhaustiveness’ and can 
be manually changed in the computing process. However increasing this will inevitably have an 
effect on processing time and so a compromise must be made between the processing time and 
the likelihood of not finding the correct binding conformation.  
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The binding output file, logs data on the proposed binding modes rating them on the affinity of 
binding to the known binding site. The higher up the list the proposed model is found, the higher 
the affinity for the binding site is. Vina also prints a score based on the distance from the best 
mode. Here it is split into two sections; the first rmsd l.b (root mean square deviation, lower bound 
value) and the second being rmsd u.b (from the upper bound value). The model proposed as the 
best fit binding model (i.e. the lowest energy binding model) is rated as number 1 and this has the 
highest affinity (kcal/mol) and both rmsd l.b and rmsd u.b are rated as 0.000. The mode (model) 
number from here increases as the affinity for the binding site decreases. The rmsd values 
fluctuate in value.   
Rmsd – matches each of the atoms in one configuration with the closest atom of the same 
element type in the other conformation.  
Rmsd u.b – matches each atom in the one configuration with itself in the other configuration and it 
ignores any symmetry (Trott 2009) 
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3.1 Enzymatic Digestion of Heparan Sulphate 
Studies required the production of a library of HS oligosaccharides that was produced by the 
digestion of Porcine mucosal HS by the enzyme heparinase III. This was compared to work 
previously carried out by Murphy (Murphy 2007).  
A profile for intact HS which had not undergone enzyme digestion (Figure 3.1, Panel A) was used 
as a comparison with the digested HS samples. This enabled us to fully attain when complete 
digestion had taken place (Figure 3.1, Panel B). The digestion process was closely monitored to 
attain this end point. The undigested HS sample showed a broad range of peaks which is 
indicative of the diverse structural nature of the HS chain (Figure 3.1, Panel A).; whereas the 
digested sample (Figure 3.1, Panel B) showed a shift in the peak elution times and an 
amplification of the profile, indicating digestion of the HS chain. Further additions of enzyme and 
longer incubation times by Hep III showed no further degradation with the digest thought to be 
complete.  
Once conditions for complete heparinase digestion had been determined, a larger digest was set 
up using 10 g of HS in 100 ml of hep III buffer. Over a course of 5 days 20 mU of enzyme was 
added over 24 hours. The following elution profile shows the enzyme digest of time 0 hours 
(Figure 3.2, Panel A) and after 120 hours (Figure 3.2, Panel B).  
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Figure 3.1  
 
 
 
 
 
 
 
 
  
 
 
Figure 3.1 Analytical TSK3000PW gel filtration profile of HS after 48 h incubation with 
10mU Hep III.   
 
Samples of 10 µg from a total digest of Celsus HS by the heparinase III enzyme were 
chromatographed on a TSK3000PW analytical gel - filtration column (30 x 0.75 cm).  
Panel A. Intact HS profile before the addition of heparinase III.  
Panel B. Gel filtration profile after 88 h incubation with 40 mU heparinase III added.  
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Figure 3.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Comparison of large sample digest carried out on an analytical TSK3000PW gel 
filtration profile of HS after 120 h incubation with 10mU Hep III.   
Here the two profiles are the same suggesting the enzyme digestion had not gone to completion. 
Further enzyme needed to be added.  
 
Panel A. Intact HS profile at 0 hours.  
Panel B. After 120 hours and the addition of 100 mU heparinase III.  
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The two graphs in Figure 3.2 indicate the same digestion profile, suggesting that the enzyme 
digest has not gone to completion at all. This was thought to be due to the large amount of hep 
buffer added to the digest. It was decided to freeze dry the samples, and re-suspend in a smaller 
amount of hep buffer. This time just 30 ml of hep buffer was added to the HS samples and the 
enzymes were again added in 20 mU aliquots until the digestion went to completion, as 
determined by analytical gel filtration (Figure 3.3).  
These results clearly show that the digestion has gone to completion; which is vital if the HS 
chain is to be fully digested to the smaller, known oligosaccharide fragments. A poor hep III 
digestion can lead to problems when identifying the oligosaccharide of choice (dp8) from the size 
exclusion column. This is because peaks tend to overlap each other making it very difficult to 
obtain a pure sample. Also confusion in which peak has actually eluted from the column, meaning 
some of the wrong peaks were collected and pooled together.  
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Figure 3.3 Comparison of the analytical gel-filtration profiles of HS digested with 140 mU 
(total) of heparinase III over a 7 day period, re-dissolved in 30 ml hep buffer.  
 
Compare to undigested profile in Figure 3.1, Panel A.  
Panel A. 24 hours after the addition of 20 mU of hep III.  
Panel B. 48 hours and an additional 20 mU of  hep III. 
Panel C. 120 hours and a further 60 mU of hep III (20 mU added every 24 hours).  
Panel D.168 hours and an additional 40 mU aliquots of hep III, added every 24 hours. 
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3.1.2 Preparative Gel Filtration Chromatography of HS Digested 
to Completion with Heparinase III 
Once the enzyme digest has fully gone to completion the HS samples were run on a preparative 
size exclusion column. Typically 2 ml aliquots of the digested sample was taken from the bulk 
sample and carefully loaded onto the column (disturbing the gel beads in the column leads to 
overlapping of peaks). A typical profile is shown in Figure 3.4 (Panels A and B) with the sized 
oligosaccharides clearly resolved. The two profiles shown are very similar to each other but show 
that no two HS digests give the same profile. This is indicative of the complex structure of HS 
oligosaccharides. Disaccharides (dp2) to dodecasaccharides (dp12) were collected and pooled 
together for further analysis; larger fragments (dp14+) were collected, pooled together and stored 
at -20 °C.  
Figure 3.4 also shows the reproducibility of the separation technique, particularly for 
oligosaccharides in the range of dp8 - dp2. Larger oligosaccharides were more susceptible to 
peak overlap due to overloading of the column. However; given this studies’ target of isolating 
octasaccharides, these overloading problems could be ignored and greatly increased the speed 
by which the digest could be processed. To combat these problems in future studies, a larger 
column (or two sizeable columns) would mean sample overload would not occur. It also gives an 
indication of how slight differences in the profile can lead to the collection of the wrong peak, 
resulting in a sample which is no longer pure.  
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Figure 3.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 4 Preparative Bio-Gel P10 gel filtration chromatography profiles of HS digested to 
completion with heparinase III.   
A typical HS gel-filtration profile (Profiles A and B), from a size exclusion column; digested to 
completion by the addition of 140 mU of heparinase III (which should be far in excess of the 
amount of enzyme needed). HS was chromatographed on a Bio-Gel P10 gel filtration column set 
at 9 ml/h, over 72 - 90 hours, (column size 3 x 120 cm) with a buffer of 0.25 M NH4HCO3. 
Samples were pooled as indicated (red lines on the graph).  
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3.1.3 SAX-HPLC of Octasaccharide (dp8) sized Oligosaccharides 
All octasaccharides samples obtained from the gel-filtration column were applied to a strong 
anion exchange column to separate on the basis of charge, to identify the number of charged 
species of oligosaccharide within the defined size group. Size defined oligosaccharide fractions 
were applied to a Pro-Pac PA-1 SAX-HPLC column (fitted with a 20 µl sample loop), the resulting 
profiles are shown in the following figures (Figures 3.5 - 3.6).  
Previous work undertaken on the smaller dp4 sized oligosaccharides (Hileman et al., 1997) 
indicated a lack of biological activity and the more recent study on dp6 sized oligosaccharides 
(Murphy 2007) lead to the analysis of the dp8 sized oligosaccharides. The characterization of 
larger HS fragments is necessary in building a library of known HS oligosaccharide structures. HS 
is such a complex polysaccharide; that in reality it would be impossible to purify the billions of 
potential sequences produced in the modification process of the chain (see Introduction, p32). If 
NMR and molecular modeling studies enabled the identification of specific patterns in Iduronate 
conformation, sulphation placement and amount of sulphation; alongside torsional geometries of 
the glycosidic bonds then this would enable us to successfully predict protein activating 
sequences. Longer fragments may be one of the fundamental factors in FGF2-HS interactions 
and so studying the longer oligosaccharides produced by enzymatic digestion could dramatically 
aid this study. If time constraints were not such a factor, then longer oligosaccharide fragments 
could also have been studied (ideally dp10 and dp12 sized oligosaccharides).  
 
Many peaks were identified in the SAX-HPLC elution profiles and those large enough to collect 
were designated peaks 1-19. The number of peaks actually taken on for further purification 
however was far fewer (5 samples underwent preliminary NMR analysis, with only 1 being 
partially assigned). This was due to the time constraints of the purification and the requirements 
for large quantities of oligosaccharide needed for NMR analysis.  
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Figure 3.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 SAX-HPLC chromatography of sized HS oligosaccharides 
 
A typical SAX-HPLC profile of the dp8 sized oligosaccharides generated by heparinase III 
digestion, purified by Bio-Gel P10 gel-filtration chromatography. Samples were applied to a Pro-
Pac PA1 SAX-HPLC column (250 mm x 9 cm); with a gradient of 0 - 1.2 M NaCl over 90 minutes. 
Detection was determined by absorbance at 232 nm. 
Each single peak or group of peaks collected, were then taken on for further analysis and are 
numbered in the following figure (Figure 3.6).  
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Figure 3.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 An expanded SAX-HPLC chromatography of sized HS oligosaccharides. 
 
A typical SAX-HPLC profile of the dp8 sized oligosaccharides generated by heparinase III 
digestion, purified by Bio-Gel P10 gel-filtration chromatography. Red arrows indicate peaks 
collected for NMR analysis.  
Panel A. An expanded HPLC profile from Figure 3.5, showing 0-35 minutes and peaks 1-5.  
Panel B. An expanded HPLC profile, showing 30-65 minutes and peaks 6-13. 
Panel C. An extended HPLC profile, showing 50-90 minutes and peak 14-19. 
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3.1.4 PAGE Analysis 
It has previously been shown that SAX-HPLC purification of Hep III derived HS oligosaccharides 
may not give a single homogeneous oligosaccharide structure. The use of PAGE is an important 
step in the purification process of HS oligosaccharides as it separates HS species on the basis of 
charge as well as on the basis of size. An example of this is the two hexasaccharide samples 
purified by Vives et al (Vives et al., 2001) in which both sequences were identical apart from the 
positioning of a 6-O-sulphate group in the chain (Figure 3.7). These eluted from the SAX-HPLC 
column at the same time, however when run through gel electrophoresis these were identified as 
two differently charged species: 
 
It was decided that this step would be carried out after NMR analysis, to conserve time. A PAGE 
step, if needed, could be used in the NMR analysis where peaks resonate at the same frequency 
but appear almost as a shadow of each other. This would create an overlapping of certain peaks 
where more then one differently charged species was present in the sample.  
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Figure 3.7 
 
HS-M6B: 
∆HexA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA - GlcNAc 
HS-m6B: 
∆HexA - GlcNS - IdoUA(2S) - GlcNS - IdoUA - GlcNAc(6S) 
 
 
Figure 3.7 An example of two different HS hexasaccharides oligosaccharides identified 
using PAGE analysis.  
 
This figure has been taken from work by Vives et al (Vives et al., 2001). Two different bands were 
identified in the gel filtration profile, but they were eluted from the SAX-HPLC column at the same 
time.  
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3.1.5 NMR 
3.1.5.1 Preliminary NMR Analysis of Octasaccharide (dp8) Samples 
 
Initial NMR analysis was carried out on a number of peaks identified in the HPLC profile (Figure 
3.6). These were analyzed by 
1
H 1 - D NMR spectroscopy. (Note not all 19 peaks were submitted 
for analysis as there was not enough in the sample to get a full COSY, TOCSY and NOESY 
profile). Chemical shifts are based on values obtained mainly from heparin derived 
oligosaccharides (Chuangt et al. 2001), but also previous work carried on HS dp6 samples 
(Murphy 2007).   
 
 
After initial 
1
H 
1
D NMR runs on several dp8 samples, it was decided that some were pure enough 
to be classed as single oligosaccharide species. Therefore PAGE analysis was deemed 
unnecessary, not just because they were thought to be pure samples but also to preserve as 
much sample as possible. That is not to say that all of the 19 peaks identified would not need this 
extra purification step. 
1
D NMR analysis showed a clean spectrum with no shadowing of any 
peaks, which is indicative of a heterogeneous sample. The UA (H4) peak is the key in identifying 
a pure sample. However the major problem with all samples was a lack of material in all the NMR 
oligosaccharide samples. Sample was lost at every stage of the purification process which means 
it is especially hard to gain enough sample to enable a full NMR assignment. Even if the 
purification process was not as demanding, collecting dp8 sized oligosaccharides from gel 
filtration was not an easy step as that sample size itself was small; making it extremely difficult to 
collect pure oligosaccharides of the correct size.  
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Figure 3.8 One-dimensional 500 mHz 
1
H-NMR spectra of HS octasaccharide dp8(1) and 
dp8(3) oligosaccharides. 
 
Oligosaccharides dp8(1) and dp8(3) were analysed by 
1
H 1-D NMR spectroscopy .However due 
to the lack of sample assignment of the proton NMR spectra was not possible. Therefore 
chemical shifts were putatively assigned with the additional information from the literature 
chemical shift values reported mainly for heparin derived oligosaccharides (Chuang et al., 2001) 
and also HS purified hexasaccharides (Murphy 2007).  
Spectra were recorded in PBS at 25°C. 
 
Panel A. dp8(1). 
Panel B. dp8(3). 
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Figure 3.8 
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3.5.5.2 Partial Spectral Assignment of HS dp8(2): 
Two dimensional COSY, TOCSY and NOESY NMR spectra were recorded for HS dp8(2), 
although there was not enough sample to assign all chemical shifts. As a demonstration of 
assignment a detailed breakdown of the proton assignment is given. The recorded spectra can be 
found in the appendix (see discussion).  
COSY spectra 
TOCSY spectra 
NOESY spectra 
 
The assignment of proton chemical shifts using 2D-NMR is regarded as standard practice, and so 
proton breakdown is not normally given; however for the purposes of assignment, the non-
reducing terminal UA will be designated by the letter “a” with any subsequent assignments made 
in the chain lettered accordingly (alphabetically).   
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Figure 3.9 Assignment of the non-reducing terminal uronic acid, residue “a” of 
oligosaccharide HS dp8(2). 
 
Using the known chemical shift for H4 of the uronic acid this was assigned using the COSY 
spectrum as 5.970 ppm. Then from here and going anti-clockwise around the ∆UA ring structure, 
H3 was assigned to 4.42 ppm, H2 to 3.99 ppm and finally H1 to 5.28 ppm.   
 
The coloured arrows in the COSY spectrum (Figure 3.7) trace the path of this proton across the 
spectrum. Cross peaks formed from this ring system are linked by the arrows: 
 
UA  H4 
 H3 
 H2 
 H1 
 
A single trans-glycosidic cross-peak is then identified in the corresponding NOESY spectrum 
(Figure 3.9), circled. This is from an unassigned proton of the linking glucosamine residue and 
was assigned to 5.529 ppm. This cross-peak is circled in panel B.  
 
Panel A.  COSY spectrum 
Panel B. NOESY spectrum 
Panel C. 
1
H spectrum 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: Results 
 
 
145 
H3 – H2 
H2 – H1 
H4-H3 
H1 H3 
H2 
 
2.0 
 
 
 
3.0 
 
 
 
4.0 
 
 
 
5.0 
 
 
 
6.0 
 
f1
 
(p
p
m
) 
Figure 3.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panel A.  
Panel B.  
6.0   5.5  5.0               4.5               4.0             3.5            3.0 
(ppm) 
H4 
O 
CO2 
-
H4 
H
H1 
O H2 
OR 
          6.0     5.5        5.0                  4.5     4.0                 3.5               3.0 
f2 (ppm) 
          6.0                5.5                    5.0                  4.5               4.0                 3.5       3.0 
f2 (ppm) 
Panel C.  
Chapter 3: Results 
 
 
146 
Figure 3.10 Assignment of glucosamine, residue “b” of oligosaccharide HS dp8(2). 
 
Using the TOCSY spectrum (Panel A), the anomeric proton H1 from the ring system containing 
the unidentified glucosamine proton at 4.085 ppm was assigned. This was identified as the H1 at 
5.552 ppm. Again using the COSY spectrum (Panel B) H2 was assigned 4.06 ppm, identifying 
this as the proton involved in the trans-glycosidic NOE from residue “a”, H3 to 4.15 ppm and H4 
to 4.41 ppm. Unfortunately H5 and H6 were not assigned due to the lack of sample (this meant a 
HSQC spectrum could not be recorded).  
The coloured arrows again correspond to the cross-peaks involved in tacking the particular proton 
of interest across the spectrum. The cross-peaks for protons H1-H4 form part of the glucosamine 
ring system.  
H4 
 H3 
 H2 
 H1 
 
Unfortunately due to lack of sample we were unable to identify any more cross-peaks in the 
NOESY spectrum. 
 
Panel A.  TOCSY spectrum 
Panel B. COSY spectrum 
Panel C. 
1
H spectrum 
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Figure 3.11 Spin System B 
 
Using the COSY spectrum (Panel A) and starting with the chemical shift for the anomeric proton, 
H1 was assigned as 5.34 ppm; H2 was assigned 4.85 ppm, H3 to 3.92 ppm and H4 to 3.54 ppm. 
There was also a possible assignment for H5 to 4.75 ppm, but this was unconfirmed as it would 
be found under the water peak seen in the spectrum.   
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1
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Figure 3.11 
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Figure 3.12 Spin System C 
 
Using the COSY spectrum (Panel A) and starting with the chemical shift for the anomeric proton, 
H1 was assigned as 5.02 ppm; H2 was assigned 4.38 ppm, H3 to 4.29 ppm and H4 to 3.57 ppm. 
Due to the lack of sample for the TOCSY and NOESY analysis, this peak was not identified.  
 
Panel A.  COSY spectrum 
Panel B. 
1
H spectrum 
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Figure 3.12 
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Figure 3.13 Spin System D 
 
Using the COSY spectrum (Panel A) and starting with the chemical shift for the anomeric proton, 
H1 was assigned as 4.93 ppm; H2 was assigned 4.59 ppm, H3 to 3.96 ppm and H4 to 3.53 ppm. 
Due to the lack of sample for the TOCSY and NOESY analysis, this peak was again unidentified.  
 
Panel A.  COSY spectrum 
Panel B. 
1
H spectrum 
Chapter 3: Results 
 
 
153 
Figure 3.13 
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Figure 3.14 A summary of the partial assignment of the 
1
H chemical shifts for the 
oligosaccharide HS dp8(2) 
 
The chemical shift assignments are summarized in Figure 3.14. Only the first two residues in the 
HS chain, assigned ‘UA’ (residue ‘a’) and ‘b’ are in sequence order. The other partial assignments 
involve COSY cross-peaks from unknown spin systems, assigned as spin system B, spin system 
C and spin system D.   
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Figure 3.14 
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3.2 Molecular Modelling 
 
3.2.1 Calculation of potential energy surfaces 
 
Potential energy surface maps for each glycosidic linkage were calculated as described under 
experimental methods and procedures. These are used as a way of identifying low energy 
linkage geometries, enabling an accurate building of molecular models. Energy surface maps 
were presented as contour plots, one for each glycosidic linkage in each oligosaccharide (data 
not shown). Static models were then built using these starting geometries and the minimum 
energy dihedral angles identified for all of the eight identified HS decasaccharides (Table 3.1) 
using the already established strategy established by Mulloy et al (Mulloy et al., 1993; Mikhailov 
et al., 1997). This approach is valid as the glycosidic linkage geometry is the main contributor in 
determining the overall 3-dimensional shape of an oligosaccharide (see Introduction).  
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Table 3.1 Minimum selected Φ° and Ψ° dihedral angles across each glycosidic linkage of 
HS disaccharides 
All dihedral angles were selected as a result of low energy minima across each glycosidic 
linkage. The potential energy was evaluated using the glycam04 force field within the AMBER 
molecular modelling suite. The conformations shown were used as the starting conformations for 
each residue in the later 1ns MD simulations for biologically active HS oligosaccharides. 
 
The corresponding contour map is an example of two identified low energy minima areas across 
the glycosidic bond between GlcUA - GlcNS. For the purpose of building static models the 
negative area was used. The contour lines present represent the global energy minima (          ) 
marked with an arrow, and intervals from this point of 3 kJ/mol above this, (         ) +3 kJ/mol 
above global minima, (         ) +6 kJ/mol above global minima, (         ) +9 kJ/mol above global 
minima, (         ) +12 kJ/mol above global minima, (         ) +15 kJ/mol above global minima, (       ) 
+18 kJ/mol above global minima. The potential energy was evaluated using the glycam04 force 
field within the AMBER molecular modelling suite. 
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Table 3.1 
Dihedral angles Linkage and Monosaccharide 
Conformation 
Ring conformations indicated in ( ) 
Φ° ψ° 
UA (
1
H2) – GlcNAc (
4
C1) 55 5 
UA (
1
H2) – GlcNS (
4
C1) -15 -30 
GlcUA (
4
C1) – GlcNAc (
4
C1) 40 5 
GlcUA (
4
C1) – GlcNAc(6S) (
4
C1) 45 15 
GlcUA (
4
C1) – GlcNS (
4
C1) -10 -35 
GlcUA (
4
C1) – GlcNS(6S) (
4
C1) 60 10 
GlcNS (
4
C1 – IdoUA (
1
C4) -40 -30 
GlcNS(6S) (
4
C1) – IdoUA (
1
C4) -75   -25 
GlcNS(6S) (
4
C1) – IdoUA(2S) (
1
C4) -50 0 
GlcNS (
4
C1) – IdoUA(2S) (
1
C4) -45 10 
GlcNS (
4
C1) – GlcUA (
4
C1) -35 -20 
GlcNS(6S) (
4
C1) – GlcUA (
4
C1) -35 -25 
IdoUA (
1
C4) – GlcNAc (
4
C1) 35 15 
IdoUA (
1
C4)  – GlcNS (
4
C1) -20 -30 
IdoUA (
1
C4) – GlcNAc(6S) (
4
C1) -30 -10 
IdoUA(2S) (
1
C4) – GlcNS(6S) (
4
C1) -50 -10 
IdoUA(2S) (
1
C4) – GlcNS 
4
(C1) 40 15 
GlcNAc (
4
C1) – GlcUA (
4
C1) -35 -20 
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3.2.2 Molecular dynamic trajectories of the glycosidic linkages Φ° and 
Ψ° 
Previous studies on the ability of different HS oligosaccharide structures to activate or inhibit 
FGF2 signalling showed that it was impossible to make a link between  biological activity and HS 
oligosaccharide structure by analysing the sequence/sulphation pattern of specific HS 
oligosaccharides (Goodger 2003). It was therefore proposed that conformational changes in HS 
oligosaccharide structure, which in turn have been shown to be linked to sulphation pattern, may 
be the source of unexplained FGF2 activatory and inhibitory activities seen with different HS 
oligosaccharide structures. The two principal variable parameters used in determining the overall 
conformation of HS oligosaccharides are the conformationally flexibility of the IdoUA rings and the 
rotation around the glycosidic linkages. It must be remembered that static molecular models of 
HS oligosaccharides alone will not give accurate relationships between structure and biological 
activities, as the oligosaccharides are in a conformational equilibrium with many different 
conformations existing. Any of these could represent the biologically active shape. The challenge 
is to identify these active/inactive conformations from MD simulations of known HS 
oligosaccharide structures and determine the specific structural/conformational features required 
for FGF2 activation, which is the main aim of this thesis.  
HS oligosaccharides studied by molecular modelling in this thesis were selected from the 
previously reported FGF2 stimulatory/inhibitory sequences. These structures are shown in 
Figures 1.23 and Figure 1.24 (see Introduction); along with their relevant activities with FGF2. 
The static models were built first followed by the MD simulations as described in the experimental 
methods.  
 
 
Molecular dynamic trajectories or torsion data were obtained for each HS oligosaccharide studied 
using the AMBER suite of programmes and the data analysed via the mdxvu software 
programme (see http://sourceforge.net/projects/mdxvu) (Murphy 2007). This software allows the 
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monitoring and analysis of the individual glycosidic linkage angles (Φ and Ψ) over the 1 ns (1000 
ps) explicit water molecular dynamic simulation. The 1000 ps timescale was used since previous 
studies using this timescale had shown that oligosaccharides would have sampled all possible 
geometries during this time frame (Murphy 2007). This data was then overlaid onto gnuplot grids 
which had previously been analysed in the static models and the low energy minima for each of 
the glycosidic torsion angles identified during the MD simulation.   
 
MD trajectories were produced for each of the selected oligosaccharides using the AMBER suite 
of programmes and three programs: gnuplot, ptraj and mdxvu were used to analyse these 
trajectories in order to identify the low energy torsion angles. Both torsion angles across the 
glycosidic linkages were analysed independently starting with the Φ (phi) angle which has been 
assigned to atoms H1, C1, O1 and C4 and then the Ψ (psi) angle assigned to atoms C1, O1, C4 
and H4 (Mulloy et al., 1994). The resulting MD data was then combined and overlaid onto the 
static model contour map previously generated.  
The results for each HS oligosaccharide are shown as contour maps (see Figures 3.17 through to 
Figure 3.25) and are found alongside the data obtained from the Cremer-Pople ring puckering 
parameter data which underwent a similar analysis and will be discussed in the following section.  
The movement of C1 and C4 is thought to be severely limited due to the addition of flanking 
residues on either side of the monosaccharide unit in question (Mulloy et al., 1993). This has 
been shown in iduronate monosaccharides modelled as individual units which undergo more free 
rotation when modelled as a separate unit, rather then alongside other ring structures (Ferro et 
al., 1990; Angulo et al., 2005).  
 
3.2.3 Puckering-torsion data 
The Cremer-Pople ring puckering parameter is a means of reducing the Cartesian coordinates, of 
the oligosaccharide sugar rings to form a set of three simple parameters: Q, θ and ф2. The 
parameter Q is the maximum puckering amplitude, involving the rms of the displacements of the 
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six ring atoms in the ring plane. θ and ф2 are angles which are found in the range of 0° < θ < 180° 
and 0° < ф2 < 360° (Forster and Mulloy, 1993).  
 
Molecular dynamic simulations were again carried out over 1 ns (1000 ps), as described in the 
experimental section to give an initial indication of any changes to the Cremer-Pople ring 
puckering parameters θ and where warranted ф2. Models were built in explicit water and kept at a 
temperature of 300 K at 1 atm (see Experimental Materials and Procedures). The starting 
structures of the IdoUA were first held in one of the three low energy conformations 
1
C4, 
2
S0 and 
4
C1 (see Introduction) to gain insight into the properties of each of the conformations during the 
length of the MD simulation (Murphy 2007). IdoUA was shown to be the only ring structure with 
the ability to change conformation and all three of the main conformations adopted by IdoUA (
1
C4, 
2
S0 and 
4
C1) in solution were shown to be present in the simulations. Variations in these 
parameters can be clearly seen with each of the IdoUA conformations having very definitive 
values for each angle. The Cremer-Pople puckering parameters for each IdoUA conformation 
were averaged out and the following values obtained: 
 
IdoUA 
1
C4  θ = 164.2° 
IdoUA 
2
S0  θ = 92.8° 
IdoUA 
4
C1  θ = 8.98° 
UA 
1
H2   θ = 131.7° 
UA 
2
H1   θ = 49.9° 
 
The above angles were used throughout this thesis as an indicator of changes in ring 
conformation during the MD simulation. These values were adapted from Murphy (Murphy 2007). 
 
The ideal 
4
C1 and 
1
C4 structures for hexapyranose rings have average data values of θ = 0° and 
180° respectfully, putting them at the north and south poles of the Cremer-Pople sphere (Forster 
and Mulloy, 1993). All constants were averaged over all 1000 structures produced during the MD 
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simulation (Figure 3.15). The addition of the 2S group on the IdoUA had no effect on the value 
obtained, hence the same average angles could be used to identify conformational changes in 
IdoUA(2S) residues in addition to un-sulphated IdoUA. In some simulations the oligosaccharide 
structures individual IdoUA rings remained in one conformation (either 
1
C4, 
2
S0 and 
4
C1) for the 
duration of the MD simulation (Figure 3.15), others underwent a conformational change as shown 
(Figure 3.16).  
These changes observed in puckering parameters during the MD simulations validated the 
glycam 04 force field in being able to sufficiently confirm and predict structural changes in HS 
oligosaccharides with regard to the low energy conformations of the iduronate ring (
1
C4, 
2
S0 and 
4
C1). This is of great importance as it would not do to predict structures that have not been shown 
to exist experimentally in solution.  
 
The puckering parameter data once analysed separately was then overlaid onto the initial torsion 
data in order to understand if the changes identified in the Cremer-Pople ring puckering 
parameters corresponded to any changes already identified in the torsion data (shown in 
Molecular dynamic trajectories of the glycosidic linkages Φ and Ψ). This data is known as the 
puckering-torsion data and has been laid out over the 1000 ps timescale (the timescale run for all 
initial molecular dynamic simulations).  
The initial conformations are shown in Table 3.1 which is then compared to the MD simulation 
results for all the decasaccharides. Molecular modelling techniques were used in a similar 
manner to those used by Forster and Mulloy (Forster and Mulloy, 1993).  
 
As will be shown later, a change in ring conformation of just a single IdoUA within HS 
oligosaccharides can result in a significant change in oligosaccharide shape and hence biological 
activities. Interestingly, not all possible IdoUA conformations or glycosidic torsion angle 
conformations are predicted to exist within HS oligosaccharides due to the limits of the MD 
simulations. This is also true with the measurement of glycosidic torsion angles which were 
shown in the MD simulations to only exist in a small number of low energy geometries, these 
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changes between torsion angles will also be shown later to result in large shifts in oligosaccharide 
shape. This data taken together will be seen to suggest a role for sulphation pattern in controlling 
conformational dynamics of HS oligosaccharides and their eventual biological activities.   
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Figure 3.15 Cremer-Pople puckering parameters for the HS oligosaccharide iduronate 
residues, alongside the ∆UA residue on the reducing terminal during a 1000 ps molecular 
dynamic simulation.  
For the ∆UA, the HS oligosaccharide used was the dp10(1) oligosaccharide, alongside the methyl 
glycoside of IdoUA which had been previously carried out by Murphy (Murphy 2007). These were 
all repeated for the purpose of this study. 
 
Panel A. θ° values starting in the 
4
C1 conformation for IdoUA.  
Panel B. θ° values starting in the 
2
S0 conformation for IdoUA.  
Panel C. θ° values starting in the 
1
C4 conformation for IdoUA.  
Panel D. θ° values starting in the 
2
H1 conformation for the ∆UA.  
Panel E. θ° values starting in the 
1
H2 conformation for the ∆UA. 
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Figure 3.15 
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Figure 3.16 Cremer-Pople puckering parameters for the internal HS oligosaccharide 
Iduronate-2-O sulphate residues during a 1000 ps molecular dynamic simulation. 
 
Panel A. IdoUA(2S) in the 
1
C4 starting conformation undergoes a conformational transition to the 
2
S0 conformation.  
Panel B. IdoUA(2S) in the 
1
C4 starting conformation undergoing two conformational transitions; 
firstly to the 
2
S0 conformation and then onto the 
4
C1 conformation.   
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Figure 3.16 
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 All active and inactive decasaccharide 1000 ps MD simulations were analysed using the program 
mdxvu, to identify the Cremer-Pople ring puckering parameters. It was hoped that differences 
would be identified between the active and inactive sequences, enabling a greater picture to be 
built up of the main reason why two groups of oligosaccharides with fairly similar structures have 
a different ability to bind to FGF2.   
 
Each monosaccharide unit was analysed to identify the conformations it sampled throughout the 
MD simulation. This was then compared to the starting conformation in which it was initially built 
in. This was then used to check against the torsion data previously analysed. Any changes 
identified in the puckering parameters would hopefully correspond to a change in the dihedral 
angle identified in the torsion data. The results confirmed what was previously known regarding 
the conformation of the glucosamines i.e. these were all identified in the fixed 
4
C1 conformation 
and remain fixed in this conformation regardless of the length of MD simulation (Ferro et al., 
1990). This has been shown in all the corresponding results over the 1000ps timescale and is 
characterised by an average θ value of 10°. Therefore the major contribution to flexibility within 
the HS oligosaccharide must come from the iduronates as stated previously (see Introduction, 
page 64). IdoUA and IdoUA(2S) occur in the three identified conformations (
1
C4, 
2
S0 and 
4
C1) 
during our MD simulations and also, as will be shown later, glycosidic torsion angles.  
 
3.2.4 Decasaccharide models 
The four decasaccharide structures that were chosen to be modelled were identified in  
sequencing FGF2 activity work carried out by Goodger (Goodger 2003); who identified a 
collection of different highly pure HS decasaccharides from a variety of sources and attempted to 
link HS sequence data with biological activity. Two of the HS oligosaccharide sequences 
activated FGF2 in biological assays and two were inactive. There was some initial confusion 
regarding the structure of the decasaccharide sequences at position nine (from the uronic acid 
terminal position) in the chain. When fully sequenced; using nitrous acid to fully depolymerise the 
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HS chain (see p50); the residue found at position 9 was never fully identified. This unit was 
identified as being a uronic acid, either GlcUA or IdoUA, hence two molecular models were built 
for each oligosaccharide with either GlcUA or IdoUA at position 9. This resulted in eight 
decasaccharide models being built designated dp10(1) - dp10(8) (see below).   
Any differences due to the change in position 9 would be interesting to note as it is unknown 
whether the reducing terminal has any influence on ring conformation of IdoUA or the glycosidic 
linkages further down the chain.   
Models were built from the reducing end first as it was easier to add models onto the growing 
chain as described in the experimental section.  
 
Active Oligosaccharides 
dp10(1). UA - GlcNAc - GlcUA - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - IdoUA - GlcNAc(6S) 
dp10(2). UA - GlcNAc - GlcUA - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - GlcUA - GlcNAc(6S) 
 
dp10(3). UA - GlcNAc - GlcUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA - GlcNS - IdoUA - GlcNAc(6S) 
dp10(4). UA - GlcNAc - GlcUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA - GlcNS - GlcUA - GlcNAc(6S) 
 
Inactive Oligosaccharides 
dp10(5). UA - GlcNAc - GlcUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - IdoUA - GlcNAc 
dp10(6). UA - GlcNAc - GlcUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - GlcUA - GlcNAc 
 
dp10(7). UA - GlcNS - IdoUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS - IdoUA - GlcNAc(6S) 
dp10(8). UA - GlcNS - IdoUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS - GlcUA - GlcNAc(6S) 
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3.2.4.1 The Reducing End Linkage - Linkage 9 for the eight 
Decasaccharide models dp10(1) - dp10(8) 
The eight decasaccharides had the following structures for linkage 9 between monosaccharide 
positions 9 and 10: 
 
IdoUA - GlcNAc(6S)  dp10(1, 3 and 7)  
GlcUA - GlcNAc(6S)  dp10(2, 4 and 8) 
IdoUA - GlcNAc   dp10(5) 
GlcUA - GlcNAc  dp10(6) 
 
The GlcUA monosaccharides were all modelled in the 
4
C1 conformation with the IdoUA 
monosaccharides modelled in the 
1
C4 conformation prior to the MD simulation. 
The reducing end terminal contains the 6-O-sulphated, N-acetylated GlcNAc reside in all 
decasaccharides apart from dp10(5) and dp10(6). In line with previous studies (Powell et al., 
2004) these were all identified only in the 
4
C1 conformation and remained in this conformation 
over the whole 1000 ps MD simulation (data not shown). The average value for this conformation 
has been identified as θ = 9° (see puckering-torsion data).  
 
Those oligosaccharides with IdoUA as the chosen residue at position 9 are dp10(1), dp10(3), 
dp10(5) and dp10(7). The three known conformations identified previously were found to be 
present in three of these four models; with the exception being dp10(5). Those oligosaccharides 
which sampled all three conformations show similar profiles in both the torsion data and the 
puckering-torsion data. In dp10(1) the ring starts in the 
1
C4 conformation; (which is the set 
conformation built at the start of the MD simulation). The corresponding glycosidic torsion angles 
here are identified in the negative area of the graph (Figure 3.17, Panel A) which has been 
assigned as geometry B, average value of Φ = -20° Ψ = -30°. As the ring makes the transition to 
the 
2
S0 conformation after approximately 100 ps and then finally onto the 
4
C1 conformation (after 
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400 ps) the values for the dihedral angle increase up to an average of Φ = 30° Ψ = 10°, identified 
as geometry A. A similar pattern is identified in dp10(3), with the torsion angle having a starting 
value of Φ = 40° Ψ = 10°, placing it in the range of positive geometry A, whilst the ring changes 
from the 
1
C4 conformation to the skew boat conformation (this occurs early on in the simulation 
after approximately 50 ps). As the ring undergoes a conformational change to the 
4
C1 
conformation the Φ and Ψ values change from geometry A to B (Φ = -30 Ψ = -30) and then back 
again (Figure 3.17, Panel C). For dp10(7) the torsion angle begins the MD simulation in the 
negative quadrant of the graph (geometry B) and remains here for 300 ps until the IdoUA 
undergoes a conformational transition to the final 
4
C1 conformation. As the ring conformation 
switches the torsion angles change to a positive value as indicated by geometry A (Φ = 40 Ψ = 
10). It remains in this area of the graph for the remainder of the simulation (Figure 3.16, Panel G).  
 
Dp10(5) behaves slightly differently in that at the beginning of the MD simulation the ring structure 
is already identified in the 
2
S0 conformation for a short time before a conformational transition to 
the 
4
C1 conformation after only 50 ps. This shows that the conformational transition from 
1
C4 to 
2
S0 has already taken place in the equilibrium process leading up to the MD simulation process. 
The position of the dihedral angle at the point where the ring is in the 
2
S0 conformation in dp10(5) 
is found in the upper right hand quadrant of the contour map, designated as geometry A. This has 
an average torsion angle of Φ = 40° Ψ = 10°, this area of the graph is sampled many times over 
the 1000 ps timescale and hence represents the most variable linkage studied so far with respect 
to the number of torsional changes during the simulation. The negative area of the graph is 
identified with average values of Φ = -20° Ψ = -20° and is designated geometry B (Figure 3.17, 
Panel E).  
These residues all end the simulation in the 
4
C1 conformation and that is regardless of the 
presence of the 6S group on the terminal residue. The transition to the apparently more stable 
conformation occurs early on in the MD simulation with all models identified in the 
4
C1 
conformation before 500 ps. Longer simulations will be needed in order to confirm that the 
4
C1 
conformation can return to the 
2
S0 or the 
1
C4, however one of the 1 ns MD simulations does show 
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an increase in the puckering parameter indicating a return shift of the 
2
S0 to the 
1
C4  so reverting 
from 
4
C1 back to the 
2
S0 could reasonably be expected over much longer simulations using our 
force field parameters.  
This realignment of the linkage involves a reorientation of not only the terminal residue but also 
has a major influence on the rest of the model in terms of its 3-dimensional shape.   
 
 
It has been suggested that the reducing end conformation is influenced by its environment and 
particularly the neighbouring residues seem to have some kind of effect on the terminal end 
conformation. The presence of either the NS or NAc substituent on the flanking amino sugar 
suggests the dominating conformations are either 
1
C4 or the 
4
C1 conformations. (Ferro et al., 
1990). These conformations identified at the reducing terminal have been identified in a foot and 
mouth disease virus-oligosaccharide receptor complex (O1BFS, which binds to HS) where the 
1
C4 
and 
4
C1 conformations are thought to dominate the reducing end conformation (Fry et al., 1999). 
The presence of the skew boat form is not as common in literature when referring to the reducing 
end residue; however it has been shown to play a role in the Goodger models studied here.  
 
Those oligosaccharides with the GlcUA modelled in position 9, remained in the 
4
C1 throughout 
the MD simulation and so have shown the previously reported lack of flexibility due to the 
presence of the rigid 
4
C1 conformation (Murphy et al., 2008). This also validates the rule that the 
rigid conformation is favoured alongside 
1
C4 when the connecting amino sugar is either N-
sulphated or N-Acetylated (Ferro et al., 1990). The flexibility around this residue will not come 
from the conformation of the ring structure but from the dihedral angle. The oligosaccharides 
dp10(6) and dp10(8) show less flexibility around the dihedral angle. They have both geometries 
present but spend the majority of the 1000 ps timescale in geometry A (Φ = 40°  Ψ = 10° for 
dp10(6) and Φ = 30°  Ψ = 10° for dp10(8) see Figure 3.16 Panels F and H respectfully). Dp10(2) 
behaves in a similar way to dp10(1 and 3) with the dihedral angle changing from a positive to a 
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negative position (Φ = 40°  Ψ = 10°, geometry A to Φ = -20°  Ψ = -20°, geometry B see Figure 
3.17, Panel B).  
The only oligosaccharide which acts in a different way is dp10(4) and that oligosaccharide is only 
present in geometry B. This is characteristic of the angle existing on average in the negative area 
of the graph and never switching to the positive section (Figure 3.17, Panel D). The observed 
results go against those obtained by Murphy (Murphy 2007) where it was identified the reducing 
terminal IdoUA – GlcNAc charged models exist in one geometry which happened to be around 
the starting geometry. Those with the sequence GlcUA-GlcNAc sampled two alternate 
geometries of Φ = 60˚, Ψ = 0˚ and Φ = 0˚, Ψ = -20˚. Here it was thought that this sequence had a 
higher degree of conformational flexibility over the IdoUA-GlcNAc linkage. Murphy (Murphy 2007) 
also suggested the importance of the 6-O-sulphate group and the fact that they influence the 
dynamics of adjacent glycosidic linkages. This effect is not seen immediately in the data 
presented here but may become present in longer MD simulations.  
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Figure 3.17 Puckering-torsion data for linkage 9 
 
IdoUA - GlcNAc(6S)  dp10(1, 3 and 7)  
GlcUA - GlcNAc(6S)  dp10(2, 4 and 8) 
IdoUA - GlcNAc   dp10(5) 
GlcUA - GlcNAc  dp10(6) 
 
Puckering parameters: all graphs show θ analysis (         ).  
Cremer-Pople ring puckering parameters during a 1000 ps molecular dynamic simulation. 
All graphs show θ analysis (ф2 not shown) and changes are compared to the values identified in 
the torsion data in chronological order. 
Torsion data: Φ° dihedral angle (        ), Ψ° dihedral angle (        ).  
The variation in Φ and Ψ torsion angles over a course of 1000 ps explicit water molecular 
dynamic simulation (the left hand side figure).  
 
Torsion data: Structures were sampled every picosecond over the course of 1000 ps in TIP3P 
explicit water. The Φ and Ψ torsion angles across each glycosidic linkage were plotted and 
connected together in chronological order ( ). Contour lines are plotted as a guideline 
reference for each linkage and represent the potential energy surface of each of the glycosidic 
linkages (the right hand side figure).  
 
 
 
 
 
 
Chapter 3: Results 
 175 
-100
-50
0
50
100
150
200
0 100 200 300 400 500 600 700 800 900 1000
Time (ps)
-80
-60
-40
-20
0
20
40
60
80
100
-100
-50
0
50
100
150
200
0 100 200 300 400 500 600 700 800 900 1000
Time (ps)
-100
-80
-60
-40
-20
0
20
40
60
80
100
 
Panel B: dp10(2) GlcUA 
4
C1 - GlcNAc(6S) 
4
C1 
Panel C: dp10(3) IdoUA 
1
C4 - GlcNAc(6S) 
4
C1 
Panel D: dp10(4) GlcUA 
4
C1 - GlcNAc(6S) 
4
C1 
 
B 
A 
B 
A 
B 
A 
B 
-100
-50
0
50
100
150
200
0 100 200 300 400 500 600 700 800 900 1000
Time (ps)
-60
-40
-20
0
20
40
60
80
-100
-50
0
50
100
150
200
0 100 200 300 400 500 600 700 800 900 1000
Time (ps)
-70
-60
-50
-40
-30
-20
-10
0
10
20
30
Panel A: dp10(1) IdoUA 
1
C4 - GlcNAc(6S) 
4
C1 
200 
 
150 
 
100 
 
50 
 
0 
 
-50 
 
-100 
 
-150 
 
-200 
-200 -150 -100  -50     0     50  100  150  200 
 
      Φ° 
 
ψ
° 
200 
 
150 
 
100 
 
50 
 
0 
 
-50 
 
-100 
 
-150 
 
-200 
-200 -150 -100  -50     0     50  100  150  200 
 
      Φ° 
ψ
° 
200 
 
150 
 
100 
 
50 
 
0 
 
-50 
 
-100 
 
-150 
 
-200 
-200 -150 -100  -50     0     50  100  150  200 
 
      Φ° 
 
ψ
° 
200 
 
150 
 
100 
 
50 
 
0 
 
-50 
 
-100 
 
-150 
 
-200 
-200 -150 -100  -50     0     50  100  150  200 
 
      Φ° 
 
ψ
° 
C
re
m
e
r-
P
o
p
le
 θ
 p
a
ra
m
e
te
r 
° 
 
C
re
m
e
r-
P
o
p
le
 θ
 p
a
ra
m
e
te
r 
° 
C
re
m
e
r-
P
o
p
le
 θ
 p
a
ra
m
e
te
r 
° 
C
re
m
e
r-
P
o
p
le
 θ
 p
a
ra
m
e
te
r 
° 
Figure 3.17 Active Oligosaccharides 
Chapter 3: Results 
 176 
-100
-50
0
50
100
150
200
0 100 200 300 400 500 600 700 800 900 1000
Time (ps)
-60
-40
-20
0
20
40
60
80
100
-100
-50
0
50
100
150
200
0 100 200 300 400 500 600 700 800 900 1000
Time (ps)
-100
-80
-60
-40
-20
0
20
40
60
80
 
Panel F: dp10(6) GlcUA 
4
C1 - GlcNAc 
4
C1 
 
Panel G: dp10(7) IdoUA 
1
C4 - GlcNAc(6S) 
4
C1 
 
Panel H: dp10(8) GlcUA 
4
C1 - GlcNAc(6S) 
4
C1 
 
200 
 
150 
 
100 
 
50 
 
0 
 
-50 
 
-100 
 
-150 
 
-200 
-200 -150 -100  -50     0     50  100  150  200 
 
      Φ° 
ψ
° 
200 
 
150 
 
100 
 
50 
 
0 
 
-50 
 
-100 
 
-150 
 
-200 
-200 -150 -100  -50     0     50  100  150  200 
 
      Φ° 
ψ
° 
200 
 
150 
 
100 
 
50 
 
0 
 
-50 
 
-100 
 
-150 
 
-200 
-200 -150 -100  -50     0     50  100  150  200 
 
      Φ° 
ψ
° 
B 
A 
A 
B 
A 
B 
B 
A 
Panel E: dp10(5) IdoUA 
1
C4 - GlcNAc 
4
C1 
-100
-50
0
50
100
150
200
0 100 200 300 400 500 600 700 800 900 1000
Time (ps)
-50
-30
-10
10
30
50
70
90
-100
-50
0
50
100
150
200
0 100 200 300 400 500 600 700 800 900 1000
Time (ps)
-60
-40
-20
0
20
40
60
80
100
200 
 
150 
 
100 
 
50 
 
0 
 
-50 
 
-100 
 
-150 
 
-200 
-200 -150 -100  -50     0     50  100  150  200 
 
      Φ° 
ψ
° 
C
re
m
e
r-
P
o
p
le
 θ
 p
a
ra
m
e
te
r 
° 
C
re
m
e
r-
P
o
p
le
 θ
 p
a
ra
m
e
te
r 
° 
C
re
m
e
r-
P
o
p
le
 θ
 p
a
ra
m
e
te
r 
° 
C
re
m
e
r-
P
o
p
le
 θ
 p
a
ra
m
e
te
r 
° 
Inactive Oligosaccharides 
Chapter 3: Results 
 177 
3.2.4.2 Linkage 8 
GlcNS(6S) - IdoUA  dp10(1and 5)  
GlcNS(6S) - GlcUA  dp10(2 and 6) 
GlcNS - IdoUA    dp10(3 and 7) 
GlcNS - GlcUA   dp10(4 and 8) 
 
The GlcNS + (6S) monosaccharides were all modelled in the 
4
C1 conformation prior to the 1 ns 
MD simulation. 
All residues here in linkage 8 are glucosamines and so are only found in the 
4
C1 conformation as 
identified recently (Powell et al., 2004). Any flexibility in these linkages will therefore come from 
changes in torsion angles and not the conformation shifts of the ring structure. There are four 
different types of disaccharides which make up linkage 8 across the range of oligosaccharides so 
it is difficult to fully compare them all. It will also be interesting to note any differences with the 
addition of the 6-O-sulphate group on decasaccharides making up this linkage.  
 
The main differences in torsion angle geometries of linkage 8 between active and inactive 
oligosaccharides appears to be with oligosaccharides dp10(3) and dp10(7) which both have the 
same flanking monosaccharides (GlcNS-IdoUA). In this instance the inactive dp10(7) 
oligosaccharide exits in a single geometry A whilst the active dp10(3) oligosaccharide has an 
additional B geometry (Figure 3.18, Panels C and G). This difference is significant and could 
influence overall biological activity. A minor difference occurs between the active dp10(1) and 
inactive dp10(5) oligosaccharide, which have the same GlcNS(6S)-IdoUA sequence, there 
appears to be 2 distinct geometries in the inactive oligosaccharide and a single geometry in the 
active structure, also the ψ angle of the inactive dp10(5) oligosaccharide (Figure 3.18, Panel E) 
has an average value in geometry A of  around + 20 degrees (Φ = -20, ψ = +20) whereas the ψ 
angle for active oligosaccharides dp10(1) remains at a relatively constant angle of .-20 degrees 
(Φ =-20,   ψ=-20); (Figure 3.18, Panel A). The dp10(5) does briefly spend some time however 
with the ψ  at -20 degrees (Φ= -20, ψ=-20), this rules this out as a potential difference between 
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active and inactive structures. Another difference is between the active dp10(2) and inactive 
dp10(6) oligosaccharides that they have the same GlcNS(6S)-GlcUA sequence in this linkage 
and both appear to occupy a similar single geometry on the contour map, however the active 
dp10(2) has an average value ψ of -30 degrees with the inactive dp10(6) oligosaccharide having 
a ψ +30 degree average. This is a significant shift and could have a bearing on the biological 
activity of the samples. 
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Figure 3.18 Puckering-torsion data for linkage 8 
GlcNS(6S) - IdoUA  dp10(1and 5)  
GlcNS(6S) - GlcUA  dp10(2 and 6) 
GlcNS - IdoUA    dp10(3 and 7) 
GlcNS - GlcUA   dp10(4 and 8) 
 
Puckering parameters: all graphs show θ analysis (         ).  
Cremer-Pople ring puckering parameters during a 1000 ps molecular dynamic simulation. 
All graphs show θ analysis (ф2 not shown) and changes are compared to the values identified in 
the torsion data in chronological order. 
Torsion data: Φ° dihedral angle (        ), Ψ° dihedral angle (        ).  
The variation in Φ and Ψ  torsion angles over a course of 1000 ps explicit water molecular 
dynamic simulation (the left hand side figure).  
 
Torsion data: Structures were sampled every picosecond over the course of 1000 ps in TIP3P 
explicit water. The Φ and Ψ torsion angles across each glycosidic linkage were plotted and 
connected together in chronological order ( ). Contour lines are plotted as a guideline 
reference for each linkage and represent the potential energy surface of each of the glycosidic 
linkages (the right hand side figure).  
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3.2.4.3 Linkage 7 
IdoUA(2S) - GlcNS(6S)  dp10(1 - 2) and dp10(5-6) 
IdoUA - GlcNS   dp10(3-4) 
IdoUA(2S) - GlcNS   dp10(7-8) 
 
The IdoUA + (2S) monosaccharides were all modelled in the 
1
C4 conformation prior to the 1 ns 
MD simulation.  
IdoUA(2S) according to literature plays a major role in the binding of the FGF2 protein as well as 
many other different proteins, the following are just a selection (Ishihara et al., 1994; Kreuger et 
al., 2001; Maccarana et al., 1993; Pellegrini et al., 2000; Pye et al., 2000; Turnbull et al., 1992; 
Wu et al., 2003). Many studies have concentrated on the conformation of the internal iduronates 
and their role in protein binding, the following list will name but a few (Rabenstein, 2002; 
(Hricovini et al., 2001; Guerrini et al., 2006; Raman, 2005; Faham et al., 1996; Fry et al., 1999).  
Models dp10(1), dp10(2) dp10(5) and dp10(6) are all comparable because they all contain the 
same sequence for this specific linkage (IdoUA(2S)-GlcNS(6S)). This forms the kink motif 
identified by Guglieri et al (Guglieri, Hricovini et al., 2008) which forms in the chain when bound to 
a protein (if taken into account the presence of the GlcNS(6S) residue preceding this sequence):  
GlcNS 6S – IdoUA 2S – GlcNS 6S/OH  
(Guglieri et al., 2008) 
Raman et al (Raman et al., 2005) identified this as a kink when working with H – I – H 
trisaccharides (where H are glucosamines + O-sulphation and I is iduronic acid). It is certainly 
well established that it is the position of the iduronate in a chain which mainly affects the 
equilibrium of the conformations identified in a chain (Rabenstein, 2002; Faham et al., 1996). 
1
C4 
and 
2
S0 conformations are clearly favoured here in the Goodger models as seven of the eight ring 
conformations are identified in one or both conformations during this simulation. The 
4
C1 
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conformation is not the favoured conformation as this is only identified in one oligosaccharide - 
dp10(8).  
Both models dp10(1) and dp10(5) are comparable as they have the  IdoUA residue for residue 9. 
They both have a starting conformation of 
1
C4 set prior to the MD simulation. Both undergo a 
conformational transition to the skew boat form. In the active dp10(1) this occurs  around 500 ps 
where as in dp10(5) this happens later on in the simulation, around 800 ps (Figure 3.19, Panels A 
and E). Here there are clear differences between active and inactive oligosaccharides which 
could have an influence on the overall biological activity. In this instance the active dp10(1) 
oligosaccharide exists in two geometries (geometry A and B). This change occurs after the 
conformational change between 600 – 700 ps. Average values for the angle before this change 
were Φ = -30° Ψ = -30° assigned as geometry B. After this transition; typical values increase to Φ 
= +40° Ψ = +10° assigned geometry A. In terms of 3-dimensional shape these changes in angle 
lead to a large change in the overall shape of the structure. The change in the inactive dp10(5) 
decasaccharide occurs before the conformational change (it should be noted that the actual time 
this transition occurs in both models is around the same time, around 600-700 ps in time). 
Although these models sample both geometries; the active structure undergoes a change in ring 
conformation first which seems to be the driving force behind the change in torsion angle. In the 
inactive model this has an opposite effect; it is the change in torsion data which drives the change 
in ring conformation. Also comparable to these structures are dp10(2) and dp10(6). These 
contain the same flanking monosaccharides but only exist in one geometry. In this instance the 
active dp10(2) exists in geometry A, whilst the inactive dp10(6) exists only in geometry B. This 
could suggest it is the presence of geometry A which influences the skew boat conformation, 
whilst geometry B influences the 
1
C4 conformation. This is a good indication of the difference 
between the active and inactive structures and could be important in biological activity.  
 
Oligosaccharides dp10(3, 4, 7 and 8) are slightly different in structure, they are not fully sulphated 
structures. The active dp10(3) and dp10(4) oligosaccharides exist in a single geometry B, with 
only the 
1
C4 conformation present. The ring conformations are identified only in the 
1
C4 
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conformation throughout the whole 1000 ps timescale; possible due to the absence of the 2-O-
sulphate group on the iduronate section of the sequence. The angle geometry for dp10(3) 
remains solely in the geometry labelled B (Φ = -40° Ψ = -20°), with a brief period in a possible 
transient geometry at the very beginning of the simulation (Figure 3.19, Panel C). The inactive 
dp10(7) and dp10(8) also exists in one geometry, geometry A. Here it has average values of Φ = 
+60° Ψ = +40° and Φ = +50° Ψ = +10°.  The 
1
C4 conformation undergoes a conformational 
transition to the 
2
S0 conformation after 200 ps.  
 
These results indicate that the presence of either the chair or skew boat conformation has an 
influence on the corresponding geometry. The chair conformation seems to have an overall 
influence on geometry B, whilst the skew boat conformation drives geometry A. This could have 
some bearing on the biological activity of the HS samples. Also there is a slight effect from 
residue 9 in the chain where the sequences differ in the reducing end terminal. This difference is 
identified in dp10(2) and dp10(6) which both contain the GlcUA at residue 9 instead of the 
alternative IdoUA in dp10(1) and dp10(5); here only one conformation in the iduronate at residue 
7 is present in the chain and not both conformations which has previously been identified (either 
2
S0 or 
1
C4  respectfully).  
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Figure 3.19 Puckering-torsion data for linkage 7 
 
IdoUA(2S) - GlcNS(6S)  dp10(1 - 2) and dp10(5-6) 
IdoUA - GlcNS   dp10(3-4) 
IdoUA(2S) - GlcNS   dp10(7-8) 
 
Puckering parameters: all graphs show θ analysis (         ).  
Cremer-Pople ring puckering parameters during a 1000 ps molecular dynamic simulation. 
All graphs show θ analysis (ф2 not shown) and changes are compared to the values identified in 
the torsion data in chronological order. 
Torsion data: Φ° dihedral angle (        ), Ψ° dihedral angle (        ).  
The variation in Φ and Ψ  torsion angles over a course of 1000 ps explicit water molecular 
dynamic simulation (the left hand side figure).  
 
Torsion data: Structures were sampled every picosecond over the course of 1000 ps in TIP3P 
explicit water. The Φ and Ψ torsion angles across each glycosidic linkage were plotted and 
connected together in chronological order ( ). Contour lines are plotted as a guideline 
reference for each linkage and represent the potential energy surface of each of the glycosidic 
linkages (the right hand side figure).  
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3.2.4.4 Linkage 6 
GlcNS(6S) - IdoUA(2S)   dp10(1 - 2) and dp10(5-8) 
GlcNS(6S) - IdoUA  dp10(3-4) 
 
The GlcNS + (6S) monosaccharides were all modelled in the 
4
C1 conformation prior to the 1 ns 
MD simulation. 
Like linkage 8, linkage 6 comprises all glucosamines of which all of them contain the additional 6-
O-sulphate group. There are two different types of disaccharide which make up linkage 6 across 
the range of oligosaccharides. For models dp10(1), dp10(2), dp10(5), dp10(6), dp10(7) and 
dp10(8); this linkage makes up the fully sulphated trisaccharide (GlcNS(6S)-IdoUA(2S)). The 
IdoUA seen in linkage 7 is unsulphated for dp10(3) and dp10(4).  
As previously discussed, the glucosamines here are rigid in the 
4
C1 conformation and so are able 
to dispose of their bulky side groups in an equatorial position (Sanderson et al., 1987). Any 
change in shape to accommodate binding with a protein will come about from the changes in the 
torsion angle. Decasaccharide dp10(1) shows the presence of two geometries of which geometry 
B is the most prominent (Figure 3.20, Panel A) and geometry A which is identified after 800 ps. 
This corresponds to a similar change in torsion angle in the neighbouring linkage (Figure 3.19, 
Panel A). The same is identified in the inactive dp10(5) with the change in the torsion angle 
occurring around the same time (Figure 3.20, Panel E). These both have geometries with 
average values of Φ = -40° Ψ = -20° (geometry B) and Φ = +30° Ψ = +30° (geometry A). This 
change in the dihedral angle could be due to the presence of the IdoUA at the terminal end 
(residue 9) as those sequences with the GlcUA do not show this change in geometry and are 
therefore only identified in geometry B (Figure 3.20, Panels B and F). Again there is a possible 
influence from the IdoUA at position 9; as oligosaccharides which contain IdoUA instead of GlcUA 
at position 9 in the chain exist in both geometries A and B. Dp10(7) and dp10(8) show similar Φ 
and Ψ values as those observed with the same geometry present (geometry B); dp10(2) and 
dp10(6). Again there is no obvious influence by the iduronic acid present at position 9 (Figure 
3.20, Panels G and H). The presence of and the combination of both the 2-O-sulphate and 6-O-
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sulphate groups in this linkage could be a contributing factor to the transient geometry identified 
in linkage 7.   
 
The main difference in the active and inactive oligosaccharides is the presence of a third 
geometry in oligosaccharides dp10(3) and dp10(4). This has been identified as geometry C 
(Figure 3.20, Panels C and D). This occupies a previously un-observed geometry which is found 
in the top left hand quadrant of the contour map with average values around Φ = -20° Ψ = +30° 
for dp10(3) and Φ = -30° Ψ = -20° for dp10(4). The difference in the angle geometry could be due 
to the lack of 2-O-sulphate on the neighbouring residue (the IdoUA discussed in linkage 7). The 
presence or absence of IdoUA here can be ruled out due to both models existing in the same 
geometry.  The presence of this additional geometry does not tie in with those identified in the 
other active sequences so it is difficult to say whether this has any bearing on the biological 
activity of these samples.  
 
 
Chapter 3: Results 
 190 
Figure 3.20 Puckering-torsion data for linkage 6 
 
GlcNS(6S) - IdoUA(2S)   dp10(1 - 2) and dp10(5-8) 
GlcNS(6S) - IdoUA  dp10(3-4) 
 
Puckering parameters: all graphs show θ analysis (         ).  
Cremer-Pople ring puckering parameters during a 1000 ps molecular dynamic simulation. 
All graphs show θ analysis (ф2 not shown) and changes are compared to the values identified in 
the torsion data in chronological order. 
Torsion data: Φ° dihedral angle (        ), Ψ° dihedral angle (        ).  
The variation in Φ and Ψ  torsion angles over a course of 1000 ps explicit water molecular 
dynamic simulation (the left hand side figure).  
 
Torsion data: Structures were sampled every picosecond over the course of 1000 ps in TIP3P 
explicit water. The Φ and Ψ torsion angles across each glycosidic linkage were plotted and 
connected together in chronological order ( ). Contour lines are plotted as a guideline 
reference for each linkage and represent the potential energy surface of each of the glycosidic 
linkages (the right hand side figure).  
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3.2.4.5 Linkage 5 
IdoUA(2S) – GlcNS(6S)    dp10(1 - 8) 
 
The IdoUA + (2S) monosaccharides were all modelled in the 
1
C4 conformation prior to the 1 ns 
MD simulation. 
The trisulphated disaccharide (IdoUA(2S)-GlcNS(6S)) makes up this linkage in all eight Goodger 
decasaccharide models and so all structures are comparable. It is this sequence, alongside 
residue 7 which potentially makes up the binding site for FGF2 binding. Here the presence of the 
2-O-sulphate and the 6-O-sulphate groups are important in this specific interaction as previously 
identified in a number of studies (Maccarana et al., 1993; Faham et al., 1996; DiGabriele et al., 
1998; Wu et al., 2003).  
 
The main difference between the active and inactive oligosaccharides appears to involve all eight 
oligosaccharides and is in respect to the different torsion angles. In three out of the four active 
models, two geometries exist (A and B), with the exception being dp10(4), which exists in only 
geometry B. The inactive oligosaccharides, with the exception of dp10(8) exist in only one 
geometry (either geometry A or B). The average data values for geometry A being Φ = +25° 
Ψ = 0° and for geometry B Φ = -30° Ψ = -20°. This difference could be significant and have an 
overall influence on biological activity.  
The corresponding Cremer-Pople Puckering parameter data for both dp10(1) and dp10(2) 
indicates no change in conformation so the ring has not undergone any conformational changes 
(Figure 3.21 Panels A and B). At the end of the simulation both dp10(1) and dp10(2) show similar 
conformational patterns to those described by Faham et al (Faham et al., 1996). The IdoUA(2S) 
of position 5 remains in the 
1
C4 conformation and the IdoUA(2S) of position 7 is in the 
2
S0 
conformation. The presence of 2-O-sulphate is thought to stabilize the 
1
C4 conformation 
(van_Boeckel et al., 1987) and this could be one of the reasons why the iduronate is unchanged 
in this conformation. The 6-O-sulphate on the flanking residues could also play an important role 
in the conformation of the IdoUA(2S) at this point in the HS chain (Pye et al., 1998).  
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For dp10(3) the IdoUA(2S) begins this simulation in the 
2
S0 conformation (suggesting it had 
already gone through one conformational transition previous to this MD simulation) with a 
conformational transition to 
4
C1 after 300 ps. Up until this point, the dihedral angle data suggests 
it exists in geometry B (Figure 3.21, Panel C). The conformational transition and the presence of 
the skew boat conformation may well be the driving force behind the switch in torsion data to the 
alternative geometry (geometry A). This is suggested by the greater fluctuation observed in the 
data values for Φ and Ψ then has been previously identified (average values for these are Φ = 
+130° Ψ = +30° at the highest value and Φ = -80° Ψ = -50° on average at the lowest value). The 
start of the MD simulation for dp10(4) shows an average puckering parameter data value of θ = 
141.7°;  which does not fit either the 
2
S0 or the 
1
C4 conformation values observed in this study 
and therefore suggests the presence of an intermediate conformation (Figure 3.21, Panel D). A 
similar angle is also identified in dp10(7) discussed below. An intermediate conformation has 
previously been identified when a fully sulphated heparin oligosaccharide binds the FMDV- 
O1BFS protein. Here a terminal iduronate was found to adopt a 
2,5
B conformation (an 
intermediate boat conformation) (Fry et al., 1999); which can be mapped on the surface of a 
globe with the poles at θ = 0° or 180°, corresponding to the canonical chair conformations 
(Hasnoot, 1992). Mikhailov et al (Mikhailov et al., 1996) also suggests the 
2,5
B conformation 
exists in equilibrium with the three other conformations (
1
C4, 
2
S0 and 
4
C1). The presence of the 
4
C1 conformation in dp10(3) is the second time it has been identified in the Goodger models for 
an internal residue (the first being for residue 7 in dp10(8); Figure 3.21, Panel H). Initially it was 
thought to occur only in the external residues (Ferro et al., 1990).  
 
The main differences in the inactive oligosaccharides is the presence of only one torsional 
geometry and also the presence of more then one ring conformation during the 1 ns MD 
simulation. The potentially important, active conformation (
1
C4) is present but there are further 
transitions made. Firstly for dp10(5) the ring conformation changes around 200 ps from the 
starting conformation to the 
2
S0 conformation, but only exists in geometry A (which has similar 
data values to those observed in the active oligosaccharides). This change in conformation is 
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similar for dp10(7); but occurs over a longer timescale. Again after the 200 ps mark, the θ value 
slowly decreases until the 
2
S0 conformation value is reached (θ = 92°). Here the only geometry 
observed is geometry B.  
The presence of the IdoUA in oligosaccharide dp10(6) (the residue identified at position 9 as 
apposed to the alternative GlcUA) has an influence on the chain as the IdoUA(2S) at position 5 is 
initially identified in the skew boat conformation suggesting it has already undergone a 
conformational transition during the minimisation process (see Experimental Materials and 
Procedures). After 200 ps there is a further transition to the original 
1
C4 conformation. The torsion 
angle is only observed in geometry B (again with similar data values to those observed in the 
active oligosaccharides, Φ = -30° Ψ = -20°.). Again further evidence for this influence from the 
GlcUA (from position 9 in the oligosaccharide) is observed in dp10(8), with not one, but two 
conformational transitions observed during the 1 ns MD simulation. Here the IdoUA(2S) flips from 
the starting 
1
C4 conformation to the 
2
S0 conformation and then back again (Figure 3.21, Panel H). 
It is this conformational change which influences the change in the dihedral angle which is the 
only one of the inactive oligosaccharides to exist in both geometries.  
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Figure 3.21 Puckering-torsion data for linkage 5 
 
IdoUA(2S) – GlcNS(6S)    dp10(1 - 8) 
 
Puckering parameters: all graphs show θ analysis (         ).  
Cremer-Pople ring puckering parameters during a 1000 ps molecular dynamic simulation. 
All graphs show θ analysis (ф2 not shown) and changes are compared to the values identified in 
the torsion data in chronological order. 
Torsion data: Φ° dihedral angle (        ), Ψ° dihedral angle (        ).  
The variation in Φ and Ψ  torsion angles over a course of 1000 ps explicit water molecular 
dynamic simulation (the left hand side figure).  
 
Torsion data: Structures were sampled every picosecond over the course of 1000 ps in TIP3P 
explicit water. The Φ and Ψ torsion angles across each glycosidic linkage were plotted and 
connected together in chronological order ( ). Contour lines are plotted as a guideline 
reference for each linkage and represent the potential energy surface of each of the glycosidic 
linkages (the right hand side figure).  
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3.2.4.6 Linkage 4 
GlcNS(6S) - IdoUA(2S)    dp10(1 - 2) 
GlcNS - IdoUA(2S)    dp10(3 - 8) 
 
The GlcNS + (6S) monosaccharides were all modelled in the 
4
C1 conformation prior to the 1 ns 
MD simulation. Again all glucosamines are found only in this conformation and so any flexibility in 
these linkages will come from changes in the torsion angles and not the conformational shifts in 
the ring structure. There are two types of disaccharide which make up linkage 4 across the range 
of oligosaccharides. Linkage 4 identified in dp10(1) and dp10(2) is not comparable to any of the 
other linkages at this position as it contains the sequence GlcNS(6S)-IdoUA(2S). Here the only 
geometry observed in these oligosaccharides is geometry B with average data values of Φ = -30° 
Ψ = -30° and Φ = -30° Ψ = -20° respectfully (Figure 3.22, Panels A and B).  
The second of the two disaccharide sequences identified in this linkage is GlcNS-IdoUA(2S); 
which makes up the remaining six oligosaccharides. Here the only difference between active and 
inactive oligosaccharides is identified in dp10(7) and dp10(8). Here they behave in a similar way 
to the active dp10(1) and dp10(2) in that they only exist in geometry B, with similar data values to 
those mentioned above. This suggests that the presence of the 6S group actually does not have 
an effect on the geometry of the dihedral angle as it appears to have no immediate effect on the 
ring structure which has previously been identified in other studies. An important binding site with 
high affinity for FGF2 involving a 6S group has been identified in this region of the chain in 
previous studies (Faham et al., 1996). This sequence also forms part of the kink motif, identified 
previously (Guglieri et al., 2008), so it is possible that there is some effect on biological activity 
but that its effects might have an influence further down the chain.  
Oligosaccharides dp10(3),  dp10(4), dp10(5) and dp10(6) all show similar torsion data profiles, 
with the existence of both geometry A and B (Figure 3.22, Panels C, D, E and F). Geometry B 
has similar data values to those previously mentioned, and geometry A is characterised with 
values of Φ = +30° Ψ = +10°. As it stands; these results have shown no significant bearing on the 
biological activity of the samples in respect to active and inactive oligosaccharides. 
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Figure 3.22 Puckering-torsion data for linkage 4 
 
GlcNS(6S) - IdoUA(2S)    dp10(1 - 2) 
GlcNS - IdoUA(2S)    dp10(3 - 8) 
 
Puckering parameters: all graphs show θ analysis (         ).  
Cremer-Pople ring puckering parameters during a 1000 ps molecular dynamic simulation. 
All graphs show θ analysis (ф2 not shown) and changes are compared to the values identified in 
the torsion data in chronological order. 
Torsion data: Φ° dihedral angle (        ), Ψ° dihedral angle (        ).  
The variation in Φ and Ψ  torsion angles over a course of 1000 ps explicit water molecular 
dynamic simulation (the left hand side figure).  
 
Torsion data: Structures were sampled every picosecond over the course of 1000 ps in TIP3P 
explicit water. The Φ and Ψ torsion angles across each glycosidic linkage were plotted and 
connected together in chronological order ( ). Contour lines are plotted as a guideline 
reference for each linkage and represent the potential energy surface of each of the glycosidic 
linkages (the right hand side figure).  
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3.2.4.7 Linkage 3 
GlcUA – GlcNS(6S)  dp10(1-2) 
GlcUA – GlcNS   dp10(3-6) 
IdoUA – GlcNS   dp10(7-8) 
 
The GlcUA monosaccharides were all modelled in the 
4
C1 conformation with the IdoUA 
monosaccharides modelled in the 
1
C4 conformation prior to the 1 ns MD simulation. As in 
previous linkages all flexibility will come from the torsion angle and not from the conformational 
shifts of the ring structure (with the exception being oligosaccharides dp10(7) and dp10(8), as 
these contain the iduronate monosaccharide as the flanking monosaccharide).  
There are no significant differences between active and inactive oligosaccharides, but this could 
be due to the diversity of the disaccharides sequences which make up this linkage in all eight 
oligosaccharides. Those linkages in dp10(1) and dp10(2) exist only in geometry A with average 
values around Φ = +30° Ψ = 0°. They are the only oligosaccharides which exist solely in this 
geometry. This could be due to the presence of the 6S group on the proceeding residue, but it is 
unclear if this a determining factor for biological activity.  
Those sequences with the sequence GlcUA-GlcNS all exist in two geometries, A and B (Figure 
3.23, Panels A – F). Geometry B is characterised with more negative data values then those 
identified in geometry A (Φ = -10° Ψ = -10°). This rules this out as a potential difference between 
the active and inactive structures.  
The addition of the iduronate at this position, as identified in oligosaccharides dp10(7) and 
dp10(8) has no major influence on the torsion angle, compared to those sequences mentioned 
above. Dp10(7) behaves in the same way as dp10(3-6), existing in both geometries (Figure 3.23, 
Panel G). Dp10(8) exists only in geometry B and is the only oligosaccharides to do so (Figure 
3.23, Panel H).  
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Figure 3.23 Puckering-torsion data for linkage 3 
 
GlcUA – GlcNS(6S)  dp10(1-2) 
GlcUA – GlcNS   dp10(3-6) 
IdoUA – GlcNS   dp10(7-8) 
 
Puckering parameters: all graphs show θ analysis (         ).  
Cremer-Pople ring puckering parameters during a 1000 ps molecular dynamic simulation. 
All graphs show θ analysis (ф2 not shown) and changes are compared to the values identified in 
the torsion data in chronological order. 
Torsion data: Φ° dihedral angle (        ), Ψ° dihedral angle (        ).  
The variation in Φ and Ψ  torsion angles over a course of 1000 ps explicit water molecular 
dynamic simulation (the left hand side figure).  
 
Torsion data: Structures were sampled every picosecond over the course of 1000 ps in TIP3P 
explicit water. The Φ and Ψ torsion angles across each glycosidic linkage were plotted and 
connected together in chronological order ( ). Contour lines are plotted as a guideline 
reference for each linkage and represent the potential energy surface of each of the glycosidic 
linkages (the right hand side figure).  
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3.2.4.8 Linkage 2 
GlcNAc – GlcUA  dp10(1-6) 
GlcNS – IdoUA    dp10(7-8) 
 
The GlcNAc and GlcNS monosaccharides were all modelled in the 
1
C4 conformation prior to the 
1 ns MD simulation. There are two different types of disaccharide which make up linkage 2 
across the range of oligosaccharides. The first is found in six of the eight oligosaccharides 
(dp10(1-6)) and involves the N-acetylated glucosamine (GlcNAc). Again the Cremer-Pople ring 
puckering parameters identify all the structures in the rigid 
4
C1 conformation. This is the most 
stable conformation identified at the non-reducing end (Coombe and Kett, 2005). Here all the 
non-hydrogen ring substituents are found in an equatorial position, apart from the anomeric OH 
group (Rabenstein, 2002). When GlcNAc is replaced by GlcNS as found in dp10(7) and dp10(8), 
there are no changes in the ring conformation (Figure 3.24, Panels G and H). 
 
There are no major differences between active and inactive oligosaccharides. All eight exist in 
geometry A, with constant, average values of Φ = -25° Ψ = +20°. There is no difference between 
those with the IdoUA at the reducing end and those oligosaccharides with a GlcUA at the 
reducing end. Oligosaccharides dp10(6) and dp10(7) have an additional B geometry with average 
values of Φ = -50° Ψ = -20°. 
Previous studies have highlighted the lack of flexibility at the non-reducing terminal end and so fit 
in with the results identified in this study (Coombe and Kett, 2005; Hricovíni and Bízik, 2007; 
Mikhailov et al., 1997; Rabenstein, 2002). Lack of variety in the dihedral angle could be due to the 
steric interactions that limit the possible Φ° and Ψ° angles available for the glucosamines 
(Rabenstein, 2002). With a high proportion of glucosamines showing considerably less biological 
activity (Mikhailov et al., 1997); when compared to the iduronates. This would agree with studies 
which indicate that the conformation of the IdoUA(2S) influences the geometry of the flanking 
GlcNS(6S) residues on the non-reducing side of the chain (Coombe and Kett, 2005; Hricovíni and 
Bízik, 2007).  
Chapter 3: Results 
 208 
Figure 3.24 Puckering-torsion data for linkage 2 
 
GlcNAc – GlcUA  dp10(1-6) 
GlcNS – IdoUA    dp10(7-8) 
 
Puckering parameters: all graphs show θ analysis (         ).  
Cremer-Pople ring puckering parameters during a 1000 ps molecular dynamic simulation. 
All graphs show θ analysis (ф2 not shown) and changes are compared to the values identified in 
the torsion data in chronological order. 
Torsion data: Φ° dihedral angle (        ), Ψ° dihedral angle (        ).  
The variation in Φ and Ψ  torsion angles over a course of 1000 ps explicit water molecular 
dynamic simulation (the left hand side figure).  
 
Torsion data: Structures were sampled every picosecond over the course of 1000 ps in TIP3P 
explicit water. The Φ and Ψ torsion angles across each glycosidic linkage were plotted and 
connected together in chronological order ( ). Contour lines are plotted as a guideline 
reference for each linkage and represent the potential energy surface of each of the glycosidic 
linkages (the right hand side figure).  
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3.2.4.9 Linkage 1 – the non-reducing end 
UA - GlcNAc  dp10(1-6) 
UA - GlcNS  dp10(7-8) 
 
All terminal ∆UA conformations were modelled in the 
1
H2 starting conformation prior to the 1 ns 
MD simulation.  
UA residues present at the non-reducing end of an oligosaccharide are the result of either 
chemical or enzymatic degradation of a longer chain. The average Cremer-Pople ring puckering 
parameter for this conformation was θ = 130°. There are two different types of disaccharide which 
make up linkage 1 across the range of oligosaccharides.  
 
There are no differences between active and inactive structures with respect to ring conformation 
and torsional geometry; indicating the non-reducing terminal plays little or no part in biological 
activity. All ring structures made a conformational transition to the 
2
H1 conformation either before 
the start of this MD simulation (dp10(1, 2, 4, 5, 6 and 7) or during the actual run (dp10(3) and 
dp10(8)). The average Cremer-Pople puckering parameter for the 
2
H1 conformation was θ = 52°. 
These positions are differentiated by above-plane and below-plane positions of the C1 and C2 
ring atoms (Mikhailov  et al., 1997). The ∆UA( unnatural in nature as it is generated through the 
action of the enzyme heparanase III); contains an unsaturated uronic acid (Linhardt, 1990).  
The 
1
H2 and 
2
H1 conformations of the ∆UA are thought to vary, depending on the neighbouring 
structure but are thought to be in equilibrium. The 
1
H2 conformation is thought to be favoured due 
to the anomeric effect brought on by the neighbouring GlcN residue (Mikhailov et al., 1996). 
Modelling work carried out by Murphy (Murphy 2007) indicates the equilibrium shifted heavily 
towards the 
2
H1 conformation. The torsion data was similar for all eight oligosaccharides. Those 
with a GlcNAc residue bonded to the UA (dp10(1-6); Figure 3.25, Panels A-F) showed the same 
profile to those with the alternative GlcNS residue (dp10(7-8); Figure 3.25, Panels G and H). The 
data suggests that the majority of the Φ° and Ψ° values lie in the positive area of the graph 
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labelled as geometry A (Φ = +50° Ψ = +10°), with a quarter of the time spent in the negative, 
lower left hand quadrant of the graph, labelled geometry B Φ = -10° Ψ = -10° (Figure 3.25).  
 
Most results from linkage 1 up to linkage 4 suggest there are no major differences between active 
and inactive oligosaccharides in both the conformation of the ring and the torsional geometries. 
This would suggest that in the case of these oligosaccharides it is not the role of the non-reducing 
end to interact with the FGF2 protein, although this role has been previously identified in the x-ray 
crystal structure of a symmetrical complex of a 2:2:2 FGF2:FGFR1:heparin ternary complex 
(Schlessinger et al., 2000). We can be quite certain with this statement as there are no 
differences to speak of which would have any effect on the biological activity of the samples.  
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Figure 3.25 Puckering-torsion data for linkage 1 
 
 
UA - GlcNAc  dp10(1-6) 
UA - GlcNS  dp10(7-8) 
 
 Puckering parameters: all graphs show θ analysis (         ).  
Cremer-Pople ring puckering parameters during a 1000 ps molecular dynamic simulation. 
All graphs show θ analysis (ф2 not shown) and changes are compared to the values identified in 
the torsion data in chronological order. 
Torsion data: Φ° dihedral angle (        ), Ψ° dihedral angle (        ).  
The variation in Φ and Ψ  torsion angles over a course of 1000 ps explicit water molecular 
dynamic simulation (the left hand side figure).  
 
Torsion data: Structures were sampled every picosecond over the course of 1000 ps in TIP3P 
explicit water. The Φ and Ψ torsion angles across each glycosidic linkage were plotted and 
connected together in chronological order ( ). Contour lines are plotted as a guideline 
reference for each linkage and represent the potential energy surface of each of the glycosidic 
linkages (the right hand side figure).  
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3.3 Long 10ns molecular dynamic simulations 
 
Longer simulations were undertaken to try to increase the understanding of the differences 
between the active and the inactive sequences with regards to the puckering parameters and the 
corresponding torsion data. Not all sequences were studied, those with a GlcUA at position 9 
were not taken on for further analysis (decasaccharides dp10(2, 4, 6 and 8)). Those with IdoUA 
present in this position were taken on for further analysis (decasaccharides dp10(1, 3, 5 and 7)). 
This consisted of running the same molecular dynamic simulations but for a longer period of time. 
Instead of just 1000ps (1ns) in time, these were ran for 10ns (10,000ps) and consisted of 
5,000,000 steps in the MD run. Mdxvu was again used for the analysis of both the Cremer-Pople 
ring puckering parameters and the torsion data. Each MD run took approximately 5 weeks to run 
and the results are as follows.  
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3.3.1 The Reducing end Linkage – Linkage 9 for the 10 ns MD 
simulation 
IdoUA - GlcNAc(6S)  dp10(1, 3 and 7) 
IdoUA – GlcNAc  dp10(5) 
 
The IdoUA(2S) monosaccharide was modelled in the 
1
C4 conformation prior to the 10 ns MD 
simulation. 
There are two different types of disaccharides which make up linkage 9 across the range of 
species, the difference being the presence of the 6-O-sulphate group on three of the four 
oligosaccharides.  
 
According to the Cremer-Pople ring puckering parameters there are no differences between 
active and inactive oligosaccharides for this linkage. For dp10(1), dp10(3) and dp10(7) all start in 
the 
1
C4 starting conformation, which was the set conformation at the start of the MD simulation 
and all contain the sequence (IdoUA-GlcNAc(6S)). There is a conformational transition to the 
skew boat conformation briefly, before a further conformational transition to the 
4
C1 conformation 
(Figure 3.26, Panels A, B and D). The inactive dp10(5), which is not comparable as it contains the 
sequence (IdoUA-GlcNAc) begins the simulation in the skew boat conformation, having already 
made the transition from the starting conformation prior to the simulation. However the torsion 
data indicates no differences in geometry, with both A and B geometries present in all four 
oligosaccharides. All four have average Φ and Ψ values of Φ = +30, Ψ = +10 for geometry A and 
Φ = -30, Ψ = -10 for geometry B.  
There are no differences between the 1 ns MD simulation and the 10 ns MD simulation (compare 
Figure 3.26 with Figure 3.17).  
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Figure 3.26 Puckering-torsion data for linkage 9 for the 10 ns MD simulation 
IdoUA - GlcNAc(6S)  dp10(1, 3 and 7) 
IdoUA – GlcNAc  dp10(5) 
 
Puckering parameters: all graphs show θ analysis (         ).  
Cremer-Pople ring puckering parameters during a 10 ns molecular dynamic simulation. 
All graphs show θ analysis (ф2 not shown) and changes are compared to the values identified in 
the torsion data in chronological order. 
Torsion data: Φ° dihedral angle (        ), Ψ° dihedral angle (        ).  
The variation in Φ and Ψ torsion angles over a course of 10 ns explicit water molecular dynamic 
simulation (the left hand side figure).  
 
Torsion data: Structures were sampled every picosecond over the course of 10 ns in TIP3P 
explicit water. The Φ and Ψ torsion angles across each glycosidic linkage were plotted and 
connected together in chronological order ( ). Contour lines are plotted as a guideline 
reference for each linkage and represent the potential energy surface of each of the glycosidic 
linkages (the right hand side figure).  
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3.3.2 Linkage 8  
GlcNS(6S) - IdoUA  dp10(1and 5)  
GlcNS - IdoUA    dp10(3 and 7) 
 
The GlcNS + (6S) were modelled in the 
4
C1 conformation, gg rotamer prior to the 10 ns MD 
simulation. Again there are two different types of disaccharides which make up this linkage. Here 
one active oligosaccharide is comparable to one inactive oligosaccharide in both sequences.  
 
As expected there are no major differences between active and inactive oligosaccharides. This 
was suspected due to the results obtained from the 1 ns MD simulation, where again there were 
no real differences between active and inactive oligosaccharides There are also no differences 
between those with the sequence GlcNS(6S)-IdoUA (dp10(1 and 5); and those with the alternate 
sequence GlcNS-IdoUA (dp10(3 and 7)).  
The Cremer-Pople puckering parameters indicate all models remain in the 
4
C1 starting 
conformation. The corresponding torsion data indicates geometries A and B are present in all four 
oligosaccharides. There are no major differences between the 1 ns MD simulation and the 10 ns 
MD simulation, apart from the presence of geometry B in dp10(7) which was not present in the 
shorter MD simulation (Figure 3.27). Compare this data set with Figure 3.18.  
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Figure 3.27 Puckering-torsion data for linkage 8 the 10 ns MD simulation 
GlcNS(6S) – IdoUA  dp10(1 and 5) 
GlcNS – IdoUA   dp10(3 and 7) 
 
Puckering parameters: all graphs show θ° analysis (         ).  
Cremer-Pople ring puckering parameters during a 10 ns molecular dynamic simulation. 
All graphs show θ analysis (ф2 not shown) and changes are compared to the values identified in 
the torsion data in chronological order. 
Torsion data: Φ° dihedral angle (        ), Ψ° dihedral angle (        ).  
The variation in Φ and Ψ torsion angles over a course of 10 ns explicit water molecular dynamic 
simulation (the left hand side figure).  
 
Torsion data: Structures were sampled every picosecond over the course of 10 ns in TIP3P 
explicit water. The Φ and Ψ torsion angles across each glycosidic linkage were plotted and 
connected together in chronological order ( ). Contour lines are plotted as a guideline 
reference for each linkage and represent the potential energy surface of each of the glycosidic 
linkages (the right hand side figure).  
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3.3.3 Linkage 7 
IdoUA(2S) - GlcNS(6S)  dp10(1) and dp10(5) 
IdoUA - GlcNS   dp10(3) 
IdoUA(2S) - GlcNS   dp10(7) 
 
The IdoUA(2S) monosaccharide was modelled in the 
1
C4 conformation prior to the 10 ns MD 
simulation. There are three different types of disaccharides which make up this linkage. 
 
There are some slight differences between the active and inactive oligosaccharides, the main one 
being the difference in geometry of the torsion angles. The oligosaccharides dp10(1) and dp10(5) 
are comparable as they contain the same IdoUA(2S) - GlcNS(6S) sequence. In this instance 
there is a slight difference in the Ψ angle in the active dp10(1) has average value in geometry A 
of 0° (Φ = +50°, Ψ = 0°); where as the Ψ angle in the inactive dp10(5) has average value in 
geometry A of +10° (Φ = +50, Ψ = +10). Geometry B also shows more of a difference in 
geometry between active and inactive oligosaccharides.  The active dp10(1) has average value in 
geometry B of Φ = -40°, Ψ = -25°); where as the inactive dp10(5) has average value in geometry 
A of Φ = -10, ψ = -10). 
Another difference between active and inactive oligosaccharides involves the active dp10(3) 
oligosaccharide. This has a slightly different sequence (IdoUA-GlcNS) and is not directly 
comparable to those mentioned previously it behaves in the same way as dp10(1). This contains 
the same Φ and Ψ data values as the other active structure. This is a significant difference and 
could cause an influence in the overall biological activity of the samples. The inactive dp10(7) 
exists in slightly different geometries then those mentioned in all the above oligosaccharides. 
Geometry A shows the same average data values as dp10(5), where as geometry B exists in a 
slightly different geometry with the Ψ angle remaining around -10° but a change in the Φ angle 
(Φ = -25, Ψ = -10).  
There is also a difference in ring conformation according to the Cremer-Pople ring puckering 
parameter data, but this is between all oligosaccharides. Dp10(1) undergoes three changes in 
Chapter 3: Results 
 224 
conformation from the starting 
1
C4 conformation to the 
2
S0 conformation after 1 ns. This then 
undergoes a second conformational transition back to the chair conformation and then a final 
transition to the skew boat conformation (Figure 3.28, Panel A). Cremer-Pople puckering 
parameters indicates two conformational changes in dp10(3). Firstly the starting conformation 
undergoes a conformational change approximately 500 ps into the timescale to the skew boat 
conformation briefly. It then undergoes a change to the 
4
C1 conformation where it remains for the 
remainder of the simulation (Figure 3.28, Panel B). For the inactive models Cremer-Pople 
puckering parameters indicate a change from the starting conformation the skew boat 
conformation after 1 ns for dp10(5). This is the final conformation observed in the 10 ns MD 
simulation (Figure 3.28, Panel C). Decasaccharide dp10(7) behaves in a similar way to the active 
dp10(3) oligosaccharide. This makes it difficult to compare a shift in conformation to biological 
activity between the active and inactive oligosaccharides (compare Figure 3.28 with Figure 3.19).  
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Figure 3.28 Puckering-torsion data for linkage 7 the 10 ns MD simulation 
IdoUA(2S) - GlcNS(6S)  dp10(1 and dp10(5) 
IdoUA - GlcNS   dp10(3) 
IdoUA(2S) - GlcNS   dp10(7) 
 
Puckering parameters: all graphs show θ analysis (         ).  
Cremer-Pople ring puckering parameters during a 10 ns molecular dynamic simulation. 
All graphs show θ analysis (ф2 not shown) and changes are compared to the values identified in 
the torsion data in chronological order. 
Torsion data: Φ° dihedral angle (        ), Ψ° dihedral angle (        ).  
The variation in Φ and Ψ torsion angles over a course of 10 ns explicit water molecular dynamic 
simulation (the left hand side figure).  
 
Torsion data: Structures were sampled every picosecond over the course of 10 ns in TIP3P 
explicit water. The Φ and Ψ torsion angles across each glycosidic linkage were plotted and 
connected together in chronological order ( ). Contour lines are plotted as a guideline 
reference for each linkage and represent the potential energy surface of each of the glycosidic 
linkages (the right hand side figure).  
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3.3.4 Linkage 6 
GlcNS(6S) - IdoUA(2S)   dp10(1), dp10(5) and dp10(7) 
GlcNS(6S) - IdoUA  dp10(3) 
 
The GlcNS + (6S) were modelled in the 
4
C1 conformation, gg rotamer prior to the 10 ns MD 
simulation.  
There are two different types of disaccharides present of which oligosaccharides dp10(1, 5 and 7) 
are all comparable to each other as they contain the sequence GlcNS(6S)-IdoUA(2S). 
Interestingly there is the presence of an unknown conformation in oligosaccharides dp10(1) and 
dp10(7). This conformation is observed for approximately 1 ns in dp10(1) and 2 ns in do10(7) 
(Figure 3.29, Panels A and D). They have average data values of 81° and 87° respectfully. This 
has not previously identified in the 10 ns simulation for linkage 6, or for any of the other linkages. 
This could be an abnormality in the results but as they take over a month in computing time a 
repeated MD run was not carried out. Another explanation for this unidentified conformation is 
that it could be a half chair conformation not previously identified. All the other oligosaccharides 
were identified in the known 
4
C1 conformation. 
There is also a slight difference in torsion data observed for dp10(3). This had been identified in 
two different geometries; however they were different to those observed for the other 
oligosaccharides. Here geometry B had average data values of Φ = -50, Ψ = -50, which was the 
observed geometry in all the oligosaccharides. The additional geometry was identified as 
geometry C and this was defined with average data values of Φ = -25, Ψ = 0 (Figure 3.29, Panel 
B). All other models were observed in geometry A which had average data values of Φ = -10, 
Ψ = -10 (Figure 3.29, Panels A, C and D).  
 
The presence of the unknown conformation was unexpected as this has not been identified 
previously in literature and so does indicate a abnormal result. Also there are many differences 
between oligosaccharides in this linkage but it is difficult to establish a difference between active 
and inactive structure (compare Figure 3.29 with Figure 3.20).  
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Figure 3.29 Puckering-torsion data for linkage 6 the 10 ns MD simulation 
GlcNS(6S) - IdoUA(2S)   dp10(1), dp10(5) and dp10(7) 
GlcNS(6S) - IdoUA  dp10(3) 
 
Puckering parameters: all graphs show θ analysis (         ).  
Cremer-Pople ring puckering parameters during a 10 ns molecular dynamic simulation. 
All graphs show θ analysis (ф2 not shown) and changes are compared to the values identified in 
the torsion data in chronological order. 
Torsion data: Φ° dihedral angle (        ), Ψ° dihedral angle (        ).  
The variation in Φ and torsion angles over a course of 10 ns explicit water molecular dynamic 
simulation (the left hand side figure).  
 
Torsion data: Structures were sampled every picosecond over the course of 10 ns in TIP3P 
explicit water. The Φ and Ψ torsion angles across each glycosidic linkage were plotted and 
connected together in chronological order ( ). Contour lines are plotted as a guideline 
reference for each linkage and represent the potential energy surface of each of the glycosidic 
linkages (the right hand side figure).  
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3.3.5 Linkage 5 
IdoUA(2S) – GlcNS(6S)    dp10(1), dp10(3), dp10(5) and dp10(7) 
 
The IdoUA(2S) monosaccharide was modelled in the 
1
C4 conformation prior to the 10 ns MD 
simulation. All oligosaccharides contain the same IdoUA(2S) – GlcNS(6S) structure so all models 
are comparable for this linkage. 
 
There are major differences between active and inactive structures regarding torsion angle 
geometries. All exist in two different geometries, with differing torsion angles. The active dp10(1) 
exists equally in geometry A as it does in geometry B. These geometries have average data 
values of Φ = +50, Ψ = -50 for geometry A and Φ = -40, Ψ = -60 for geometry B. Oligosaccharide 
dp10(3) shows similar results for geometry A with a slight change in the Φ value of -60° (Φ = -60, 
Ψ = -60). When compared to the inactive sequences, although they both contain both geometries 
(geometry A again shows the same data values as those identified in the active structures); 
geometry B is very different. Both dp10(5) and dp10(7) only briefly spend time in geometry B and 
here the Ψ angle remains at a relatively constant -60°, with a major difference in the Φ value (Φ = 
-25, Ψ = -60). This difference is significant and could influence overall biological activity. 
 
Moving on to compare the Cremer-Pople puckering parameters there is a slight difference 
between active and inactive structures. For dp10(3) the puckering parameter data shows a 
change in conformation from the skew boat conformation to the 
1
C4 conformation and then back 
again (Figure 3.30, Panel B). This is the same final conformation as that observed in both dp10(1) 
and dp10(5) (Figure 3.30, Panels A and C). However these only make the one conformational 
transition during the simulation, from the starting 
1
C4 conformation to the final 
2
S0 conformation. 
The fact that the inactive dp10(5) oligosaccharide shows similar changes in conformation 
suggests the influence for biological activity is also due to the available torsional geometries.  
Dp10(7) shows very different results in that, like dp10(3) it undergoes two conformational 
transitions these occur opposite to those previously described. Here the 
1
C4 conformation is 
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present at the start of the simulation. It undergoes a conformational transformation to the skew 
boat form after 1 ns remaining at the conformation for approximately 5 ns before returning to the 
1
C4 conformation (Figure 3.30, Panel D). 
 
The data for this linkage suggests it is the combination of the torsional geometries alongside the 
iduronate conformation which is significant for biological activity. Compare this data with Figure 
3.21. 
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Figure 3.30 Puckering-torsion data for linkage 5 the 10 ns MD simulation 
IdoUA(2S) – GlcNS(6S)    dp10(1), dp10(3), dp10(5) and dp10(7) 
 
Puckering parameters: all graphs show θ analysis (         ).  
Cremer-Pople ring puckering parameters during a 10 ns molecular dynamic simulation. 
All graphs show θ analysis (ф2 not shown) and changes are compared to the values identified in 
the torsion data in chronological order. 
Torsion data: Φ° dihedral angle (        ), Ψ° dihedral angle (        ).  
The variation in Φ and Ψ torsion angles over a course of 10 ns explicit water molecular dynamic 
simulation (the left hand side figure).  
 
Torsion data: Structures were sampled every picosecond over the course of 10 ns in TIP3P 
explicit water. The Φ and Ψ torsion angles across each glycosidic linkage were plotted and 
connected together in chronological order ( ). Contour lines are plotted as a guideline 
reference for each linkage and represent the potential energy surface of each of the glycosidic 
linkages (the right hand side figure).  
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3.3.6 Linkage 4 
GlcNS(6S) - IdoUA(2S)    dp10(1)  
GlcNS - IdoUA(2S)    dp10(3), dp10(5) and dp10(7) 
 
The GlcNS + (6S) were modelled in the 
4
C1 conformation, gg rotamer prior to the 10 ns MD 
simulation. The longer simulation for linkage 4 shows no differences in ring conformation between 
the active and inactive oligosaccharides.  
 
There are slight differences between results from the 1 ns MD simulation and the 10 ns MD 
simulation. The torsional geometry in the 1 ns MD simulation shows the presence of only 
geometry B for oligosaccharides dp10(1) and dp10(7). Both geometries A and B existed in 
dp10(3) and dp10(5) for the 1 ns MD simulation. In the 10 ns MD simulation all four 
oligosaccharides exist in both A and B geometries (Figure 3.31).  
 
We can assume from the 10 ns MD simulation, which are similar to the 1 ns MD simulation 
results that there is no role in FGF2 protein interactions for the non-reducing terminal. This has 
been reached based on observations from both the 1 ns and 10 ns MD simulations and so the 
final three linkages for the 10 ns simulations will not be discussed here. This is due to there being 
no differences between the longer simulation and the shorter 1 ns MD simulation (results not 
shown).  
 
To identify any real differences in active and inactive oligosaccharides longer simulations would 
need to be performed. Length of computing time required to perform each simulation was a major 
factor in this study, but to be competing with molecular simulations in industry longer simulations 
really are needed. A 50 ns MD simulation would be the next step in this kind of study to really 
determine any major changes and to really compete with other studies. Compare Figure 3.31 to 
the 1 ns MD simulation data in Figure 3.22.  
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Figure 3.31 Puckering-torsion data for linkage 4 the 10 ns MD simulation 
GlcNS(6S) - IdoUA(2S)    dp10(1)  
GlcNS - IdoUA(2S)    dp10(3), dp10(5) and dp10(7) 
 
Puckering parameters: all graphs show θ° analysis (         ).  
Cremer-Pople ring puckering parameters during a 10 ns molecular dynamic simulation. 
All graphs show θ analysis (ф2 not shown) and changes are compared to the values identified in 
the torsion data in chronological order. 
Torsion data: Φ° dihedral angle (        ), Ψ° dihedral angle (        ).  
The variation in Φ and Ψ torsion angles over a course of 10 ns explicit water molecular dynamic 
simulation (the left hand side figure).  
 
Torsion data: Structures were sampled every picosecond over the course of 10 ns in TIP3P 
explicit water. The Φ and Ψ torsion angles across each glycosidic linkage were plotted and 
connected together in chronological order ( ). Contour lines are plotted as a guideline 
reference for each linkage and represent the potential energy surface of each of the glycosidic 
linkages (the right hand side figure).  
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3.3.7 Oligosaccharide sequence after 10 ns MD simulation 
The ring conformations for the iduronates after the 10 ns MD simulation are as follows: 
 
dp10(1) Active 
UA – GlcNAc – GlcUA – GlcNS(6S) – IdoUA(2S) – GlcNS(6S) – IdoUA(2S) – GlcNS(6S) – IdoUA – GlcNAc(6S) 
 
 
 
dp10(3) Active 
UA – GlcNAc – GlcUA – GlcNS – IdoUA(2S) – GlcNS(6S) – IdoUA – GlcNS – IdoUA – GlcNAc(6S) 
 
 
 
dp10(5) Inactive 
UA – GlcNAc – GlcUA – GlcNS – IdoUA(2S) – GlcNS(6S) – IdoUA(2S) – GlcNS(6S) – IdoUA – GlcNAc 
 
 
 
dp10(7) Inactive 
UA – GlcNS – IdoUA – GlcNS – IdoUA(2S) – GlcNS(6S) – IdoUA(2S) – GlcNS – IdoUA – GlcNAc(6S) 
 
 
 
It is only dp10(7) which contains all three iduronate conformations present after the 10 ns MD 
simulation. Surprisingly, dp10(1) and dp10(5) show the same ring conformation profiles even 
though dp10(1) is the active oligosaccharide and dp10(5) is the inactive oligosaccharide.  
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3.4 Docking results of HS Decasaccharides 
3.4.1 Preliminary results of 1BFC and 1FQ9 
Docking of molecules and compounds into the binding site of a receptor is an important part of 
structure based drug design.  A thorough understanding of the principles that determine strength 
of a protein/ligand complex, alongside accurate and fast docking protocol is essential in computer 
aided drug design. Alongside this is the ability to actually visualise the binding geometries created 
as visual screening of libraries is fast becoming standard practice in modern drug discovery.  
 
3.4.1.1 1BFC 
The initial docking analysis was carried out to assess the viability of using Autodock Vina (here 
after referred to as Vina) as reliable docking software, alongside UCSF Chimera alpha, version 
1.4 (build 29530). Also checked; as a comparison to this were Autodock 4.2 and also Dock 6.2. 
The first of the two test models was that from the file 1BFC from the Protein Data Bank. This is a 
bFGF (FGF2) complexed with a hexamer heparin fragment (Faham et al., 1996). The original x-
ray structure can be seen on the left of (Figure 3.32, Panel A), with the predicted Vina results on 
the right hand side of the figure (Figure 3.32, Panel B with the predicted structure shown in 
green).  
 
Chimera was firstly used to select and create two separate pdb files, the first being the FGF 
protein file, which was saved as a protein.pdb file; then the heparin oligosaccharide also saved as 
a .pdb file (Trott and Olsen, 2010). These files were then used to assess all three docking 
programmes (Vina, Autodock and Dock 6.2). After initial tests it was decided Vina was by far the 
easiest and the most accurate of the docking programmes and so all dockings from here onwards 
were carried out using Vina.  
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Visualization of the predicted geometries was carried out in PyMol molecular graphics system 
(DeLano 2002). 
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Figure 3.32 
 
 
 
Figure 3.32 A comparison of the X-ray crystal structure of a bFGF (FGF2) complexed with a 
hexamer heparin fragment alongside the Vina docked model. 
 
Panel A. The original x-ray crystal structure from file 1BFC obtained from the protein data bank 
and originally identified by work carried out by Faham et al (Faham et al., 1996). 
Panel B. Shows the original x-ray crystal structure alongside the Vina predicted result shown by 
the red hexasaccharide. As this shows, Vina was successful in identifying the correct binding 
position for the heparin hexasaccharide. 
 
 
B. A. 
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The binding site; shown by the arrow on the right hand side of the figure (Figure 3.32, Panel B) 
involves the two sulphate groups from the heparin fragment interacting with the protein binding 
site. When referring to the binding site in the Vina results, it is with reference to these two 
highlighted sulphate groups. An extended version of this binding site can be seen in the following 
figure (Figure 3.25) which has the binding site highlighted. This binding site highlights those 
important amino acid residues identified earlier in the report (Figure 1.21, p91). This includes 
residues 27, 28, 101, 102, 103 and 120-137 (Faham et al., 1996; Schlessinger et al., 2000). 
The hydrogen bonding function used in Chimera was used to identify the interactions between the 
heparin hexasaccharide and the FGF and is clearly shown by the connecting blue lines (Figure 
3.33).  
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Figure 3.33 
 
 
 
Figure 3.33 The important binding residues identified between FGF2 and a heparin 
hexasaccharide. 
 
This figure was obtained from the protein data bank (file 1BFC) and has been adapted from the 
original structure by Faham et al (Faham et al. 1996). The important binding residues are clearly 
identified which were previously discussed (Introduction, p91).  
 
 
Asn 
102 
Lys 
27 
 
Gly 
134 
Arg 
121 
Lys 
126 Ala 
137 
Asn 
28 
Gln 
135 
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3.4.1.2 1FQ9 
 
The file 1FQ9, taken from the Protein Data Bank was also used to check the accuracy of Vina as 
a relevant molecular docking software programme. The structure is taken from a 2:2:2 complex of 
ternary bFGF-FGFR1-heparin complex, however for the purposes of the docking only one FGF: 
heparin chain was used. (Both the FGFR’s are removed as are one complex of FGF: heparin). As 
above the original pdb file was separated and then docked back together again, going through 
the same process as described above (p124). The image on the left of the diagram (Figure 3.34) 
shows the original x-ray crystal structure. The image on the right shows the predicted Vina result 
with the predicted result shown in green. As before; the predicted Vina result is the same as seen 
in the x-ray crystal structure, thus providing evidence that Vina can be used as a credible docking 
programme for predicting the binding of other HS/heparin fragments.  
An extended version of the binding site can be seen in Figure 3.35 (Schlessinger et al. 2000). 
The find H bond function used in 1BFC was also used here to identify which parts of the chain 
hydrogen bond to the FGF protein. These bind to similar parts of the protein previously identified 
in 1BFC.  
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Figure 3.34  
 
 
 
Figure 3.34 A comparison of the x-ray crystal structure of a 2:2:2 complex of ternary bFGF-
FGFR1-heparin complex alongside the Vina predicted model. 
 
Panel A. Shows the original x-ray crystal structure from file 1FQ9 obtained from the Protein Data 
Bank (Schlessinger et al. 2000). 
Panel B. The Vina predicted docking results compared to the x-ray crystal structure. The binding 
site was identified by x-ray crystallography; with the binding site identified by the white arrow. 
 
 
B. A. 
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Asn 
27 
Lys 
129 
Lys 
119 
Lys 
125 
Gln 
134 Ala 
136 
Gln 
134 
Asn 
120 
 Figure 3.35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.35 The important binding site residues identified in a 2:2:2 complex of ternary 
bFGF-FGFR1-heparin complex. 
 
This figure has been adapted from Schlessinger et al (Schlessinger et al., 2000) obtained from 
file 1FQ9 from the Protein Data Bank. 
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Following on from the preliminary docking, further docking work was carried out on the Goodger 
dp10 oligosaccharides. This purpose of this was to analyse the ability of the Vina docking 
program to dock the Goodger oligosaccharides to the same binding site as identified in both X-ray 
structures used in the preliminary dockings (Figures 3.32 and 3.34).  
 
3.4.2 Docking of active and inactive dp10 structures 
Those oligosaccharides which were used for docking in this section of the study were dp10(1), 
dp10(3), dp10(5) and dp10(7). These were docked into the 1BFC x-ray crystal structure only. 
Time constraints meant only one of the three or four potential x-ray crystal structures could be 
analysed. Different frames from the initial molecular dynamic simulations were identified as it was 
impossible to run all frames involved due to the computational time needed for the docking 
simulations (the longer 10ns simulations each contain 10,000 frames, with each frame taking 
exceeding more than 48 hours computational docking time). Selected frames were initially 
docked as rigid structures (all bonds were left as non-rotatable), as shown in the preliminary 
dockings above and a global search of just the known binding site was performed. Luckily the 
binding site is known due to the previous work carried out with the resultant x-ray crystal 
structures (Faham et al. 1996; Schlessinger et al. 2000). If the same docking calculations were to 
be carried out on an unknown binding site, then the entire protein would have to be searched, 
leading to greatly extended computational docking times.  
The binding site for the two known x-ray crystal structures both involved the following sequence 
(Table 3.2). 
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Table 3.2 
IdoUA(2S) GlcNS(6S) 
Residue 4 Residue 5 
Binding position X Binding position Y 
 
Table 3.2 The known binding site identified in the known X-ray crystal structures. 
 
This binding information was identified in a number of studies (Faham, Hileman et al. 1996; 
Schlessinger et al. 2000).  
 
 
All dockings carried out will be in reference to these particular ring structures; with particular 
attention on the positioning of the sulphate groups highlighted in the sequence.  
Models dp10(1), dp10(3), dp10(5) and dp10(7),were chosen because of the presence of the 
IdoUA at position 9 in the sequence. Those sequences with GlcUA in the same position were not 
taken on for docking analysis (models dp10(2), dp10(4), dp10(6) and dp10(8)). Table 3.3 contains 
information on the frames identified for the docking analysis for each model. Each frame 
corresponds to a change in either the dihedral angle or a conformational change in the iduronate 
ring structure.   
If time constraints had not been an issue then all eight decasaccharide oligosaccharides would 
have been used in the docking analysis, as according to the puckering-torsion data analysis the 
presence of the GlcUA may play more of a role in the binding affinity then initially thought.  
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Table 3.3   
 
Decasaccharide 
1ns timescale 
Frame 
number 
Decasaccharide 
10ns timescale 
Frame 
number 
45 200 
350 1300 
600 3000 
900 8300 
25 250 
200 440 
650 560 
800 2900 
 6000 
30 500 
850 1050 
 4000 
 6000 
50 250 
150 750 
200 5000 
1 
 
 
 
3 
 
 
 
 
 5 
 
 
 
7 
900 
1 
 
 
 
3 
 
 
 
 
5 
 
 
 
7 
 
 
 
Table 3.3 Frame numbers chosen for docking analysis with Vina. 
These were the frames which were chosen on the basis of either a conformational change and/or 
torsional angle change, identified in the puckering/torsion data.  
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3.4.3 The 1 ns Docking simulations 
 
3.4.3.1 Oligosaccharide dp10(1): 
Model dp10(1) was docked to the FGF2 protein in the file 1BFC using the identified four frames. 
The time period chosen for analysis in Vina (with the corresponding frame numbers) were 28ps, 
218ps, 600ps and 900ps (frames 45, 315, 975 and 1463) out of a possible 1600 frames (Table 
3.4).  Each frame counts for 0.625 ps in time from the 1 ns timescale (1000 ps). All frames were 
chosen mainly based on the conformation of the iduronic acids in the sequence; with these being 
the most conformationally flexible residues in the chain (see Introduction, p64). Other factors 
such as the dihedral angle data was also taken into account, which has already been shown to 
change over the 1 ns timescale (see Results, puckering/torsion data).   
The main area of interest for all docking calculations was the identified binding site observed in 
the x-ray crystal structure of the bFGF complex (file 1BFC). In particularly the position of the two 
sulphate groups identified in the bound heparin fragment were studied in detail (Figure 3.32). For 
all models these two sulphate groups were used as a point of reference for the binding site since 
these were the two key positions identified as important for binding and activation of a HS:FGF 
complex (see Introduction p82 onwards).  
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Table 3.4  
 
Residue Frame: 45 
Time in ps: 28 
Frame: 350 
Time in ps: 218 
Frame: 975 
Time in ps: 600 
Frame: 1463 
Time in ps: 900 
UA 
 
2
H1 
2
H1 
2
H1 
2
H1 
GlcNAc 
 
4
C1 
4
C1 
4
C1 
4
C1 
GlcUA 
 
4
C1 
4
C1 
4
C1 
4
C1 
GlcNS(6S) 
4
C1 
4
C1 
4
C1 
4
C1 
IdoUA(2S) 
1
C4 
1
C4 
1
C4 
1
C4 
GlcNS(6S) 
4
C1 
4
C1 
4
C1 
4
C1 
IdoUA(2S) 
1
C4 
1
C4 
2
S0 
2
S0 
GlcNS(6S) 
4
C1 
4
C1 
4
C1 
4
C1 
IdoUA 
 
1
C4 
2
S0 
4
C1 
4
C1 
GlcNAc (6S) 
4
C1 
4
C1 
4
C1 
4
C1 
 
Table 3.4 Conformations of all the ring structures for dp10(1) in the frames chosen for 
docking using Vina.   
 
The iduronates highlighted in red were of particular interest due to their ability to change 
conformation during the MD simulation.  
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Vina successfully predicted 11 high affinity low energy structures as potential docking 
conformations during the first rigid docking performed. Frame 45, the first structure docked into 
the 1BFC binding site comprises all iduronates in the 
1
C4 conformation. Of the 11 structures, 
model 1 had the highest binding affinity of -13.0 kcal/mol and rmsd values of 0.000 (for both l.b 
and u.b values). These values suggest it is the ideal candidate for binding to the protein with both 
rmsd values at zero and the lowest possible affinity value.   
Here the HS chain has the N-sulphated group of the GlcNS(6S) of residue 6 in binding position X 
with the neighbouring residue, the 2-O-sulphate group of the iduronate in binding position Y 
(Figure 3.36, Panel A and B). This positions the chain in the opposite direction then that identified 
in the x-ray crystal structure and although is not an exact fit the sulphate groups are orientated in 
the exact position identified in the crystal structure.  
There were other structures predicted but these did not fit to both binding sites present in the 
crystal structure. Other structures which had been ranked based on the binding affinity could be 
dismissed from the search due to the position of the sulphate groups in the HS chain. One such 
model had been ranked as model number 10 out of 11 and had a binding affinity of -10.1 kcal/mol 
(Table 3.6). However there was no match to the binding site identified in the crystal structure. The 
full range of docking results can be found in the appendix section of this study.  
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Figure 3.36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.36 The highest affinity binding structure as predicted by Vina for dp10(1) frame 
45, from the rigid 1 ns MD simulation 
 
This is the structure with the highest affinity (kcal/mol) and is rated as model number 1 in the Vina 
search.  It has a binding affinity of -13.0 kcal/mol and rmsd values of 0.000 (for both l.b and u.b 
values).The protein in blue shows the FGF2 protein in the x-ray crystal structure, alongside the 
heparin fragment from the x-ray crystal structure. The lighter coloured decasaccharide is the 
Goodger model. 
 
Panel A. Frame 45, model 1with both binding positions predicted.   
Panel B. The magnified image of frame 45, with both binding sites X and Y highlighted.    
 
Binding position 
X 
Binding position 
Y 
A. 
 
B. 
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The presence of the first 
2
S0 conformation identified (residue 9) has no influence on the docking, 
possibly due to its position next to the reducing terminal. 14 low energy structures were created 
with the best fit model identified as model number 7. The sulphate group from the IdoUA(2S) at 
residue 7 is in binding site X, however the actual positioning of the HS chain is not the expected 
conformation for binding in nature as it does not lie planar against the FGF2 molecule. Other 
models identified were models 10 and 11 and again those do not show a good fit to the x-ray 
crystal structure (data shown in appendix). For this reason these structures were dismissed as 
viable structures after the docking process. Four structures out of 19 were identified in frame 975 
(600ps). Here in this frame, all three iduronate conformations are present in the HS chain (Table 
3.5). 
 
Table 3.5 
 
Residue IdoUA(2S) IdoUA(2S) IdoUA 
Position in chain 5 7 9 
Conformation 
1
C4 
2
S0    
4
C1 
 
 
Table 3.5 The conformation of the different iduronates in dp10(1) for frame 975. 
 At this point in the MD simulation, all three iduronate conformations are present in the chain. 
 
 
 
Although the HS chain is found in a more central position to bind the FGF2 molecule; again none 
were thought to be viable docking structures due to the nature of the sulphate groups. The model 
identified as having the highest affinity binding according to Vina had no sulphate groups in the 
either binding site (model 1). The 6-O-sulphate group of residue 6, the GlcNS(6S) appears to be 
the closest to this binding site (binding site Y), however when the structure is rotated this is 
further from the binding site then first observed.  
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All the above frames were chosen because of a conformational change. The final frame, frame 
1463 was chosen because it corresponded to a change in the torsion data corresponding to both 
Φ and ψ angles. 20 models were generated from Vina and of those; model 3 and 15 were 
thought to be the best fit. Model 15 has possibly the best fit model with the IdoUA(2S) of residue 
5 in binding position X and the residue 4 near to the binding position Y (when rotated, again this 
is not as near as first thought). Model 15 has an affinity of -9.9 kcal/mol with rmsd values of rmsd 
l.b at 11.727 and the u.b at 19.515. This could be an ideal candidate for forming the tertiary 
complex due to its position against the FGF protein.  
 
Table 3.6 
 
Frame used Mode Affinity 
(kcal/mol) 
1 -13.0 
2 -11.1 
3 -11.0 
4 -10.9 
5 -10.6 
6 -10.4 
7 -10.4 
8 -10.2 
9 -10.2 
10 -10.1 
45 
11 -10.0 
 
Table 3.6 Energy values for each Vina predicted model for dp10(1), frame 45 
Model number 1 has been highlighted as the best highest affinity binding model for the 1 ns MD 
simulation. This was based on the predicted position of the sulphate groups in relation to the 
X-ray crystal structure.  
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3.4.3.2 Oligosaccharide dp10(3): 
Model dp10(3) was docked to the FGF2 protein in the file 1BFC using the identified four frames. 
The time period chosen for analysis in Vina (with the corresponding frame numbers) were 15 ps, 
200 ps, 650 ps and 800 ps (frames 25, 125, 1056 and 1300) out of a possible 1600 frames (Table 
3.8). 
Vina successfully predicted 20 high affinity low energy structures as potential docking 
conformations during the rigid docking performed for frame 25. None of the predicted structures 
were deemed close enough to the X-ray crystal structure and so were dismissed. Another 20 
structures were predicted for frame 125, of which model number 3 was identified as the best fit 
model. Here the iduronates at positions 5 and 9 are in the skew boat conformation with the 
iduronate at position 7 in the 
1
C4 conformation. Here it is just the GlcNS(6S) of residue 6 in 
binding position X. The predicted binding affinity for this model was -10.6 kcal/mol. Models 10, 12 
and 18 all had the N-sulphate group from the GlcNS at position 8 in or around binding position Y 
with model 10 showing the closet fit model amongst these. All had a similar value for the binding 
affinity (-9.8, -9.6 and -9.0 kcal/mol respectfully); (Table 3.7).  
Vina predicted 20 structures for frame 1056, with model number 11 identified as the best fit 
model. This has an affinity of -9.9 kcal/mol with the IdoUA(2S) of sequence position 5 and the 
unsulphated IdoUA of position 9 identified in the 
4
C1 conformation. The iduronate at sequence 
position 7 is in the 
1
C4 conformation. Here the iduronate at position 5 is in binding position X with 
the neighbouring residue, the GlcNS of residue 4 in binding position Y. This positioning puts the 
residues in the opposite direction to those in the crystal structure. This however is not the best fit 
structure, this is found in frame 1300, which is the final frame for dp10(3). This frame was chosen 
for the change in torsion data rather than a conformational change. Of the 12 predicted Vina 
models, model number 3 was thought to be the best fit (Figure 3.37). It has the 2S of IdoUA(2S) 
at position 5 in the first binding site (site X), then following on from this is the neighbouring 
residue 4 the GlcNS in the second binding site (site Y). This positioning/placement reflect that in 
the crystal structure in that it is an iduronate in the first binding position. However on the Goodger 
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oligosaccharide the reducing end is found towards the left hand side of the protein, which places 
it in the opposite direction in the x-ray crystal structure. Here the binding affinity for model 3, 
frame 1300 is -10.8 kcal/mol and the rmsd are as follows; rmsd l.b 12.712 and rmsd u.b 27.207. 
 
 
Table 3.7 
 
Frame used Mode Affinity 
(kcal/mol) 
1 -12.8 
2 -11.4 
3 -10.8 
4 -10.8 
5 -10.4 
6 -10.2 
7 -10.2 
8 -10.2 
9 -10.1 
10 -10.0 
11 -10.0 
1300 
12 -9.9 
 
Table 3.7 Energy values for each Vina predicted model for dp10(3), frame 1300 
 
Model number 3 has been highlighted as the best highest affinity binding model for the 1 ns MD 
simulation. This was based on the predicted position of the sulphate groups in relation to the 
X-ray crystal structure. 
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Figure 3.37  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.37 The highest affinity binding structure as predicted by Vina for dp10(3) frame 
1300, from the rigid 1 ns MD simulation.  
 
The protein molecule in blue shows the FGF2 protein in the x-ray crystal structure, alongside the 
heparin fragment from the x-ray crystal structure. The lighter coloured decasaccharide is the 
Goodger model. It has a binding affinity of -10.8 kcal/mol and the rmsd are as follows; rmsd l.b of 
12.712 and rmsd u.b of 27.207.  
 
Panel A. Frame 1300, model 3. 
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Table 3.8  
 
Residue Frame: 25 
Time in ps: 15 
Frame: 200 
Time in ps: 125 
Frame: 1056 
Time in ps: 650 
Frame: 1300 
Time in ps: 800 
UA 
 
2
H1 
2
H1 
2
H1 
2
H1 
GlcNAc 
 
4
C1 
4
C1 
4
C1 
4
C1 
GlcUA 
 
4
C1 
4
C1 
4
C1 
4
C1 
GlcNS  
4
C1 
4
C1 
4
C1 
4
C1 
IdoUA(2S) 2S0 
2
S0 
4
C1 
4
C1 
GlcNS(6S) 
4
C1 
4
C1 
4
C1 
4
C1 
IdoUA  
1
C4 
1
C4 
1
C4 
1
C4 
GlcNS  
4
C1 
4
C1 
4
C1 
4
C1 
IdoUA 
 
1
C4 
2
S0 
4
C1 
4
C1 
GlcNAc (6S) 
4
C1 
4
C1 
4
C1 
4
C1 
   
Table 3.8 Conformations of all the ring structures for dp10(3) in the frames chosen for 
docking using Vina. 
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3.4.3.3 Oligosaccharide dp10(5): 
 
Model dp10(5) was docked to the FGF2 protein in the file 1BFC using the identified two frames. 
The frames chosen were frame 30 and 1381 (corresponding to 18 ps and 850 ps; Table 3.10). 
For frame 30, Vina successfully predicted 11 low energy models with model 9 identified as the 
best fit model (Table 3.11). Here it was residue 4 which was identified with the sulphate group in 
binding position Y. However there was no identifiable sulphate in binding site X (data in 
appendix). In this frame the first iduronate at position 5 is in the 
1
C4 conformation as in the one at 
position 7. The position 9 Iduronate is found in the 
2
S0 conformation (Table 3.10).  Model number 
11 was also identified as another best fit model. This has an affinity of -9.9 kcal/mol with the 
IdoUA(2S) of sequence position 5 and the unsulphated IdoUA of position 9 identified in the 
4
C1 
conformation.  
The data for the two best fit models are identified in Table 3.9. Model 2 for frame 30 has a more 
negative affinity binding, suggesting it is the best fit model produced from Vina. However; when 
the structure is rotated using the molecular viewer Pymol, the sulphate groups around the binding 
position are actually further away from the binding site then first observed.  
 
Frame number 1381 corresponds to 850ps, with Vina successfully predicting 20 low binding 
structures. Of these, five were deemed as best fit models. Three were identified with the 2S group 
of the IdoUA(2S) of position 5 in sulphate position X (models 4, 8 and 9, model 9 is shown in 
Figure 3.38, all others are in the appendix). There are other sulphate groups near to binding site 
Y, however when rotated these structures are not as close as they first appear (frames 5 and 19; 
Table 3.11). These other two structures involve firstly the 2S group of residue 7 (the IdoUA(2S) 
shown in model 5); and residue 6 involving the NS of GlcNS(6S) in the first sulphate position 
(model 19, Table 3.9).  
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Table 3.9 
Model 4 5 8 9 19 
Affinity -11.0 -11.0 -10.7 -10.7 -9.3 
Rmsd l.b 8.241 3.132 7.150 11.497 5.089 
Rmsd u.b 21.285 4.550 23.104 24.104 10.658 
 
 
Table 3.9 The Vina predicted models for dp10(5) frame 1381. 
This frame corresponds to 850 ps in time and from 20 predicted models, five were identified 
based on their positioning near the binding site.  
 
 
None of these structures discussed above involve two neighbouring sulphate groups occupying 
the mentioned binding structure identified in the x-ray crystal structure. The occupation of these 
structures in the binding site involves one site or the other, with no preference to one specific 
area. The chosen frames do not contain all three mentioned iduronate conformations (
1
C4, 
2
S0 
and 
4
C1), which have been identified in the known active sequences (see Discussion section). 
The inability of the final iduronic acid to occur in all three conformations may play a major part in 
this. 
 
All these structures have the same positioning with the reducing terminal found towards the left 
hand side of the protein, putting it opposite to the known x-ray crystal structure.  
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Figure 3.38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.38 The highest affinity binding structure as predicted by Vina for dp10(5) frame 
1381, from the rigid 1 ns MD simulation.  
 
The protein molecule in blue shows the FGF2 protein in the x-ray crystal structure, alongside the 
heparin fragment from the x-ray crystal structure. The lighter coloured decasaccharide is the 
Goodger model. It has a binding affinity of -10.7 kcal/mol and the rmsd are as follows; rmsd l.b of 
11.497 and rmsd u.b of 24.593.  
 
Panel A. Frame 1381, model 9. 
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Table 3.10 
 
Residue Frame: 30 
Time in ps: 18 
Frame: 1381 
Time in ps: 850 
UA 
 
2
H1 
2
H1 
GlcNAc 
 
4
C1 
4
C1 
GlcUA 
 
4
C1 
4
C1 
GlcNS  
4
C1 
4
C1 
IdoUA(2S) 
1
C4 
2
S0 
GlcNS(6S) 
4
C1 
4
C1 
IdoUA(2S)  
1
C4 
2
S0 
GlcNS(6S) 
4
C1 
4
C1 
IdoUA 
 
2
S0 
4
C1 
GlcNAc 
4
C1 
4
C1 
 
 
Table 3.10 Conformations of all the ring structures for dp10(5) in the frames chosen for 
docking using Vina 
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Table 3.11 
Frame used Mode Affinity 
(kcal/mol) 
1 -11.5 
2 -11.2 
3 -11.2 
4 -11.0 
5 -11.0 
6 -10.9 
7 -10.8 
8 -10.7 
9 -10.7 
10 -10.4 
11 -10.4 
12 -10.3 
13 -10.3 
14 -10.1 
15 -9.9 
16 -9.8 
17 -9.7 
18 -9.5 
19 -9.3 
1381 
20 -9.1 
Table 3.11 Energy values for each Vina predicted model for dp10(5), frame 1381 
Model number 9 has been highlighted as the best highest affinity binding model for the 1 ns MD 
simulation. This was based on the predicted position of the sulphate groups in relation to the 
X-ray crystal structure. 
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3.4.3.4 Oligosaccharide dp10(7): 
Finally, dp10(7) was the final sequence chosen for docking analysis and again it was docked to 
the FGF2 protein in the file 1BFC using the identified three frames. The frames chosen were 
frames 50, 200 and 1463 (corresponding to 31 ps, 125 ps and 900 ps). This is the only structure 
with four iduronic acid ring structures in the chain. Two of these are unsulphated and two have 
the 2S group as a chain modification (see Modifications, p32). The IdoUA at position 3 is the 
additional residue identified in the chain; in previous sequences this has always been found as a 
GlcUA. Throughout this 1000 ps time period it did not change from the 
4
C1 conformation (Table 
3.13).  This in itself is something to consider as it was initially thought that the iduronates found in 
an internal position were found only in the 
1
C4 and 
2
S0 conformations (Ferro et al. 1990; 
Rabenstein 2002).   
The three other iduronates all change conformation at some point during this 1000 ps timeframe, 
so the first frame chosen for docking was frame 50 which equates to 31 ps in time. Here all the 
iduronates are found in the 
1
C4 conformation apart from the previously mentioned IdoUA at 
position 3. Of the 20 proposed models it was model 10 which showed similarity to the binding 
site. The 2S group of residue 7, the IdoUA(2S) interacts around the binding site X (Figure 3.39). 
This predicted structure has a binding affinity of -10.0 kcal/mol. Model 19 also has residue 7 in a 
similar position and model 18 has residue 6 in the same binding position (data shown in 
appendix). This had a lower binding affinity of -9.2 kcal/mol (Table 3.14).  
Frame 200 also produced 20 proposed models. Models 2, 7 and 15 have the whole binding site 
occupied, with the first two models showing the same residues interaction in the same position 
(the GlcNS of residue 4 and the IdoUA(2S) of residue 5).This is found with the non-reducing 
terminal towards the left hand side of the protein and all three iduronate conformations are 
present. Here the iduronate at position 3 was identified in the 
4
C1 conformation. Iduronates at 
positions 5 and 7 were in the 
1
C4 conformation and finally the iduronate at position 9 was in the 
skew boat conformation.  
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Model 15 shows residues 6 and 7 interacting in the binding site of the protein. The binding data 
for these models show model number 2 has a greater affinity to bind to the protein then the other 
models mentioned (Table 3.12). 
 
Table 3.12 
  
Model 2 7 15 
Affinity -10.7 -9.8 -9.0 
Rmsd l.b 12.847 12.739 12.684 
Rmsd u.b 15.900 15.856 17.995 
 
Table 3.12 The best fit Vina predicted models for dp10(7); frame 200. 
Here it was identified that model 15 was the best fit model as it had the best fit according to the 
X-ray crystal structure. 
 
  
However model 15 was thought to be the best fit model in terms of binding to the known binding 
site identified in the x-ray crystal structure (Figure 3.38).  
The final frame; number 1463 corresponds to 900 ps and in this frame residues 5, 7 and 9 have 
all changed conformation. As mentioned previously the IdoUA at position 3 does not change at all 
during this simulation.  
The only Vina predicted models which interact with the binding site are models 5 and 15 and it is 
the NS group of residue 6, the GlcNS(6S) which is found in binding site Y. Here model 5 is 
thought to be the best fit model (data shown in appendix).  
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Figure 3.39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.39 The highest affinity binding structure as predicted by Vina for dp10(7) frame 
200, from the rigid 1 ns MD Simulation.  
 
The protein molecule in blue shows the FGF2 protein in the x-ray crystal structure, alongside the 
heparin fragment from the x-ray crystal structure. The lighter coloured decasaccharide is the 
Goodger model. It has a binding affinity of -9.0 kcal/mol and the rmsd are as follows; rmsd l.b of 
12.684 and rmsd u.b of 17.995.  
 
Panel A. Frame 200, model 15. 
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Table 3.13 
 
Residue Frame: 50 
Time in ps: 31  
Frame: 200 
Time in ps: 125 
Frame: 1463 
Time in ps: 900 
UA 
 
2
H1 
2
H1 
2
H1 
GlcNS 
 
4
C1 
4
C1 
4
C1 
IdoUA 
 
4
C1 
4
C1 
4
C1 
GlcNS  
4
C1 
4
C1 
4
C1 
IdoUA(2S) 
1
C4 
1
C4
 2
S0
 
GlcNS(6S) 
4
C1 
4
C1 
4
C1 
IdoUA(2S)  
1
C4 
1
C4
 2
S0
 
GlcNS  
4
C1 
4
C1 
4
C1 
IdoUA 
 
1
C4 
2
S0
 4
C1
 
GlcNAc (6S) 
4
C1 
4
C1 
4
C1 
 
 
Table 3.13 Conformations of all the ring structures for dp10(7) in the frames chosen for 
docking using Vina. 
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Table 3.14 
Frame used Mode Affinity 
(kcal/mol) 
1 -10.9 
2 -10.7 
3 -10.2 
4 -10.0 
5 -9.9 
6 -9.8 
7 -9.8 
8 -9.7 
9 -9.7 
10 -9.6 
11 -9.6 
12 -9.6 
13 -9.4 
14 -9.3 
15 -9.0 
16 -9.0 
17 -9.0 
18 -8.9 
19 -8.9 
250 
20 -8.6 
Table 3.14 Energy values for each Vina predicted model for dp10(7), frame 250 
Model number 15 has been highlighted as the best highest affinity binding model for the 1 ns MD 
simulation. This was based on the predicted position of the sulphate groups in relation to the 
X-ray crystal structure. 
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 3.4.4 The 10 ns Docking simulations 
10 ns molecular dynamic simulations were undertaken and so docking analysis was also carried 
on specific frames within these sequences. In each of these sequences one frame equals 1 ps in 
time; therefore 10,000 ps (10 ns) equal 10,000 frames. For the longer docking analysis the 1BFC 
protein was again used as it was in the 1000 ps docking analysis but is shown in a different 
colour (purple). This was used to signify the different timescales in the docking calculations.  
 
3.4.4.1 Oligosaccharide dp10(1) 
The four chosen frames for the rigid docking analysis in dp10(1) were frame numbers 200, 1300, 
3000 and 8300 (corresponding to 200 ps, 1.3 ns, 3.0 ns and 8.3 ns, Table 3.15). Again these 
were based on iduronic acid ring structures and also torsion angle data. Vina produced 11 
potential docking structures for frame 200 with models 1, 2, 5 and 7 occupying just one binding 
position. Models 1 and 2 have only the 2S group of residue 7, the IdoUA(2S) in the binding 
position. Model 5 has residue 8 the GlcNS(6S), near to the binding site and finally model 7 is 
identified with the sulphate in binding position X.  
 
 
There were 19 structures created from frame 1300 and of these it was only model 11 which had 
any similarity to the x-ray crystal structure. For frame 3000 Vina successfully predicted 20 
structures and of those; model 1 was identified as the best fitting, lowest energy structure. This 
however had only the one sulphate group of residue 6 (the NS part of the GlcNS(6S)) in the 
correct binding position. The other models identified in Vina do not have sulphate groups in the 
specific binding site. There were groups identified in and around the vicinity of the binding site, 
such as model 7; which had the NS part of the GlcNS(6S) of residue 6 approximately nearby; 
model 20 which had the 2S group of the IdoUA at position 5 near to binding site Y.  
Then finally frame 8300, Vina successfully predicted 13 structures. The lowest energy structure 
identified was model 2, which had only residue 8 (the GlcNS(6S))  in proximity to the binding site. 
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Models 4, 9, 10 and 11 showed a similar interaction (data not shown). The final model, model 12 
was the only frame which when analysed had two residues interacting in the binding site. These 
interactions were from residues 5 and 4; the 2S and NS groups respectively. Here model 12 for 
frame 8300 was thought to be the best fit model according to the x-ray crystal structure (Table 
3.16). Here there is no presence of the 
1
C4 conformation, with residues 5 and 7 in the skew boat 
conformation and the terminal residue iduronate in the 
4
C1 conformation (Figure 3.40).  
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Figure 3.40 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.40 The highest affinity binding structure as predicted by Vina for dp10(1) frame 
8300, with the best fit for the x-ray crystal structure for the rigid 10 ns MD simulation. 
 
The protein molecule in purple shows the FGF2 protein in the x-ray crystal structure, alongside 
the heparin fragment from the x-ray crystal structure. This is the same structure used in the 
shorter simulations, but for the purpose of the longer MD simulations is shown in a different 
colour. The lighter coloured decasaccharide is the Goodger model. It has a binding affinity of -9.2 
kcal/mol and the rmsd are as follows; rmsd l.b of 9.778 and rmsd u.b of 16.151.  
 
Panel A. Frame 8300, model 12. 
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Table 3.15  
 
Residue Frame: 200 
Time in ns: 0.2 
Frame: 1300 
Time in ns: 1.3 
Frame: 3000 
Time in ns: 3 
Frame: 8300 
Time in ns: 8.3 
IdoUA(2S) 
Residue 5 
1
C4 
2
S0 
2
S0 
2
S0 
IdoUA(2S) 
Residue 7 
1
C4 
2
S0 
1
C4 
2
S0 
IdoUA 
Residue 9 
1
C4 
1
C4 
4
C1 
4
C1 
  
Table 3.15 Conformations of the iduronic acid ring structures for dp10( 1) for the 10 ns MD 
simulation. 
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Table 3.16 
 
Frame used Mode Affinity 
(kcal/mol) 
1 -11.9 
2 -10.5 
3 -10.4 
4 -10.1 
5 -9.9 
6 -9.8 
7 -9.8 
8 -9.7 
9 -9.5 
10 -9.4 
11 -9.3 
12 -9.2 
8300 
13 -9.1 
 
Table 3.16 Energy values for each Vina predicted model for dp10(1), frame 8300 
 
Model number 12 has been highlighted as the best highest affinity binding model for the 10 ns 
MD simulation. This was based on the predicted position of the sulphate groups in relation to the 
X-ray crystal structure. 
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3.4.4.2 Oligosaccharide dp10(3): 
Those frames identified for dp10(3) were frame numbers 300, 430, 550, 2900 and finally 6000 
(corresponding to 300 ps, 430 ps, 550 ps, 2.9 ns and finally 6.0 ns). None of the predicted Vina 
models placed the Goodger structures in the binding site identified in the x-ray crystal structure. 
This could potentially be due to the lack of all three conformations which had been previously 
identified in the active oligosaccharides in the shorter simulations (Table 3.17).   
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Table 3.17 
  
Residue Frame: 300 
Time in ns: 
0.3 
Frame: 430 
Time in ns: 
0.43 
Frame: 550 
Time in 
ns:0.55 
Frame: 2900 
Time in ns: 
2.9 
Frame: 6000 
Time in ns: 
6.0 
IdoUA(2S) 
Residue 5 
2
S0 
2
S0 
2
S0 
1
C4 
2
S0 
IdoUA 
Residue 7 
1
C4 
1
C4 
2
S0 
4
C1 
4
C1 
IdoUA 
Residue 9 
1
C4 
2
S0 
4
C1 
4
C1 
4
C1 
 
Table 3.17 Conformations of the iduronic acid ring structure for dp10(3) for the 10 ns MD 
simulation. 
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3.4.4.3 Oligosaccharide dp10(5): 
 
Four frames were identified in dp10(5) corresponding to changes in the Cremer-Pople puckering 
parameters. The chosen frames were frame 500, 1050, 4000 and 6000 (corresponding to 0.5 ns, 
1.05 ns, 4.0 ns and 6.0 ns).  
 
Frame 500 had one identified best fit model out of the 13 Vina predicted models. This was in fact 
model 13, the model with the lowest affinity binding value according to Vina. Here the NS group 
of residue 6, the GlcNS(6S) was identified in binding position X (shown in appendix). The flanking 
iduronic acid of residue 7, which is in the 
2
S0 conformation, is in close proximity to the binding 
site. Vina successfully predicted 12 models for frame 1050, of which model 6 was identified as 
the best fit model. Here residue 5, which is in the 
1
C4 conformation is in close proximity to binding 
site X and the neighbouring residue, the glucosamine in close proximity to binding site Y. During 
this frame all three conformations are present in each of the iduronates (Table 3.19), with the first 
IdoUA(2S) at position 5 interacting in that identified binding site.    
 
There are no Vina predicted models which fit the x-ray binding site for frame 4000 (4.0 ns). This 
could be due to the overall change in shape of the molecule as the iduronic acid at position 5 
undergoes its first conformational change to the skew boat conformation. Finally frame 6000 
produced 20 Vina predicted models, of which model number 5 was identified as the best fit 
model. Here the NS group of residue 6, the GlcNS(6S) was identified in binding position X (Figure 
3.41). The flanking iduronic acid of residue 7, which is in the 
2
S0 conformation, is near to the 
binding site but not in it (the IdoUA(2S) is identified in the 
4
C1 conformation around the second 
binding position). This is also the best fit structure in terms of the positioning of the HS chain 
across the protein. The non-reducing terminal is found towards the left of the protein matching the 
x-ray crystal structure. It then spans the whole of the protein again like that found in the crystal 
structure. The binding affinity for this model is 9.5 kcal/mol, which is less then those identified in 
the shorter 1000 ps MD simulation. There was no change in conformation between frame 4000 
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and 6000 with just the change in dihedral angle taken into account. This slight change has 
allowed the Vina predicted model for frame 6000 to produce a model which fits the binding site 
better then those predicted for frame 4000. The model for frame 6000 is the best fit model of all 
the models predicted by Vina for the whole of the 10 ns MD simulation (Table 3.18).  
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Table 3.18 
Frame used Mode Affinity 
(kcal/mol) 
1 -11.0 
2 -10.9 
3 -10.4 
4 -10.2 
5 -10.1 
6 -10.1 
7 -10.0 
8 -9.9 
9 -9.9 
10 -9.8 
11 -9.4 
12 -9.1 
13 -9.0 
14 -8.9 
15 -8.8 
16 -8.6 
17 -8.6 
18 -8.6 
19 -8.6 
6000 
20 -8.5 
 
Table 3.18 Energy values for each Vina predicted model for dp10(5), frame 6000 
Model number 15 has been highlighted as the best highest affinity binding model for the 10 ns 
MD simulation. This was based on the predicted position of the sulphate groups in relation to the 
X-ray crystal structure. 
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Figure 3.41 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.41 The highest affinity binding structure as predicted by Vina for dp10(5) frame 
6000, with the best fit for the x-ray crystal structure for the rigid 10 ns MD simulation. 
 
The protein molecule in purple shows the FGF2 protein in the x-ray crystal structure, alongside 
the heparin fragment from the x-ray crystal structure. The lighter coloured decasaccharide is the 
Goodger model. It has a binding affinity of -10.1 kcal/mol and the rmsd are as follows; rmsd l.b of 
7.375 and rmsd u.b of 22.001.  
 
Panel A. Frame 6000, model 5. 
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Table 3.19 
 
Residue Frame: 500 
Time in ns: 0.5 
Frame: 1050 
Time in ns: 1.05 
Frame: 4000 
Time in ns: 4.0 
Frame: 6000 
Time in ns: 6.0 
IdoUA(2S) 
Residue 5 
1
C4 
1
C4 
2
S0 
2
S0 
IdoUA(2S) 
Residue 7 
1
C4 
2
S0 
2
S0 
2
S0 
IdoUA 
Residue 9 
2
S0 
4
C1 
4
C1 
4
C1 
 
Table 3.19 Conformations of the iduronic acid ring structures for dp10(5) for the 10 ns MD 
simulation. 
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3.4.4.4 Oligosaccharide dp10(7): 
Three frames were chosen for the final decasaccharide used in the docking analysis. These were 
frames 250, 750 and 5000 (corresponding to 0.25 ns, 0.75 ns and 5.0 ns). This decasaccharide 
contains four iduronic acid ring structures in the chain making it potentially the most flexible 
sequence of all the structures. The first iduronate in this sequence is found at position 3 and does 
not change conformation throughout the whole 10 ns timescale (Table 3.20). This reflects the 
result identified in the shorter 1000 ps timescale shown previously (see p182).   
 
For frame 250, Vina successfully predicted 20 models of which model 14 had been identified as 
the best fit model (the only predicted structure to fit into the known binding structure). Here the 
sulphate group around the binding position is the 2S group of the IdoUA(2S) of residue 5 (Figure 
3.42). This is positioned in the first of the two sulphate positions (binding site X). It has a binding 
affinity of -9.7 kcal/mol; (Table 3.21). For frame 750 there was only one identifiable frame in the 
binding site and this was model number 1; the lowest energy binding structure. Here only the NS 
group of residue 8 (the GlcNS) was identified near to the binding site, however once the model is 
rotated it becomes clear that the NS group is further away then first identified. The final frame 
(frame 5000) gave a number of predicted models close to that of the x-ray crystal structure with 
model number 2 showing only the NS of residue 6 (the GlcNS(6S)) in position Y. Model 8 shows 
the binding site complete with the 2S group of the IdoUA(2S) at residue 7 in binding position X 
and the NS group of GlcNS (residue 8) in binding position Y. Vina predicted models 10 and 12 
show a similar result to model 8. Other models identify one sulphate group in the binding site, 
such as the NS of residue 4 in position X for model 12. Model 20, with the highest affinity binding 
site also mirrors the results identified in models 8, 10 and 12. This shows that it does not have to 
be the lowest affinity binding model which Vina predicts to bind in the correct binding position and 
therefore those with a higher affinity binding value should not be so easily dismissed.  
Chapter 3: Results 
 282 
Figure 3.42 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 3.42 The highest affinity binding structure as predicted by Vina for dp10(7) frame 
250, with the best fit for the x-ray crystal structure for the rigid 10 ns MD simulation. 
 
The protein molecule in purple shows the FGF2 protein in the x-ray crystal structure, alongside 
the heparin fragment from the x-ray crystal structure.  The lighter coloured decasaccharide is the 
Goodger model. It has a binding affinity of -9.7 kcal/mol and the rmsd are as follows; rmsd l.b of 
8.335 and rmsd u.b of 24.010.  
 
Panel A. Frame 250, model 14.  
 
 
A. 
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Table 3.20 
Residue Frame: 250 
Time in ns: 0.25 
Frame: 750 
Time in ns: 0.75 
Frame: 5000 
Time in ns: 5.0 
IdoUA 
Residue 3 
4
C1 
4
C1 
4
C1 
IdoUA(2S) 
Residue 5 
1
C4 
1
C4 
2
S0 
IdoUA(2S) 
Residue 7 
1
C4 
1
C4 
2
S0 
IdoUA 
Residue 9 
1
C4 
2
S0 
4
C1 
 
 
 
Table 3.20 Conformations of the Iduronic acid ring structures for dp10(7) for the 10 ns MD 
simulation. 
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Table 3.21 
Frame used Mode Affinity 
(kcal/mol) 
1 -11.4 
2 -11.0 
3 -11.0 
4 -10.5 
5 -10.4 
6 -10.4 
7 -10.4 
8 -10.3 
9 -10.3 
10 -10.2 
11 -10.0 
12 -10.0 
13 -9.9 
14 -9.7 
15 -9.6 
16 -9.6 
17 -9.6 
18 -9.5 
19 -9.4 
250 
20 -9.4 
 
Table 3.21 Energy values for each Vina predicted model for dp10(7), frame 250 
Model number 14 has been highlighted as the best highest affinity binding model for the 10 ns 
MD simulation. This was based on the predicted position of the sulphate groups in relation to the 
X-ray crystal structure. 
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3.4.5 Flexible Dockings 
The chosen frames which were analysed for rigid docking calculations were again analysed with 
all dihedral angles left rotatable (all other bonds were set as rigid). This was to allow the torsion 
angles to fall into their own preferred angle and to allow Vina to dock them in that sense. Each 
frame took an average of 48 hours to run; compared to just 12 hours for the shorter docking 
simulations. Again the same process was followed, with the number of modes sent to the output 
file kept at 40.  
 
3.4.5.1 The 1 ns Flexible Docking Analysis 
 Vina successfully predicted 20 potential binding structures for the first of the flexible docking 
studies (frame 45) for dp10(1). The best fit binding model was identified as model 1 which was 
identified with residue 8 (the glucosamine) in binding site Y of the x-ray structure. Due to the 
nature of the bending in the chain there is also the sulphate group from residue 5 (the IdoUA(2S)) 
identified in binding site X. However when this is rotated it is actually much further away from the 
binding site then first thought (Figure 3.43, Panel A). Models 2, 6, 7 and 10 show similar results 
and model 14 is identified with the 2S group of the IdoUA(2S) of residue 7 in binding site X of the 
crystal structure (data not shown). Model 1 has the highest affinity of -4.6 kcal/mol (Table 3.22) 
which; compared to values obtained previously is considered to be a relatively low value for the 
binding affinity.  
Frame 350 produced 20 Vina predicted models of which only model 17 had any interaction with 
the binding site. This was only from reducing end GlcNAc(6S) residue of which it was the NS 
group identified near to binding site Y. The same again was identified for frame 975, with only one 
model interacting with the binding site. This was model 18 and again it showed the reducing end 
GlcNAc(6S) near to the binding site (data not shown).  
The final frame; frame 1463 corresponds to 900 ps in time and Vina successfully predicted 20 
models. Of these it was identified that model 1 was the best fit model against the x-ray crystal 
structure. Again it was the GlcNAc(6S) near the binding position identified in the x-ray crystal 
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structure. Due to the positioning of the chain along the FGF2 protein and also the interaction of 
the non-reducing terminal with the binding site, these models can be dismissed as likely docking 
structures. 
  
Dp10(3) as dp10(1) before it did not produce any best fit models which could be deemed as 
important when referring to the binding site. Model 6 was identified as the best fit for frame 25 
with model 18 identified for both frames 200 and 1056. All had binding affinity values of 
-7.8 kcal/mol and -7.7 kcal/mol respectfully; which were considered quite low compared to the 
binding affinities identified in their corresponding rigid structures.  For frame 200 it was residue 8 
(the glucosamine) which was identified in the centre of the binding structure, but was not found in 
either site X or Y. Residue 6; also the glucosamine residue for frame 1056 was found in the same 
position as that in frame 200. The final frame, 1300 gave model 1 as the best fit model and again 
this had a low binding affinity of -8.4 kcal/mol. It was the NS group of residue 6 (GlcNS(6S)) 
which was identified close to the binding site (data shown in appendix).  
 
Only one frame produced any docking data which somewhat matched the x-ray crystal structure 
for dp10(5) which was frame 1381. This was a model which Vina had predicted as the last model 
out of 20 to fit into the binding site due to the binding affinity being the lowest out of all the 20 
predicted structures (-7.4 kcal/mol; Table 3.22). Interesting this was the only identified structure 
which involved the 2S group of the IdoUA(2S) of residue 5 interacting in the binding site (Figure 
3.43, Panel B). Although this group is identified in the binding region of the protein it was not 
identified specifically in either binding site X or Y. Again this structure was dismissed on grounds 
that it did not fully comply with the x-ray crystal structure.   
 
The final decasaccharide used in the 1000 ps docking analysis was dp10(7). Here like in dp10(5), 
it was residue 5 which was identified in the FGF binding site in frame 50.  Here it was model 11 
which showed the 2S group in the binding position; however once the structure was rotated this 
group is actually nowhere near to the binding site (Figure 3.43, Panel C shown in appendix). This 
structure had a binding affinity of -9.3 kcal/mol. 
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Table 3.22 
Frame used Mode Affinity 
(kcal/mol) 
Frame used Mode Affinity 
(kcal/mol) 
1 -4.6 1 -8.3 
2 4.6 2 -8.2 
3 -4.5 3 -8.0 
4 -4.4 4 -8.0 
5 -4.4 5 -8.0 
6 -4.3 6 -7.9 
7 4.2 7 -7.8 
8 -4.1 8 -7.8 
9 -4.1 9 -7.8 
10 -4.1 10 -7.7 
11 -4.1 11 -7.7 
12 -4.1 12 -7.7 
13 -4.1 13 -7.7 
14 -4.0 14 -7.7 
15 -4.0 15 -7.6 
16 -4.0 16 -7.6 
17 -3.9 17 -7.6 
18 -3.9 18 -7.5 
19 -3.9 19 -7.4 
45 
20 -3.8 
1381 
20 -7.4 
Table 3.22 Energy values for each Vina predicted model for the flexible dockings for 
dp10(1), frame 45 and frame 1381 for dp10(5), from the 1 ns MD simulation. 
Models 1 and 20 have been highlighted as the best, high affinity binding models for the 1 ns MD 
simulation. This was based on the predicted position of the sulphate groups in relation to the 
X-ray crystal structure. 
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 Figure 3.43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.43 The highest affinity binding structure as predicted by Vina for dp10(1) frame 45 
and dp10(5) frame 1381, with the best fit for the x-ray crystal structure for the flexible 1  ns 
MD simulation. 
 
The protein molecule in blue shows the FGF2 protein in the x-ray crystal structure, alongside the 
heparin fragment. The lighter coloured decasaccharide is the Goodger oligosaccharides. Frame 
45 has a binding affinity of -4.6 kcal/mol and the rmsd are as follows; rmsd l.b of 0.000 and rmsd 
u.b of 0.000. Frame 1381 has a binding affinity of -7.4 kcal/mol and the rmsd are as follows; rmsd 
l.b of 5.860 and rmsd u.b of 14.899.  
 
Panel A. dp10(1). Frame 45, model 1. 
Panel B. dp10(5). Frame 1381, model 20.  
 
 
 
 
A. 
B.  
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3.4.5.2 The 10 ns Flexible Docking Analysis 
 
The longer simulations did not produce any reliable docking results when compared to the 1BFC 
x-ray crystal structure. As in the 1000 ps docking simulations above, all the dihedral angles were 
left rotatable with all the other bonds kept rigid. Frame 200 from dp10(1) produced the only Vina 
predicted structure which in any way resembled the known binding site. This again was identified 
by the sulphate groups highlighted (from the x-ray crystal structure): 
    
IdoUA(2S) – GlcNS(6S) 
               Residue 4     Residue 5 
 
This sequence is the same as that identified in dp10(1), with the 2S group of the IdoUA(2S) of 
residue 5 in binding site X and the NS group of GlcNS(6S) of residue 6  in binding site Y (Figure 
3.44). The best fit model here was model 12 out of the 20 models produced by Vina and had a 
binding affinity of -8.6 kcal/mol; (Table 3.23). Model 8 was also identified as another low energy 
binding model; however this had only residue 8 identified near to the binding site.  
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Figure 3.44 
  
 
 
 
 
 
 
 
 
 
 
Figure 3.44 The highest affinity binding structure as predicted by Vina for dp10(1) frame 
200,  with the best fit for the x-ray crystal structure for the flexible 10 ns MD simulation. 
 
The protein molecule in purple shows the FGF2 protein in the x-ray crystal structure, alongside 
the heparin fragment from the x-ray structure. The lighter coloured decasaccharide is the 
Goodger oligosaccharide. It has a binding affinity of -8.6 kcal/mol and the rmsd are as follows; 
rmsd l.b of 8.797 and rmsd u.b of 16.421.  
 
Panel A. Frame 200, model 12. 
 
 
 
A. 
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Table 3.23 
Frame used Mode Affinity 
(kcal/mol) 
1 -9.4 
2 -9.3 
3 -9.0 
4 -9.0 
5 -8.9 
6 -8.9 
7 -8.8 
8 -8.7 
9 -8.6 
10 -8.6 
11 -8.6 
12 -8.6 
13 -8.6 
14 -8.5 
15 -8.5 
16 -8.4 
17 -8.4 
18 -8.4 
19 -8.2 
250 
20 -8.2 
Table 3.23 Energy values for each Vina predicted model for the flexible dockings for 
dp10(1), frame 200 in the 10 ns MD simulation. 
Model number 1 has been highlighted as the best highest affinity binding model for the 10 ns MD 
simulation. This was based on the predicted position of the sulphate groups in relation to the 
X-ray crystal structure. 
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3.4.6 Docking Implications 
For the amount of work carried out in this study on HS:FGF2 docking interactions it is very difficult 
to determine the differences between active and inactive oligosaccharides. It can be said that 
oligosaccharide dp10(1) gave the best docking results in terms of binding affinity and also the 
amount of Vina predicted models created throughout the docking section of this study. The 
highest affinity binding identified was in the 1 ns docking for dp10(1) with all bonds set rigid.  It 
was frame 1 out of the 11 Vina predicted models and had a binding affinity of -13.0 kcal/mol. This 
was by far the best binding affinity for all the active and inactive oligosaccharides. This model had 
GlcNS(6S)-IdoUA(2S) of residues 6 and 7 in the known binding site. All of the iduronates in this 
frame were interestingly in the 
1
C4 conformation. Oligosaccharide dp10(1) also produced good 
Vina predicted models for the 1 ns flexible docking and for both flexible and rigid dockings in the 
10 ns docking analysis. For the flexible 1 ns docking, it was also model 1 which was deemed as 
the best fit model with a binding affinity of -4.6 kcal/mol. This value is much lower then those 
identified in the rigid dockings and could be due to the placement of the HS fragment in the 
docking position. In fact in all the flexible dockings the HS chain was wrapped around the protein 
and/or itself and so this suggests an inability for Vina to predict the correct binding, using the 
default settings, which were set at the start of the process. This lead to the assumption that the 
majority of the flexible dockings can be completely dismissed as they are just not an accurate 
reflection of the binding seen in many of the x-ray crystal structures (Digabriele et al., 1998; 
Faham et al., 1996; Pellegrini et al., 2000; Schlessinger et al., 2000). However; with some 
refinement of the settings, such as a widening of the search area on the protein which was set by 
the size X, Y, and Z coordinates. Also the centre of the box could be checked and altered if 
needed (see p124). Another area that could be altered is the ‘exhaustiveness’, which can be 
changed manually at the start of the Vina docking process. This was set to 8, which was the 
default setting but can be increased. This can add considerably large amounts of computing time 
onto each individual docking process, so for the purpose of this study was kept as the default 
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setting. However, based on the flexible docking results this would definitely be an area to monitor, 
changing the setting as necessary.  
The other active oligosaccharide; dp10(3) produced the second highest affinity binding value of 
the best fit models. This was from again from 1 ns MD simulation with the rigid dockings. Here is 
was frame 1300, model 3 of 12 which had a binding affinity of -10.8 kcal/mol. Interestingly; the 
iduronate conformations present in this frame were 
4
C1, 
1
C4 and 
4
C1 respectfully. For both the 
active models, in the frames chosen as being the best fit models neither contained the skew boat 
conformation, which the puckering-torsion data indicated as being essential for FGF2 binding.  
The inactive oligosaccharides; overall gave lower binding affinities for the rigid structures 
according to the Vina predicted models. This was even the case when looking at the model Vina 
predicted as having the highest binding affinity. This could have great implications for binding, 
between active and inactive sequences.  
If these results could be refined and if time was not such a factor then the docking analysis could 
have provided some invaluable data. Carbohydrate-protein docking interactions are at the 
forefront of modelling simulations, particularly between HS-FGF interactions. It will be MD 
simulations, alongside docking simulations which will ultimately allow for carbohydrate-protein 
interactions to go one step closer, to aid in specific drug design for HS-FGF interaction. With 
more time and the ability to change some of the default settings, it will be possible to determine 
the differences between the active and inactive HS oligosaccharides presented in this report.  
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4.1 The Digestion of HS by Heparinase III 
Many studies use the enzyme heparinase III to degrade polymeric HS into the shorter 
oligosaccharide chain lengths. The quantity of enzyme required is not usually addressed, but is 
important when determining how much is needed to fully digest the HS sample.  
Cleavage of HS occurs through a β-elimination, which generates the un-natural ∆4, 5 unsaturated 
uronic acid at the non-reducing end of the oligosaccharide. It absorbs U.V. light at a wavelength 
of 232 nm, making it ideal for following the progression of the heparinase digestion. Long 
incubation times and large amounts of buffer lead to difficulties in the spectrometer readings so 
the minimum amount of both is essential.  
The minimum amount of enzyme required for the digestion to be classed as fully completed was 
found to be 140 mU to digest 500 mg of HS.    
 
4.2 Gel Filtration and SAX-HPLC Chromatography of HS 
Octasaccharides 
Each SAX-HPLC profile from the octasaccharides showed variations in the digested sample. This 
could have been due to the slight overloading of the gel filtration column, leading to overlapping 
of the different sized oligosaccharides. This would have lead to possible overlapping of peaks and 
the presence of contaminants in the sample. Any slight overlap in the sample leads to a increase 
in sample heterogeneity in terms of size and length; making purification of homogenous size and 
charge defined oligosaccharides more difficult. The extent of the enzyme digestion should be 
closely monitored so that all samples are digested completely. Partial digests can lead to a more 
complex SAX-HPLC profile.  
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4.3 Analysis of HS dp8 NMR Profiles 
The aim of the study was the purification of homogenous size and charged defined dp8 
oligosaccharides; with an aim to assign and determine the structure of these samples using NMR 
structural refinement. Unfortunately due to lack of sample in all those purified this task proved to 
be too difficult. At each stage of the purification process, material was lost making the purification 
process more difficult with every step taken. The amounts actually produced by enzyme 
degradation for these larger oligosaccharides is relatively small in comparison to the smaller 
fragments previously purified (Murphy 2007). With each oligosaccharide size increase, the 
complexity of the possible HS sequences available becomes more complex. This makes the 
number of each possible sequence available increase on quite a large scale. Current estimates 
for dp8 sized oligosaccharides are that there could potentially be more then 5 billion different 
combinations and therefore purifying these would be impossible. This massive increase in 
sequence diversity is due to the nature of the modification process, which is non-random and very 
highly regulated (Wei et al., 1993). The larger the oligosaccharide fragments are that are purified; 
the less there is produced by the enzyme digestion, so this also makes purifying larger quantities 
needed for characterization much more difficult. These issues combined have made it extremely 
difficult to produce enough samples, purified to the level required for NMR analysis. For a 
reasonable NMR profile, 200 mg of purified sample is required with an average of 150 mg 
produced for the HS dp8 oligosaccharides. This was collected over a two and a half year period 
and gives some indication of the amount of time and energy required to produce these amounts 
needed (Figure 3.4).  
 
4.4 The Requirement for Binding 
Much of the work carried out in literature has been focused on the requirements for binding 
between HS/heparin chains and proteins, with most studies being on the minimum length 
required to form an active signalling complex (specifically for many of the FGF family, IL-8, AT III 
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and EGF). In actual fact this signalling complex is far more complicated then first thought, as 
activity is not only due to the length of chain. Many factors need to be taken into account; 
including sulphation pattern, sulphate content and placement within the chain, iduronate 
conformation and torsional geometry.  
In reality, HS/heparin chains are not rigid and static in shape. In actual fact they sample many 
different configurations and 3-dimensional shapes over a very small timeframe; constantly 
oscillating between conformations and torsional geometries, enabling them to sample different 
conformations until they identify the required one needed for binding (Harmer 2006). It is clear 
from this study and from many other studies (DiGabriele et al., 1998; Faham et al., 1996; 
Maccarana et al., 1993)  to see that affinity is not dependant on one thing alone (specifically the 
size of the chain). Instead it takes into account many different requirements including chain 
length, sulphation pattern and density, the GAG backbone and the internal residue conformation 
(Guglieri et al., 2008).  
 
4.4.1 The Minimum Length Required for Binding 
The suggested minimum chain length required for binding and activating specific proteins will be 
different for each. A minimum HS chain length for binding FGF2 has been identified as a dp4 
sized oligosaccharide (Guglieri et al., 2008), where as other studies have shown larger  HS sizes 
are required, such as a decasaccharide oligosaccharide (Goodger et al., 2008). The minimum 
tetrasaccharide identified has a sequence of: 
 
GlcNS + 6S/OH – IdoUA(2S) – GlcNS + 6S/OH – IdoUA 
(Guglieri et al., 2008).  
 
An oligosaccharide longer then dp4 would then allow for further contacts to be made to the 
protein ligand via the NS-domains but this contact would likely occur outside of the core binding 
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site (Deakin et al., 2009). Genuine FGF:FGFR interactions are much more likely to involve longer 
saccharide chains as those at the physiological level are 100-300 saccharide units long (Harmer 
et al., 2006); much longer then those studied at any level to date. 
A number of HS oligosaccharides have been identified with the ability to display high affinity 
binding to hepatocyte growth factor/scatter factor (HGF/SF) which is secreted by mesenchymal 
cells to regulate cell growth, motility and morphogenesis. The minimum sizes identified in this 
study were trisaccharides with differing affinities; and a tetrasaccharides with high affinity binding 
(Figure 4.1). Here the final trisaccharide (number 4) is prepared from tetrasaccharide (number 3), 
and is generated by mercuric ion-catalyzed removal of the unsaturated hexuronate from the non-
reducing end). A higher ratio of HS to HGF/SF is needed to illicit the same binding affinity as that 
identified in the tetrasaccharide. 
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Figure 4.1 
1. GlcNS(6S) – IdoUA(2S) – GlcNS(6S) 
2. GlcNAc(6S) – IdoUA – GlcNAc(4S) 
3. ∆Hex – GlcNS(6S) – IdoUA(2S) – GlcNS 
4. GlcNS(6S) – IdoUA(2S) – GlcNS  
 
Figure 4.1 The minimum identified HS oligosaccharides which have been identified to bind 
to FGF2. 
 
These sequences have been taken from (Deakin et al., 2009) and contain three identified 
trisaccharides and one tetrasaccharide which bind to HGF/SF.  
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Wu et al (Wu et al., 2003) identified a dp6 oligosaccharide which was involved in full binding and 
activation with two FGF1 proteins (see p86). The published x-ray crystal structures of three 
heparin decasaccharides have identified dp10 sized oligosaccharide as the minimum for binding 
FGF1 and FGF2 respectfully (Figure 4.2); (Digabriele et al., 1998; Pellegrini et al., 2000; 
Schlessinger et al., 2000).  
 
It must be taken into account that some studies describe the requirements for binding only the 
FGF molecule. Other studies describe the length of chain required for activation of the complex 
(with both the FGF and FGFR).  
The most well-known of these complexes are the Symmetrical Complex and the Asymmetrical 
Complex which look at the complex formation between FGF with both HSPG and FGFR’s, 
leading to receptor dimerization (see Introduction, p74); (Pellegrini, et al., 2000; Schlessinger et 
al., 2000). Here in both studies the minimum sized heparin chain was a dp10 sized 
oligosaccharide chain.  
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Figure 4.2 
 
A. IdoUA(2S) – GlcNS(6S) – IdoUA(2S) – GlcNS(6S) – IdoUA(2S) – GlcNS(6S) – IdoUA(2S) – GlcNS(6S) – 
IdoUA(2S) – GlcNS(6S) 
 
 
B . ∆UA(2S) – GlcNS(6S) – IdoUA – GlcNS(6S) – IdoUA – GlcNS(6S) – IdoUA(2S) – GlcNS(6S) – IdoUA(2S) – 
GlcNS(6S) 
 
Figure 4.2 Two HS oligosaccharides which have been identified to interact with FGF1 and 
FGF2 respectfully.  
 
Panel A. Taken from the PDB (file 1E0O) and is known as the Asymmetrical Complex (Digabriele 
et al., 1998; Pellegrini et al., 2000). 
Panel B. Taken from the PDB (file 1FQ9) and is known as the Symmetrical Complex 
(Schlessinger et al., 2000). 
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Although it has been widely accepted that the smaller sized HS chains can bind to FGF2 (Guglieri 
et al., 2008), much larger chains are thought to be required for the activation of the protein-ligand 
complex (Digabriele et al., 1998; Goodger et al., 2008; Pellegrini et al., 2000; Schlessinger et al., 
2000). Stability of the HS chain is due to both the amount and positioning of the sulphate groups 
as well as from the carboxyl groups (Bitomsky and Wade, 1999; Hricovíni and Bízik, 2007) with 
the surrounding solvent/solution having an influence on the configuration of internal residues, due 
to the change in pH of the solution (Sanderson et al., 1987).   
 
4.4.2 The Effect of Temperature and Cations on the HS Chain  
Temperature (Sanderson et al. 1987) and the presence of certain cations have also been shown 
to have an effect on the solution conformational dynamics of internal residues,; specifically within 
DS (Sanderson et al. 1987); heparan sulphate (Coombe and Kett, 2005); and also heparin (Rudd 
et al., 2007). The addition of certain cations has an influence on the overall ring conformation of 
the iduronates, with the presence of Zn2+ ions showing a preference for the 1C4 conformation due 
to the nature of the monovalent cations having an effect on the radii and coordination geometry 
with non-charged parts of the molecule. Sulphate groups have the ability to neutralise one of the 
charges of a divalent cation; which has an effect on orientation and conformation of neighbouring 
residues and intervening glycosidic linkages (Rudd et al., 2007).  
 
4.5 The Implications for Iduronate Conformation and Sulphation 
Patterns within HS chains 
This study identifies the conformational equilibrium of the iduronate residues in the FGF2 
activatory and inhibitory decasaccharides sequenced by Goodger (Goodger 2003) as one of the 
major influences in biological activity. Initial findings suggest the iduronates would be identified in 
predominately different conformations. Additional modifications; in the form of sulphate groups 
around the iduronates (in the neighbouring glucosamine residues) has been shown to have an 
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effect on these conformations. The presence of 6-O-sulphate on flanking glucosamines around 
the iduronates, have some influence on iduronate conformation in this study (see Linkage 5- 8, 
p170 onwards). This area of research will play a major role in biological activity in the Goodger 
oligosaccharides and may well show the differences between the active and inactive 
oligosaccharides.  
 
The positioning of 6-O-sulphate groups has been suggested as a requirement for promoting 
FGF1 and FGF2 mitogenic activity (Pye et al., 2000; Kreuger et al., 2001; Wu et al., 2003). This 
modification is almost certainly under tight control and is thought to be highly regulated; 
regardless of whether the sulphate group is located centrally in the chain or positioned at the 
reducing terminal (Merry et al., 1999; Goodger 2003).  In the following sequence conformational 
flexibility is thought to be influenced by the central 6-O-sulphate group:  
 
 
UA-GlcNS-IdoUA(2S)-GlcNS-IdoUA(2S)-GlcNS(6S)-IdoUA(2S)-GlcNS-IdoUA-GlcNAc 
(Merry et al., 1999) 
 
The central residues are similar in sequence to the Goodger oligosaccharides used in this study. 
In linkage 8 for the 1 ns MD simulation the 6-O-sulphate group had only a slight influence on  only 
the torsional geometry between GlcNS(6S)-IdoUA (residues 8 and 9 in dp10(1) and dp10(5)); 
where as it had a larger impact on the torsional geometry for the same decasaccharides in 
linkage 7. As for linking it to purely conformational changes, this is more complex. Indeed there 
are changes in iduronate conformation observed in the Goodger oligosaccharides when 
comparing active and inactive oligosaccharides. However it can not be said if this conformational 
transition is due to the presence or absence of the 6-O-Sulphate groups present in the HS chain.  
 
The iduronate in position 3 in the oligosaccharide mentioned above (Merry et al., 1999) is found 
predominately in the 1C4 conformation (approx 75%). Those at positions 5 and 7 are thought to be 
1      2        3  4 5      6  7 8 9 10 
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more in equilibrium between two conformations; (the 1C4 and 
2S0.). This sulphate positioning will 
have some effect on the conformational equilibria; both proceeding and preceding the iduronate 
residues. This also has an influence on the torsional geometry; which has been observed in this 
study (Figures 3.17 – 3.21). This kind of modification has been shown to have some effect on the 
Goodger oligosaccharides, on both the iduronate conformation and the torsional geometries 
observed.  Initial studies carried out by Goodger (Goodger 2003) and continued by Murphy 
(Murphy 2007); identified the conformations were present in equilibrium and were deduced in the 
ratio 50/50 (50% 1C4, 50% 
2S0). No dominating conformation was determined with no differences 
shown between active and inactive oligosaccharides (Goodger 2003; Murphy 2007). 
 
The Goodger oligosaccharide sequences, as determined by Goodger (Goodger 2003) along with 
the deduced conformations in equilibrium (shown in red; Murphy 2007) are identified in Figure 
4.3. 
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Figure 4.3 
 
Active dp10(1) 
UA - GlcNAc - GlcUA - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - IdoUA - GlcNAc(6S) 
 
 
Active dp10(3) 
UA - GlcNAc - GlcUA - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - IdoUA - GlcNAc(6S) 
 
 
Inactive dp10(5) 
UA - GlcNAc - GlcUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - IdoUA - GlcNAc 
 
 
Inactive dp10(7) 
 
UA - GlcNS - IdoUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS - IdoUA - GlcNAc(6S) 
 
 
Figure 4.3 The conformation of the iduronates before undergoing Cremer-Pople analysis.  
 
These conformations were initially deduced by Murphy (Murphy 2007), from the Goodger 
oligosaccharides (Goodger 2003).  
50:50 50:50 50:50 
50:50 
50:50 50:50 
50:50 50:50 
50:50 50:50 50:50 
50:50 
50:50 
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The first two oligosaccharides were shown to be able to illicit a mitogenic response from a FGF2-
FGFR1 IIIc receptor complex in a Baf cell mitogenesis assay, whereas the second two 
oligosaccharides were unable to produce any response (Goodger 2003). 
 
These oligosaccharides above which were studied for biological activity (Goodger 2003); were 
studied used in both the molecular modelling and docking sections of this study. Here the 
conserved 2-O-sulphate group (found in residue 5 in all active and inactive oligosaccharides) is 
present, suggesting other structural features are also required for biological activity.  
The presence of the 6-O-sulphate group on the reducing end terminal residue could be a 
determining factor in promoting biological activity. This could be because more 6-O-sulphate is 
present in the active oligosaccharides then in the inactive oligosaccharides. Also the positioning 
of this modification in previous reviews (Kreuger et al., 2001; Merry 1999; Wu et al., 2003); 
suggest roles for this modification when it is placed in the centre of the chain. This is identified in 
the Goodger oligosaccharides where all the active models contain this additional sulphate group; 
whereas only two of the inactive groups contain the same modification. This is made even more 
complex; as in reality dp10(1) and dp10(2) contain all sulphated glucosamines with both 6-O and 
N-sulphated groups, whereas dp10(3) and dp10(4) contains 6-O-sulphated glucosamines, at 
position 6 and 10 only.  Also dp10(7) and dp10(8) have only one 6-O-sulphate group less than 
the ‘active’ dp10(1) and dp10(2); on residue 8 there is an absence of the 6S group. Potentially 
this additional sulphate group could increase binding in the active oligosaccharides and could 
knock out the biological activity of what otherwise could be assumed to be an active saccharide.  
 
When the Goodger oligosaccharides are compared to the Schlessinger model (a symmetrical 
complex of a 2:2:2 FGF2:FGFR1:heparin ternary complex) and the Pellegrini model (an 
asymmetrical FGF1:FGFR2:heparin complex); there are many sequence similarities. However, 
the Schlessinger and Pellegrini oligosaccharides are very highly sulphated compared to the 
Goodger oligosaccharides. Therefore this study indicates a fully sulphated sequence is not 
essential for binding activity, as both dp10(1) and dp10(3) are not fully sulphated sequences. This 
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indicates only specific sulphation is required, alongside iduronate flexibility and torsional 
geometry for biological activity. 
 
The modelling study described in this report suggests specific sulphation is required for biological 
activity. The 6-O-sulphate group on the reducing terminal of the active Goodger oligosaccharides 
only a slight influence on torsional geometry, not conformational geometry (data not shown); and 
so has no major influence on biological activity (Figure 3.17).  Torsional differences are also 
observed in linkage 4 for the 1 ns MD simulation, with reference to the presence and/or absence 
of the 6S group in the oligosaccharide.  Here the presence of the 6-O-sulphate group seems to 
influence geometry B for the torsion angles observed in the active dp10(1) and dp10(2); (Figure 
3.22, Panels A and B). The other active oligosaccharides do10(3) and dp10(4) do not contain the 
6S group and are observed in both torsional geometries A and B (Figure 3.22, Panels C and D).  
 
The following studies suggest that the 6-O-sulphate modification is not required in ligand binding. 
Oligo-H a dp14 oligosaccharide which binds to FGF2, was isolated from human skin fibroblast 
HS. It also has high affinity to FGF2 with a sequence of: 
 
GlcUA - GlcNS - IdoUA(2S) - GlcNS - IdoUA(2S) - GlcNS - IdoUA(2S) - GlcNS - IdoUA(2S) - 
GlcNS - IdoUA(2S) - GlcNS - IdoUA - GlcNAc 
(Turnbull et al., 1992) 
 
It is rich in N-sulphation and 2-O-sulphation, but interestingly and quite distinctly has an absence 
of 6-O-sulphate (Turnbull et al., 1992; Gallagher and Turnbull, 1992). Unfortunately there was no 
conformer analysis given with this study, but it is an indication of just how complex biological 
activity is.  
Ishihara et al (Ishihara et al., 1994) also identified octasaccharides and hexasaccharides rich in 
IdoUA(2S) - GlcNS(6S) with a high affinity for FGF2. Their study could not determine the 
requirement for 6-O-sulphate, in particular with the GlcNS residues. Their previous studies 
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indicated an increase in charge on the heparin correlated to an increase in binding for 
immobilised FGF2. Their study concluded that the 6S group was a neutral structure which is 
modified for FGF2 recognition. It is the 2S and carboxyl groups which are required for mitogenic 
activity of FGF2. Here they were unable to tie in activity with 6-O-sulphation, but the results 
shown here show this specific modification has an overall effect on torsional geometry. This in 
turn influences biological activity. 
 
4.5.1 Linkage 7 - Conformations 
The internal environment created by the surrounding glucosamines residues, influences the 
neighbouring iduronate residues. This leads to oscillations in iduronate conformation between the 
three known conformations (1C4, 
2S0 and 
4C1). These changes in environment allow for the 
different equi-energetic conformations to exist (Coombe,  2005) with changes from the chair to 
the skew boat form being slower then the overall molecular re-orientation of the structure (Mulloy 
et et al., 2000). The energy barrier between the three forms present in the iduronates is high with 
a value of 9 Kcal/mol (Ferro et al., 1990). This changing of conformations enables an optimal 
binding fit for ionic bonding and van der Waals contacts, therefore finding the best fit is 
imperative.  
In our data, the transition between the different conformations is clear. It shows the iduronates in 
the Goodger oligosaccharides undergo these changes looking for the optimal binding 
conformation. Some conformational transitions occur fairly rapidly (Figure 3.26, Panel A); 
whereas some changes in conformation occur over a longer timescale (Figure 3.28, Panel D). 
 
The iduronates which make up linkage 7 are found in the following conformation at the end of the 
1 ns MD simulation (Figure 4.4; shown in red and taken from data collected from Figure 3.19):  
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Figure 4.4 
 
Active dp10(1).  
UA - GlcNAc - GlcUA - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - IdoUA - GlcNAc(6S) 
Active dp10(2).  
UA - GlcNAc - GlcUA - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - GlcUA - GlcNAc(6S) 
 
Active dp10(3). 
UA - GlcNAc - GlcUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA - GlcNS - IdoUA - GlcNAc(6S) 
Active dp10(4).  
UA - GlcNAc - GlcUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA - GlcNS - GlcUA - GlcNAc(6S) 
 
Inactive  dp10(5).  
UA - GlcNAc - GlcUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - IdoUA - GlcNAc 
Inactive dp10(6).  
UA - GlcNAc - GlcUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - GlcUA - GlcNAc 
 
Inactive dp10(7).  
UA - GlcNS - IdoUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS - IdoUA - GlcNAc(6S) 
Inactive dp10(8).  
UA - GlcNS - IdoUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS - GlcUA - GlcNAc(6S) 
 
 
Figure 4.4 The conformation of the iduronates at linkage 7 after the MD simulation. 
 
The conformations are specifically highlighted in red with an obvious change observed from the 
starting conformation.  
2S0 
4C1 
2S0 
1C4 
2S0 
2S0 
1C4 
1C4 
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This study suggests that biological activity is not just influenced by iduronate conformation alone. 
If this was the case then the data above would be very confliction. Torsional geometry also has to 
be taken into account and it is this information combined which actually gives more of an 
indication as to why oligosaccharides dp10(1-4) are active and dp10(5-8) are inactive. The 
biggest difference between active and inactive oligosaccharides was observed quite clearly in the 
torsional geometry. The active oligosaccharide dp10(1) was identified in both torsional 
geometries A and B  and this change occurred quite significantly after the conformational change. 
So far, clear differences have been observed in the Goodger oligosaccharides within torsional 
geometry. For the first time here, it is the change in iduronate conformation which seems to drive 
that change in torsional geometry. The inactive dp10(5) undergoes similar changes, but quite 
significantly this change is observed before the conformational transition (Figure 3.18, Panels A 
and E). Both oligosaccharides dp10(1) and dp10(5) are sulphated in the same position 
(IdoUA(2S) - GlcNS(6S)); and so on this occasion sulphation position is shown to have no 
influence on biological activity of these HS samples.  
 
4.5.2 Linkage 5 - Conformations 
A comprehensive analysis of the literature suggests it is the presence of the 1C4 conformation 
and/or the presence of the 2S0 conformation, when considering HS: FGF binding (Pellegrini et al., 
2000; van-Boeckel et al., 1987).  
It is possible that it is the presence of both conformations in a polymeric HS/heparin chain which 
is favoured for activity as shown in the literature (Faham et al., 1996; Chuang et al., 2000). For 
the first time in this study, the results seem to suggest and indeed agree with this statement 
above.  According to the 1 ns MD simulation it can be suggested that it is indeed the presence of 
both the 1C4 conformation, alongside the 
2S0 conformation which plays an important role in 
biological activity. Here we are suggesting both conformations need to be present, in two or more 
iduronates in any one HS chain to allow for active binding to FGF2. This can clearly be seen in 
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three out of the four active oligosaccharides. The presence of both conformations alongside the 
torsional geometry established by the corresponding glycosidic bond, allows for activation and 
mitogenic response from a FGF2-FGFR1 IIIc receptor complex in a Baf cell mitogenesis assay. 
For oligosaccharide dp10(1 and 2), the 1C4 conformation is observed in the iduronate at position 
5, with the skew boat conformation observed for the iduronate at position 7. The conformation 
position is then switched around for dp10(4), with the skew boat conformation observed in 
residue 5, followed by the 1C4 conformation. The exception to the rule here is dp10(3), which is 
initially identified in the 4C1 conformation for residue 5 and the 
1C4 conformation for the iduronate 
at position 7 in the HS chain. Excluding dp10(3), the three other active oligosaccharides after 1 ns 
of MD simulation could show valuable information concerning biological activity.  
 
The iduronate residues which make up linkage 5 and 7 are found in the following conformations 
at the end of the 1 ns MD simulation (Figure 4.5; shown in red and taken from Figure 3.19 and 
Figure 3.21):  
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Figure 4.5 
 
Active dp10(1).  
UA - GlcNAc - GlcUA - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - IdoUA - GlcNAc(6S) 
Active dp10(2).  
UA - GlcNAc - GlcUA - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - GlcUA - GlcNAc(6S) 
 
Active dp10(3).  
UA - GlcNAc - GlcUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA - GlcNS - IdoUA - GlcNAc(6S) 
Active dp10(4).  
UA - GlcNAc - GlcUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA - GlcNS - GlcUA - GlcNAc(6S) 
 
Inactive dp10(5).  
UA - GlcNAc - GlcUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - IdoUA - GlcNAc 
Inactive dp10(6).  
UA - GlcNAc - GlcUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS(6S) - GlcUA - GlcNAc 
 
Inactive dp10(7).  
UA - GlcNS - IdoUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS - IdoUA - GlcNAc(6S) 
Inactive dp10(8).  
UA - GlcNS - IdoUA - GlcNS - IdoUA(2S) - GlcNS(6S) - IdoUA(2S) - GlcNS - GlcUA - GlcNAc(6S) 
 
Figure 4.5 The conformation of the iduronates at positions 5 and 7 in the HS chain. 
 
The conformations are highlighted in red and were taken from Cremer-Pople puckering 
parameter data carried out in this study. 
2S0 
2S0 1C4 
1C4 
1C4 
1C4 
4C1 
2S0 
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The inactive oligosaccharides are observed in different conformations compared to the active 
oligosaccharides and this could be a significant indication of biological activity in these samples. 
Here at the end of the MD simulation the inactive oligosaccharide iduronates at position 5 and 7 
in the chain follow a different pattern to that observed in the active oligosaccharides. For dp10(5), 
both are confirmed in the skew boat conformation. The same conformational data is observed in 
inactive dp10(7). Decasaccharide dp10(6) is observed in on the 1C4 conformation, even though is 
has the same sequence as dp10(5). Finally dp10(8), different again from the other three inactive 
oligosaccharides shows the iduronate at position 5 is present in the 1C4 conformation, alongside 
this is the iduronate at position 7 which is observed in the rigid 4C1 conformation.  
 
4.5.3 The Binding According to Literature 
The following section will provide an overview of information regarding the conformation of 
iduronates in FGF interactions and also other proteins (EDF/SF, histamine, AT III and O1BFS) 
and how they relate to the information obtained in this study from the Goodger oligosaccharides.  
 
4.5.3.1 The Proposal for Iduronic Acid 1C4 Conformation: Protein 
Interactions 
In histamine-heparin interactions the population of the 1C4 conformation increased when in the 
bound form (when the heparin oligosaccharide was bound to histamine). The binding of histamine 
to the heparin hexasaccharide did initially identify a role for both conformations 1C4 and 
2S0 
(Rabenstein, 2002). However the 1C4 conformation was identified as the dominating 
conformation. The bound oligosaccharide sequence was identified from literature as: 
 
∆UA (2S) – GlcNS(6S) – IdoUA(2S) – GlcNS(6S) – IdoUA(2S) – GlcNS(6S) 
 A          B      C  D         E      F 
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The conformation of the iduronate at residue E was identified with and without histamine bound, 
and identified a role for both conformations 1C4 and 
2S0 conformations.  
 
Alongside the conformational changes reported in the literature, were also minor changes in the 
glycosidic linkage when in the bound form. The final linkage between the IdoUA(2S)-GlcNS(6S); 
residue E-F changes from Φ = 43° Ψ = 12° in the unbound form to Φ = 49° Ψ = 22° when bound. 
This indicates a decrease in the skew boat conformation when bound to histamine. This same 
process could be observed in the Goodger decasaccharides, if the Cremer-Pople puckering 
parameters were analysed with and without binding FGF2. We have already identified changes in 
glycosidic geometry in our modelling data (See Results, p172 onwards), which suggests the 
torsional geometry my change further when bound to FGF2.  
 
One of the earliest studies on iduronate conformation was carried out by van-Boeckel et al 
(van-Boeckel et al., 1987) on the conformational analysis of synthetic heparin-like di and 
trisaccharides. The disaccharides indicated equilibrium between all three conformations, with the 
presence of the 2-O-sulphate group influencing the population of the 1C4 conformation. When 
increased to trisaccharides, the skew boat and 1C4 chair conformation dominated and when 
increasing the temperature the population of the skew boat conformation was found to increase 
further (Sanderson et al., 1987; van-Boeckel et al., 1987). Although our study did not look at the 
effect of temperature, it did show an equilibrium between the two most popular conformations; 
both 1C4 and 
2S0 conformations. However, it was not determined if there was in fact one 
conformation which dominated more then the other. Also identified was a slight influence on 
certain internal iduronate residues from the 4C1 conformation (Figure 3.19, Panel H; Figure 3.21, 
Panel C; Figure 3.28, Panel B).  
Studies on a heparin polysaccharides indicate the 1C4 conformation as the active conformation in 
which all the sulphate groups are presented on one  side of the chain (Mulloy et al., 1993). This 
sulphation pattern has been identified in these molecular modelling studies, where the sulphate 
groups are presented in patterns on one side of the HS chain.  
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Trisaccharide analysis by Raman et al (Raman et al., 2005) suggests the 1C4 conformation 
dominates due to the position of the glycosidic bond in the axial position. This had been identified 
in the following sequence: 
 
GlcN – IdoUA – GlcN 
 
All of the Goodger molecular modelling sequences used in this study were set in the axial 
position, at the start of the MD simulation. It is interesting to see that in the structure above they 
have identified the 1C4 conformation as the dominating conformation when the bond is in the axial 
position. This is the only study in which the axial conformation is mentioned in literature, in 
relation to torsional geometry.   
 
Work carried out by Ferro et al (Ferro et al., 1986) on monosaccharides, disaccharides and 
pentasacchaides, again suggests the 1C4 conformation dominates over the skew boat form 
(Figure 4.6). This study suggested monomers of IdoUA(2S) were dominated by the 1C4 
conformation, but only when found as a single residue.  
 
The work carried out on IdoUA(2S) - α Me glycoside; (which was the structure used for the 
identification of iduronate Cremer-Pople puckering parameter dimensions, Figure 3.15) and was 
an extension of the work by Murphy (Murphy 2007) identified slight domination from the skew 
boat ring conformation. Duplicate MD simulations were carried out to identify the correct 
puckering parameter data values for each conformation. It was determined that those models with 
a starting conformation of 1C4 made a conformational transition to the 
2S0 conformation during the 
MD simulation (1000 ps MD simulation). However further investigation carried in this study 
indicated a further conformational transition was observed in some MD simulations, resulting in a 
change to the 4C1 conformation (Figure 3.15 and Figure 3.16).    
 
1C4 
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Figure 4.6 
 
IdoUA(2S) - α Me glycoside 
IdoUA(2S) – GlcNS(6S) 
GlcNS(6S) – GlcUA – GlcNS(6S) – IdoUA(2S) – GlcNS(6S) 
 
Figure 4.6 The monosaccharide, disaccharide and pentasaccharide in which the 
1
C4 
conformation was thought to dominate.  
 
This has been taken from (Ferro et al., 1986) with only the iduronate residue studied.  
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4.5.3.2 The Proposal for 2S0:  
The skew boat conformation has not been identified in literature with reference to FGF2 
interactions. It is also most commonly studied with the related proteoglycan heparin, rather then 
with HS. A study involving modified heparins, all of which had a high proportion of the 2S0 
conformation were identified (Mulloy et al., 1994). These included native heparin, and other 
structurally modified heparins such as N-desulphated, re-acetylated heparin, N and O-
desulphated, re-N-acetylated heparin, N- and O-desulphated, re-sulphated heparin and N- and 6-
O-desulphated, re-N-sulphated heparin. All were shown to have a high proportion of the skew 
boat conformation amongst the iduronates.  
A heparin derived tetrasaccharide containing only one iduronate was identified in the 2S0 
conformation. This was thought to bring all the substituents into a preferred equatorial position 
(the exo-anomeric affect) and has a sequence of (Mikhailov  et al., 1996): 
 
∆UA – GlcNS(6S) – IdoUA(2S) – GlcNS(6S) 
 
 
The discovery of the skew boat conformation indicated how important it is in binding when it was 
identified in the AT III binding sequence (Ferro et al., 1990). Here it had been identified as an 
important  feature in the HS chain as it facilitates electrostatic interactions but is not directly 
involved in the binding (Coombe and Kett, 2005; Guerrini et al., 2006). It is thought to dominate 
the equilibrium between the two conformations because the 1C4 conformation is too bulky. 
Hricovini et al (Hricovini et al., 2001) studied a synthetic heparin pentasaccharide (the synthetic 
version of the AT III binding pentasaccharide). It contained the following sequence where again 
the skew boat conformation was identified: 
 
GlcNS(6S) – GlcUA – GlcNS (3S) – IdoUA(2S) – α Me glycoside 
 
2S0 
2S0 
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Das et al (Das et al., 2001) also compared a synthetic pentasaccharide differing in its structure 
due to the presence of a methylated section of the chain (which binds to AT III). Again the 
iduronate was identified in the ‘favourable’ 2S0 form.  
The data from both the 1 ns and 10 ns MD simulations shows a role for the skew boat 
conformation. It is not clear if this is the dominating conformation in our results, but it certainly 
plays a role in biological activity, alongside the changes in torsional geometry. The skew boat was 
identified in the majority of the active oligosaccharides but this was alongside the 1C4 
conformation, suggesting a role for both conformations.  
 
4.5.3.3 The Importance of both 1C4 and 
2S0 Conformations: The 
FGF Interactions 
The most studied and well known heparin structure to date is the work on a heparin 
hexasaccharide bound to FGF2 with the work resulting in an x-ray crystal structure (file 1BFC 
from the RCSB Protein Data Bank; Faham et al., 1996). This work is directly comparable to the 
work carried out in this study as it involved the binding of a heparin hexasaccharide and 
tetrasaccharide specifically to FGF2 (bFGF). This was also the x-ray crystal structure used in the 
docking section of this thesis. Here the different dp10 Goodger oligosaccharide structures were 
docked into the FGF2 protein molecule with the use of AutoDock Vina.  
The heparin hexasaccharide and the tetrasaccharide are made up of the same sequence as each 
other (below) with the tetrasaccharide reducing sugar assigned as ring number 4 (Figure 4.7, 
Panel A). The high affinity binding site involved rings 2 and 3 and therefore is found in both 
oligosaccharides. The additional low affinity binding site is identified as rings 5 and 6; therefore 
the tetrasaccharide will only contain this low affinity binding region. The conformation of the 
iduronate in the high affinity binding region in the Faham structure has been identified in the 1C4 
conformation. The iduronate in the low affinity binding region again of the Faham structure was 
identified in the 2S0 conformation. It is therefore presumed that it the presence of both 
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conformations in the hexasaccharide structure which allows for binding of the heparin chain to 
FGF2.  
 
Residues 4 through to 7 in the active Goodger models; dp10(1) and dp10(3) contain the FGF2 
binding motif identified by Guglieri et al (Guglieri et al., 2008) which had been identified by NMR 
spectroscopy. Here both conformations are present when bound to both FGF1 and FGF2 (Figure 
4.7, Panel B).  
The Faham and Guglieri structures show similarities with the Goodger decasaccharide models 
built during this study. The IdoUA(2S) in position 5 in all of the Goodger decasaccharide models 
is identified in the 1C4 conformation like those models presented (Faham et al. 1996; Guglieri et 
al., 2008); with the second iduronate following on from this in the 2S0 conformation. For the 
Goodger oligosaccharides, active dp10(1) and dp10(3) this particular iduronate happens to be 
positioned in the centre of the HS chain and also happen to be the first iduronate you come 
across from the non-reducing end of the chain.  
Both conformations are present in the active Goodger oligosaccharides, but we have also seen 
both conformations present in the inactive oligosaccharides; just in varying ratios and presented 
at different times in the MD simulations. Our results do suggest that both conformations are 
necessary for biological activity, but this alone does not ultimately decide it. Other factors need to 
be taken into consideration, such as torsional geometry.  
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Figure 4.7  
 
 
A. ∆UA – GlcNS(6S) – IdoUA(2S) – GlcNS(6S) – IdoUA(2S) – GlcNS(6S) 
 
 
 
B. GlcNS (6S/OH) – IdoUA(2S) – GlcNS (6S/OH) – IdoUA  
(Guglieri, Hricovini et al., 2008) 
 
Figure 4.7 Two HS/heparin oligosaccharides which indicate the requirement for both the 
1C4 and the 
2S0 conformations present for binding.  
  
Panel A. Shows a heparin hexasaccharide and a tetrasaccharide of the same sequence with both 
conformations present (Faham et al., 1996). 
Panel B. The binding motif as identified by Guglieri et al (Guglieri et al., 2008) also with both 
conformations indicated as a requirement for biological activity.  
 
1  2        3      4   5         6 
1C4 
2S0 
    1C4                 
1C4/
2S0 
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4.5.3.4 The Importance of both 1C4 and 
2S0 Conformations: Other 
Protein Interactions 
The previously mentioned foot and mouth disease protein (O1BFS; Fry et al., 1999) behaves in a 
similar way to FGF2 as identified by Faham et al. (Faham et al., 1996). It selects and binds to a 
fully sulphated heparin of which the three central rings are made up of: 
 
GlcNS(6S) – IdoUA(2S) – GlcNS(6S) 
 
The glucosamine residues as well as the terminal IdoUA adopt chair conformations. The central 
iduronate appears to adopt the skew boat conformation but also the 1C4 chair conformation (Fry 
et al., 1999).   
 
Two heparin octasaccharides Octa A and Octa B were isolated from Lovenox (enoxaparins) and 
studied. These are low molecular weight heparins obtained by β-eliminative cleavage of a porcine 
mucosal heparin (Guerrini et al., 2006) and have similar sequences to the Goodger 
oligosaccharides. Here Octa A and Octa B contain the AT-binding properties previously identified 
(Hricovini et al., 2001) alongside the rare 3-O-sulphate modification (Figure 4.8). NMR studies 
suggest that in a free state both 1C4 and 
2S0 conformations are present in Octa A with the 
equilibrium driven towards the 2S0 conformation when bound to antithrombin III (Figure 4.8). For 
Octa B, the IdoUA(2S) in the AT-binding sequence contains both conformations with the non-
sulphated iduronic acid preceding this sequence identified only in the 1C4 conformation. Guerrini 
et al (Guerrini et al., 2006) suggests that when in a bound state the conformation of IdoUA(2S) is 
driven towards the 2S0 conformation; shown when the oligosaccharide was in solution and the 
equilibrium was found with ratios (%) towards the 2S0 conformation: 60: 40 (
2S0: 
1C4). (This was 
identified specifically in the AT pentasaccharide binding sequence). The 2S0 conformation is 
thought to form part of a high affinity binding site in the heparin chain (Raman et al., 2005) with 
the low affinity site further down the chain. 
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Binding studies were not carried out during this study, so it is difficult to compare this data from 
literature to the modelling data obtained here in this study. It has been identified in this study that 
a presence of both conformations in the active oligosaccharides which suggest both needs to be 
present for biological activity. However, it is difficult to compare bound and unbound states as 
described above. Certainly there is a need for more then one conformation to be present which 
has been identified in the Goodger oligosaccharides dp10(1, 2 and 4). Oligosaccharide dp10(3) is 
the exception with both chair forms present at the end of the 1 ns MD simulation, with no sign of 
the skew boat conformation. This is not observed in the inactive oligosaccharides, where it is the 
presence of only one conformation after the MD simulation (the 2S0 conformation in dp10(5) and 
dp10(7); and the 1C4 chair conformation for dp10(6)). The exception to this is dp10(8); which 
shows a similar pattern to dp10(3) with both chair conformations present. 
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Figure 4.8 
 
 
Octa A: 
∆UA – GlcNAc(6S) – GlcUA – GlcNS (3, 6S) – IdoUA(2S) – GlcNS(6S) – IdoUA(2S) – GlcNS(6S) 
 
Octa B: 
∆UA (2S) – GlcNS(6S) – IdoUA – GlcNAc(6S) – GlcUA – GlcNS (3, 6S) – IdoUA(2S) – GlcNS(6S) 
 
 
Figure 4.8 The two heparin octasaccharides; which contain the rare 3-O-sulphate 
modification and have been identified in both the 1C4 and the 
2S0 conformations. 
 
Octa A and Octa B have both been isolated from Lovenex and are produced by a β-eliminative 
cleavage of a porcine mucosal heparin (Guerrini et al., 2006). 
 
AT-binding sequence 
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4.5.3.5 Biological Implications 
The information above gives an indication to the complexity of biological activity in HS chains. All 
views have been put across with data that backs up each argument. According to the data 
obtained through the MD simulations it could be the presence of both conformations in the chain 
which leads to a biologically active HS chain. This subtle difference in conformation of the 
iduronates in the internal environment of the chain would allow for the protein ligand to selectively 
fit into the conformation it requires. The HS chain in turn would offer both a low and a high affinity 
binding site with both conformations present. The presence of both conformations could aid in the 
deviation or kink identified previously (Guglieri et al., 2008). As more conformational transitions 
occur the effects from the presence of the kink could become more apparent and/or dramatic; 
therefore having an overall influence on the biological activity of the HS chain.  
It can be identified that the conformation of the iduronates plays a major role in biological activity. 
It is not this alone however, which dictates biological activity. The torsional geometry data can not 
be ignored as there is a clear indication in this data that this has a major effect on biological 
activity in the active oligosaccharides. This has been identified in dp10(1) and dp10(3), where the 
presence or absence of a particular geometry, alongside specific iduronate conformation which 
seems to have an influence on this activity. 
 
4.7 The Contribution from the 4C1 Conformation  
The presence of the 4C1 conformation in the 1 ns MD simulation for the iduronate at sequence 
position 7 in dp10(8), (Figure 3.19, Panel H) and also residue 5 in dp10(3); is the first time this 
conformation has been identified in any of the Goodger oligosaccharides, for an internal residue. 
This has previously only been identified in iduronates at terminal ends. There is work in the 
current literature which suggests the presence of the 4C1 conformation, for internal structures. 
This was identified in work specifically with dermatan sulphate (not heparan sulphate). Inoue et al 
(Inoue et al., 1990) looked at conformer populations in a DS tetrasaccharides (Figure 4.9). 
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The internal IdoUA for sequence 1 has equilibrium of; 54: 42-44: 4 (1C4: 
2S0:
 4C1) with sequence 2 
having a ratio of 54: 44: 2 (1C4: 
2S0:
 4C1). Conformer populations were also described in this way 
by work also carried out on DS by Casu et al (Casu et al., 1986). The non-reducing IdoUA in the 
hexasaccharide (Sequence 3) is in equilibrium with equal populations of all three conformers: 30: 
40: 30 (1C4: 
2S0:
 4C1).   
Although these are not directly comparable because the work has been carried out on DS, which 
contains galactosamine in replacement of glucosamine found in HS; it is worthy to note the 4C1 
conformation has been identified as an internal conformation elsewhere. This proves the ability of 
the iduronates to undergo conformational transitions in order to produce optimal binding 
conditions which allow for a good structural fit for ionic and van der Waals interaction (Raman et 
al., 2005).  
It is not clear however if this aids in biological activity in the Goodger oligosaccharides as this was 
identified at residue 7 in an inactive oligosaccharide dp10(8); but also in the active dp10(3) 
oligosaccharide in residue 5. Because of this it is not clear if this aids in biological activity in these 
HS samples.  
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Figure 4.9 
 
Sequence 1: I – H – I – H 
Sequence 2: G – H – I – H  
Sequence 3: I – H – I – H – I – H  
 
Where   I – IdoUA 
G – GlcUA 
H – GalNAc 
 
Figure 4.9 Conformational data for iduronate internal structures, identified in dermatan 
sulphate.  
The 4C1 conformation for the first time in literature has been identified for an internal structure 
iduronate, according to Inoue et al (Inoue et al., 1990).  
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4.8 The Potential Role for Terminal ∆UA Residues 
The presence of the ∆UA at the non-reducing end of an oligosaccharide as previously mentioned 
is a result of the enzymatic degradation process. Previous studies have all but ignored the 
presence of this residue in protein binding due to its unnatural presence in the chain. A key role 
has been established for this in the work carried by Schlessinger et al (Schlessenger et al., 2000); 
identified in their x-ray crystal structure of an FGF2:FGFR1:heparin complex. Here the terminal 
UA residues on both heparin chains are identified in the centre of the canyon, which runs 
between the two receptor molecules (see introduction, page 78). Here their terminal unit was the 
IdoUA(2S) and so it would not be directly comparable to the Goodger oligosaccharides. It is 
difficult to say if this has any effect on biological activity in the Goodger oligosaccharides as there 
are no conformational or torsional differences between the active and inactive oligosaccharides in 
either simulation (1ns or 10 ns MD simulation).  
 
 
4.9 The 3-Dimensional Structure of Heparin and the Influence it 
has on the Binding Site 
There have been many NMR studies on polymeric heparin oligosaccharides and this is due to the 
relative ease of the purification process for purifying heparin compared to HS (Mulloy et al.,1993; 
Mulloy et al., 1994; Mikhailov et al., 1996; Mikhailov et al., 1997; Hricovini et al., 2001; Angulo et 
al., 2005).  The purification process for HS is more complex making it more difficult to achieve the 
levels needed for any analytical process, but especially NMR molecular refinement. The longer 
oligosaccharides are more difficult to purify because there is not as much produced during the 
enzyme degradation of the chain (when compared to the shorter oligosaccharides dp2-dp6). The 
use of molecular modelling, alongside NMR structural refined is important in determining 
molecular models with accurate structures. Those identified using NMR spectroscopy are an 
accurate reflection of those identified in nature, whereas molecular models could predict 
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conformations and structures which are not naturally found in nature. Comparing molecular 
models with different ring conformations is an important process in determining how these affect 
the overall 3-dimensional structure. Two 3-D models have previously been produced for a heparin 
dodecasaccharide (using NMR structural refinement); which identifies the subtle differences 
between the different iduronate conformations, specifically the 1C4 and 
2S0 forms (Mulloy et al., 
1993). These subtle changes in the overall 3-dimensional structure can be observed in the 
following figure (Figure 4.10). Here one molecular model has all the iduronates set in the chair 
conformation with the second of the two models in the skew boat conformation. These 
differences; in only the conformation of the iduronic acid ring structure, show that when in the 1C4 
conformation the positioning of the iduronic sulphate groups means they are closer together 
spatially. When converted to the 2S0 conformation the same sulphate groups are extended further 
away into the molecular space surrounding the molecule.  
It is these subtle changes in the structure (and they are very subtle changes in the overall 3-
dimensional shape); which leads to an overall change in the specific way these groups interact 
with protein ligands (Mulloy and Forster, 2000).  
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Figure 4.10 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 10 Three dimensional models of two heparin dodecasaccharides. 
 
The coordinates were taken from the Protein Data Base, file 1HPN (Mulloy et al., 1993). They 
each consist of the same sequence of 6 disaccharide repeats of GlcNS(6S) - IdoUA(2S). 
Panel A. All of the IdoUA(2S) units set in the 2S0 conformation. 
Panel B. All of the IdoUA(2S) units set in the 1C4 conformation. 
A
B
A. 
B. 
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4.10 Molecular Dynamic Studies on Glycosidic Bonds 
The construction of molecular models on the basis of NMR structural data (obtained from NOE 
interactions) represents only average structures, when in reality a molecule in solution would 
sample many alternate conformations and 3-dimensional shapes. The important thing to note 
about these models is that they are able to sample these different geometries as shown in the 
results section. Most structures actually remained close to their starting geometry as modelled at 
the start of the simulation (an example of the data values for dp10(1) is shown in Table 4.1). The 
next step in this process if there were no time constraints would be to obtain NMR structural 
refinement data for the Goodger oligosaccharides to check that these identified conformations 
predicted by the MD simulations exist in nature. 
All molecular dynamic simulations carried out as part of this thesis work were deliberately set up 
in a way so that only influences from immediate residues were taken into account. Only the 
influences from neighbouring residues would have an effect on the ring conformation and the 
torsional geometry of the glycosidic bonds. This was achieved by setting the influence of charges 
to a cut off point of 6 Å, therefore no electrostatic interactions from residues further down the 
chain would have any influence on the chain (see Minimisation 1 in Experimental Materials and 
Procedures). This would mean only the immediate environment of any residue (the connecting 
glycosidic bond and the neighbouring residues only) is only influenced by its neighbours. For 
example, residue 5 in all the oligosaccharides would only be influenced by residue 4 and 6, and 
the connecting bonds. There would be no further influence any further upstream or downstream 
from this position. 
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Table 4.1  
Dihedral angles set at the 
star of the MD simulation 
Dihedral angles identified at 
the end of the MD simulation 
Linkage and 
Monosaccharide 
Conformation Φ° ψ° Φ° ψ° 
UA 1H2 – GlcNAc 
4C1 55 5 -20 
30 
-20 
10 
GlcNAc 4C1 – GlcUA 
4C1 -35 -20 -30 10 
GlcUA 4C1 – GlcNAc(6S) 
4C1 45 15 40 0 
GlcNS(6S) 4C1 – IdoUA(2S) 
1C4 
-50 0 -30 -30 
IdoUA(2S) 1C4 – GlcNS(6S) 
4C1 
-50 -10 -30 
40 
-20 
10 
GlcNS(6S) 4C1 – IdoUA(2S) 
1C4 
-50 0 -40 
30 
-20 
30 
IdoUA(2S) 1C4 – GlcNS(6S) 
4C1 
-50 -10 -30 
40 
-30 
-10 
GlcNS(6S) 4C1 – IdoUA 
1C4 -75 -25 -30 -30 
IdoUA 1C4 – GlcNAc(6S) 
4C1 -30 -10 -20 
30 
-20 
-30 
10 
-20 
 
Table 4.1 A comparison of the dihedral angles for dp10(1) set at the start of the MD 
simulation and those observed as an average value at the end of the MD simulation.  
 
For those with more then one identified low energy minima, the negative values were used to 
build the Goodger models. Here the ∆UA for example, was initially set at Φ = +55° Ψ = +5°. At 
the end of the MD simulation this geometry was identified as being Φ = -20° Ψ = -20° and 
identified as geometry A and Φ = +30° Ψ = +10°, identified as geometry A.  
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Torsional geometries in this study have been identified to play a major part in biological activity in 
the HS samples. The results presented here indicate an overall influence of the ring conformation 
of the iduronates on the torsional geometry of the glycosidic bonds. The results have identified 
that the presence of either the 1C4 and/or the 
2S0 conformation has an influence on the 
neighbouring torsional geometry. In linkage 7, of the 1 ns MD simulation the chair conformation 
seems to influence geometry B which is the negative geometry identified. The skew boat 
conformation has the opposite influence, on geometry A (the positive geometry) also in linkage 7 
(Figure 3.19). Geometry A and the skew boat conformation are identified in the active 
oligosaccharides dp10(1 and 2); whereas geometry B and the chair conformation is identified 
mostly in the inactive oligosaccharides dp10(5 and 6). This is identified in both structures with the 
2S group attached to the iduronate residue. In those residues without this modification to the HS 
chain, the results vary from that described above. 
Torsional geometries are also identified as a difference between active and inactive 
oligosaccharides in linkage 6 (involving the GlcNS(6S) identified in all eight oligosaccharides). An 
additional geometry C was identified in dp10(3 and 4); which had not been previously identified. 
This was thought to be due to the lack of 2-O-sulphate on the neighbouring iduronate residue. 
Linkage 5 also shows considerable differences between active and inactive oligosaccharides 
specifically to do with torsional geometry. Of the active oligosaccharides three out of the four exist 
in two geometries (A and B). The inactive oligosaccharides exist in only one torsional geometry, 
which is either geometry A or B.  
It does seem to indicate that these subtle changes in torsional geometry actually play a major role 
in biological activity. These changes go alongside the conformational ring transitions observed 
throughout both MD simulations. It is fairly accurate to predict that biological activity is most 
definitely defined by iduronate ring conformation and glycosidic linkage torsion geometries. One 
or the other is not enough on its own to stand outright and be the dominating factor between 
inactive and active HS oligosaccharides.   
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4.11 The Biological Implications for the Docking Experiments 
The need for a good fit in the docking experiments would bring this research closer in being able 
to successfully predict HS structures for molecular drug design. This would put this research one 
step closer to being able to successfully predict the actual requirements for HS-FGF2 binding. 
This would involve specific iduronate conformation, sulphation pattern, positioning and type of 
sulphation needed, glycosidic linkage torsional geometries and also chain length. Up until now; a 
large amount of information has concentrated on the size of the HS chain in being able to illicit a 
biological response. The following are just a selection (Digabriele et al., 1998; Pellegrini et al., 
2000; Schlessinger et al., 2000; Wu et al., 2003; Guglieri et al., 2008; Goodger et al., 2008; 
Deakin et al., 2009). There have also been many papers on the sulphation requirements and 
patterns of sulphation required for biological activity. The following are again just a selection 
(DiGabriele et al., 1998; Faham et al., 1996; Guglieri et al., 2008; Kreuger et al., 2001; 
Maccarana et al., 1993; Pye et al., 1998; Schlessinger et al., 2000). 
 
The docking studies carried out here took into account not only the size of the HS chain, but also 
the conformation of the iduronates and the positioning of the sulphate groups, which were 
obtained from the MD simulations carried out in this study. Important frames in the MD 
simulations were taken and analysed using AutoDock Vina, against the x-ray crystal structure 
1BFC (from the Protein data bank). Each frame was chosen for a specific change in either ring 
conformation, or torsional geometry.  These were chosen because it has been shown that each of 
these factors has an influence on biological activity, shown in this study. Unfortunately; due to the 
nature of the docking simulations and the time constraints in this study, only one FGF signalling 
complex model was studied during the docking experiments. This was file 1BFC from the protein 
data bank (an FGF2 protein complexed with a hexamer heparin fragment). Other candidates for 
this docking were file 1FQ9; a 2:2:2 complex of ternary bFGF-FGFR1-heparin complex, however 
it was decided that file 1BFC was the most similar in terms of this study.  
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As discovered in the docking studies; the majority of the Vina predicted models were instantly 
dismissed due to their predicted docking of the Goodger decasaccharide models sulphate groups 
in comparison to the hexasaccharide of the 1BFC crystal structure. Many of the rigid (these were 
set rigid at the start of the docking simulation, dockings were identified wrapped around 
themselves, rather then stretched out across the binding site on the protein. These kinds of 
predicted structures were dismissed on the basis of not docking into the correct binding site 
(Faham et al., 1996; DiGabriele et al., 1998; Schlessinger et al., 2000). The non-reducing 
terminal of the heparin hexasaccharide in the crystal structure has no visible interaction with the 
binding with FGF2.  However, this is not always the case, as a previous study by Schlessinger et 
al (Schlessinger et al., 2000) identified the non-reducing ends of both HS chains in the crystal 
structure, in the centre of the binding canyon. The remainder of the molecule was found to 
interact with a further high affinity binding site further away. An example of this is shown in Figure 
1.21 of the Introduction (page 79). This indicates that any docking structures predicted by Vina 
which involve either the non-reducing or indeed the reducing ends in the binding region must not 
be dismissed based on this information alone. As identified by Faham et al (Faham et al., 1996); 
there could be both a high affinity binding site alongside a low affinity binding site. The size of the 
Goodger oligosaccharides would indicate that the presence of both binding sites could be a 
distinct possibility.  
 
It would be wrong to dismiss Vina as a useful docking tool on the basis that most, if not all of the 
flexible dockings and some of the rigid dockings were dismissed due to them being not correctly 
positioned in the binding site. Ideally, the highest affinity binding structure would be the best for 
model according to the crystal structure. In this study, only one model fitted in accurately with the 
binding site and had been ranked model number 1 in the Vina predicted binding structures. This 
was for dp10(1), frame 45 of the 1 ns MD simulation. Model number 1 had the highest predicted 
binding affinity with a value of -13.0 Kcal/mol. The preliminary dockings indicate Vina is a reliable 
piece of docking software due to its ability to successfully bind two of the known x-ray crystal 
structures into the correct binding site. These files had previously been taken apart, creating 
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separate protein and ligand files following the step by step process offered by Trott (Trott 2009). 
Increasing the exhaustiveness setting in Vina would have increased the likelihood of Vina finding 
the correct binding conformation. During this study it was set as the default 8, as increasing this 
would lead to considerable longer docking times. This would be something to reconsider during 
future docking simulations. It must also be noted that the frames chosen for docking were only 
1 ps in time as only one frame was docked at any one time. To gain a better insight into the 
required docking features; many more frames would need to be studied in order to increase the 
probability of finding the correct conditions needed for binding.   
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This study has demonstrated that molecular modelling data has enabled significant new insights 
to be gained into the role of iduronate ring conformation and torsional angle geometry. These 
have both shown to be significant factors and play a major role in biological function with 
differences identified between inactive and active HS oligosaccharides. The study has shown that 
glycosidic linkages do not have to be fixed in a certain position or geometry favoured as a result 
of the exo-anomeric effect. Static and flexible MD simulations have shown that alternate 
geometries occur in all linkages, allowing for the movement away from its usual 3-dimensional 
shape. The data indicates a link to possible biological activity with the presence of these alternate 
geometries; however HS-FGF2 biological activity is not due to this alone. Our data indicates a 
significant amount of torsional geometry is due to the presence of certain iduronate 
conformations. Cremer-Pople puckering parameters indicate the role of both the 
1
C4 and 
2
S0 
conformations are essential for biological activity. The ratio of these conformations is still 
relatively unknown but the data indicates that certain sulphation patterns on flanking residues in 
the chain are also responsible for biological activity. These sulphate groups induce a ‘kink’ in the 
chain again removing the HS chain away from its original 3-dimensional shape.  
Definite differences have been identified between the active and inactive Goodger 
oligosaccharides, which will become more apparent on longer MD simulations. These differences 
aid in the ability to determine how FGF2 activation occurs in the active dp10(1) oligosaccharide, 
as opposed to the inactive dp10(5) oligosaccharide.  
The docking studies have indicated that AutoDock Vina is a reliable docking software, however 
further work is necessary to fully explore all of the functions available in this docking software. 
The results have shown that it has the ability to accurately predict certain x-ray crystal structures, 
by correctly docking into the known binding site. The active dp10(1) oligosaccharide gave the 
most promising results in Vina, which was able to bind in with relative accuracy in the correct 
binding site. This could be improved with more through knowledge and understanding of the 
docking software.  
Finally the experimental work has shown that some of the experimental difficulties can be 
overcome when working with heterogeneous HS samples. Large dp8 sized oligosaccharides are 
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incredibly difficult to purify, with the purification process becoming more complex with every 
oligosaccharide size increase. Valuable structural data can be gathered for authentic HS derived 
oligosaccharides through NMR molecular refinement. In this study, only a partial structural 
assignment was obtained and this was due to the highly complex nature of the purification 
process. Larger amounts of purified HS fragments could be obtained over a longer timescale.  
Virtual screening of HS libraries will become invaluable in modern drug discovery. This would 
allow for suitable targets to be screened with little or no purification of structures required. Being 
able to accurately predict binding patterns and required structures would allow for faster drug 
design without the complications or a difficult purification process.  
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Figure 3.36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 3.36. The highest affinity binding structure as predicted by Vina for dp10(1) for the 
1000 ps MD simulation. This is the structure with the highest affinity (kcal/mol) and is rated as 
mode number 1 in the Vina search.   
Panel A. Frame 45, model 1 with both binding positions predicted.   
Panel B. The magnified image of frame 45.  
Panel C. Frame 45, model 6. 
Panel D. Frame 45, model 9.  
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Panel E. Frame 350, model 7. 
Panel F. Frame 350, model 10. 
Panel G. Frame 350, model 11. 
F. G. 
E. 
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Panel H. Frame 975, model 1. 
Panel I. Frame 975, model 3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panel J. Frame 1463, model 3. 
Panel K. Frame 1463, model 15. 
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Figure 3.37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.37. The highest affinity binding structure as predicted by Vina for dp10(3) with the best 
fit for the x-ray crystal structure for the 1000 ps MD simulation.  
Panel A. Frame 200, model 3.  
Panel B. Frame 200, model 10.   
Panel C. Frame 1056, number 16. 
Panel D. Frame 1300, number 3. 
B. A. 
C.  
D. 
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Figure 3.38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.38. The highest affinity binding structure as predicted by Vina for dp10(5) with the best 
fit for the x-ray crystal structure for the 1000 ps MD simulation. 
Panel A. Frame 30, model 2. 
Panel B. Frame 30, model 11. 
Panel C. Frame 1381, model 9.  
Panel D. Frame 1381, model 5. 
A. B. 
C. D. 
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Figure 3.39. The highest affinity binding structure as predicted by Vina for dp10(7) with the best 
fit for the x-ray crystal structure for the 1000 ps MD simulation. 
A. Frame 50, model 10. 
B. Frame 200, model 2.  
C. Frame 200, model 15. 
D. Frame 1463, number 5.  
A. 
B. 
C. 
D. 
Figure 3.39 
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Figure 3.40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.40. The highest affinity binding structure as predicted by Vina for dp10(1) with the best 
fit for the x-ray crystal structure for the 10 ns MD simulation. 
A. Frame 200, model 1. 
B. Frame 1300, model 11. 
C. Frame 3000, model 1. 
D. Frame 8300, model 12. 
 
A. B. 
C. D. 
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Figure 3.41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.41. The highest affinity binding structure as predicted by Vina for dp10(5) with the best 
fit for the x-ray crystal structure for the 10 ns MD simulation. 
Panel A. Frame 500, model 13.  
Panel B. Frame 1050, model 6. 
Panel C. Frame 6000, model 5.  
A. 
B. 
C. 
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Figure 3.42. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.42. The highest affinity binding structure as predicted by Vina for dp10(7) with the best 
fit for the x-ray crystal structure for the 10 ns MD simulation. 
Panel A. Frame 250, model 14.  
Panel B. Frame 750, model 1. 
Panel C. Frame 5000, model 8. 
C.  
A. B.  
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Figure 3.43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.43 The highest affinity binding structure as predicted by Vina for dp10(1), dp10(3), 
dp10(5) and dp10(7) with the best fit for the x-ray crystal structure for the 1 ns MD simulation 
flexible dockings. 
Panel A. Decasaccharide 1, Frame 45, model 1. 
Panel B. Decasaccharide 1, Frame 45, model 14. 
Panel C. Decasaccharide 3, Frame 1300, model 1.  
Panel D. Decasaccharide 5, Frame 1381, model 20. 
A. B.  
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Panel E. Decasaccharide 7, Frame 50, model 11. 
Panel F. Decasaccharide 7, Frame 200, model 14.  
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Figure 3.44. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.44. The highest affinity binding structure as predicted by Vina for dp10(1) with the best 
fit for the x-ray crystal structure for the 1 ns MD simulation flexible dockings. 
 
Panel A. Decasaccharide 1, Frame 200, model 12. 
 
 
